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Zusammenfassung 
 
Es ist bekannt, dass sich VACV GLV-1h68 sowohl als diagnostischer als auch 
therapeutischer Vektor eignet, der sich in Tumoren ansiedelt, darin repliziert und dass mit 
dessen Hilfe die Lokalisation von Tumoren bestimmen werden kann. Weiterhin konnte bereits 
gezeigt werden, dass der Effekt von GLV-1h68 auf die Tumor-Kolonisierung, das 
Tumorwachstum, die -regression und  -vernichtung zustande kommt, ohne dass irgendwelche 
bekannten Gene mit anti-tumoraler Aktivität dazu notwedig wären. Um die differentielle 
Proteinexpression vergleichend sowohl zwischen uninfizierten und infizierten Tumorzellen 
als auch zwischen den korrespondierenden uninfizierten und infizierten Tumoren zu 
untersuchen, wurden proteomische Methoden  angewandt. Ziel dieser Arbeit war es, mehr 
über die onkolytische Fähigkeit von GLV-1h68 auf Proteinebene zu erfahren. 
Die dargestellten Effekte der VACV GLV-1h68 Infektion auf die zelluläre 
Proteinexpression legen eine selektive Vernichtung von Tumorzellen nahe. In dieser Arbeit 
wurde die differentielle zelluläre Proteinexpression zu verschiedenen Zeitpunkten nach 
Infektion mit Hilfe der zweidimensionalen Gelelektrophorese (2-DE) gefolgt von MALDI-
TOF/TOF-Identifikation der Proteine analysiert. Die vergleichende Analyse mehrerer 2-DE 
Gele zeigte, dass sich das Proteinexpressionsmuster bei Zellen aus in vitro Kulturen 48 hpi 
dramatisch verändert. Bei Zellen aus solidem Tumorgewebe erfolgen 42 Tage nach Infektion 
ebenfalls derartige dramatische Veränderungen. Mittels Massenspektroskopie wurden in GI-
101A-Zellen 68, in HT-29-Zellen 75 und in PC-3-Zellen 159 alteriert exprimierte zelluläre 
Proteine nach VACV-Infektion beobachtet. Davon werden 30, 23 bzw. 49 hochreguliert und 
38, 52 bzw. 110 niederreguliert. Diese „up“- bzw. „down“-Regulation erfolgte zwischen 12 
und 48 h nach Virusinfektion. In Virus-besiedelten Xenograft-Tumoren wurden mittels 
Massenspektroskopie in GI-101A-, HAT-29- bzw. PC-3-Tumoren 270, 101 bzw. 91 alteriert 
exprimierte Proteine festgestellt. Von diesen wurden zwischen 7 und 42 Tagen nach Infektion 
89, 70 bzw. 40 „up“-reguliert und 181, 31 bzw. 51 „down“-reguliert. 
Interessanterweise sind die in den Zelllinien differentiell regulierten Proteine meist mit 
metabolischen Prozessen, besonders mit dem primären Energiemetabolismus wie Glucose-
Katabolismus, Zitronensäurezyklus und der Milchsäure-Produktion assoziiert. Eine VACV 
GLV-1h68-Infektion generall führt zur Umfunktionierung des Wirts-Translationsapparates 
zur Synthese von Virusproteinen, zur Umgestaltung des Zytoskeletts und zur Derangierung 
des Ubiquitin-anhängigen Proteasom-Abauweges. 
Insbesondere in Virus-infizierten Tumor-Xenograften ist eine weitere Palette von 
zellulären Prozessen alteriert. Dies umfasst die Signaltransduktion (einschließlich derjenigen, 
die zum Zelltod führen), Transportprozesse (hier ist vor allem der Eisentransport betroffen) 
und die Zellmigration. Ein gemeinsamer Signalweg, der sowohl in Zelllinien als auch in den 
Tumoren hochreguliert ist, ist die „unfolded protein response (UPR)“. Bemerkenswerterweise 
beeinflusst die VACV GLV-1h68-Infektion die anti-apoptotischen Signalwege in GI-101A 
und PC-3-Zellen, deren korrespondierende Tumoren nach Virusinfektion eine Regression 
aufweisen (regressive Tumoren), nicht jedoch in HT-29-Xenograften, die nach Infektion nicht 
mit Regression reagieren (nicht-regressive Tumoren). So werden z.B. in Virus-infizierten GI-
101A-Xenograften 12 Proteine mit Anti-Apoptose-Funktion vermindert exprimiert, darunter 
tumor protein-translationally-controlled (H-TPT1), rho-GDP-dissociation inhibitor alpha (H-
GDIa), ywhaq protein (M-1433T), H-PRDX4, serin/theronin-protein phosphatase-2A-
catalytic subunit beta isoform PP2A (M-Ppp2cb), eukaryotic translation initiation factor 2-
subunit alpha-35kDA (H-eIF2), H-actinin-α1 (ACTN1), annexn A1 (H-A1), annexin A5 (H-
A5), mouse albumin 1 (M-Alb1), dimethylarginine dimethylaminohydrolase 2 (H-DDAH2). In 
PC-3-Xenograften werden lediglich drei anti-apoptotisch aktive Proteine, ARP3 actin-related 
protein-3-homolog (H-ARP3), human FLNA protein und rho GDP dissociation inhibitor 
(GDI) alpha (H-GDIa), niederreguliert.  Im Gegensatz dazu werden in den nicht-regressiven 
HT-29-Tumoren anti-apoptotische Proteine sogar verstärkt exprimiert. Diese gehören vor 
allem zu den Peroxiredoxin-Proteinen. Diese Erkenntnisse geben Hinweise darauf, mit 
welchen Mechanismen HT-29-Tumorzellen der Apoptose entgehen. Die Vaccinia-Virus-
Infektion scheint vor allem die UPR und Anti-Apoptose-Proteine zu beeinflussen. 
Weitere Untersuchungen sind in Zukunft nötig, um im Detail herauszufinden, wie die 
VACV-Infektion die UPR in Tumorzellen induziert und ob einige Elemente der UPR 
möglicherweise neue Ansätze zu einer verbesserten Tumortherapie darstellen könnten. 
 
 
 
 
 
 
 
  
 
 
ABSTRACT 
 
 
 
          VACV GLV-1h68 was reported as a diagnostic/therapeutic vector which enters, 
replicates in, and reveals the locations of tumors in mice. Furthermore, the effect on tumor 
colonization, on tumor growth, regression and eradication by VACV GLV-1h68 without the 
need of any known genes with anti-tumoral activities was determined. To investigate 
differential protein expression between infected tumor cells and corresponding tumors, as 
well as between infected tumor cells, between infected tumors, proteomics is particularly 
used, possibly contributing to the understanding oncolytic ability on the protein level of 
VACV GLV-1h68. 
The given effects of VACV GLV-1h68 infection on cellular protein expression 
support tumor cell killing. In this study, differential protein expression was analyzed at 
different time points with two-dimensional gel electrophoresis (2DE) followed by MALDI-
TOF/TOF identification. Comparative analysis of multiple 2-DE gels revealed that the 
majority of protein expression changes appeared at 48 hours post infection in cell cultivation 
and at 42 days post infection in tumors. Mass spectrometry identified 68, 75, 159 altered 
cellular proteins in the GI-101A, HT-29, PC-3 infected cells, respectively, including 30, 23, 
49 up-regulated proteins and 38, 52, 110 down-regulated proteins 12 to 48 hours after 
infection. For xenografts, mass spectrometry identified 270, 101, 91 altered cellular proteins 
in the infected GI-101A, HT-29, PC-3 tumors, respectively, including 89, 70, 40 up-regulated 
proteins and 181, 31, 51 down-regulated proteins 7 to 42 days after infection.  
In general, in the cell lines, the proteins found to be differentially regulated are most 
often associated with metabolic processes, in particular with primary energy metabolism 
(glucose catabolism, TCA and lactate production). VAVC GLV 1h68 infection results in 
hijacking of the host translation apparatus, alteration of cytoskeleton networks, induce 
ubiqitin proteasome pathway (UPP) disorders. 
Particularly in tumors, the responses cover a much broader panel of cellular processes, 
including signalling (e.g., cell death), transport (in particular of iron ions) and migration. A 
common pathway to be up-regulated in both tumors and cell lines is the "unfolded protein 
response". Notably, VACV GLV-1h68 affected the anti-apoptosis pathways in GI-101A and 
PC-3 cancer cells but not in HT-29 xenografts. For example, GI-101A xenografts in mice 
appear 12 proteins associated with anti-apoptosis function. They were found down-regulated, 
including tumor protein-translationally-controlled (H-TPT1), rho-GDP-dissociation inhibitor 
alpha (H-GDIa), ywhaq protein (M-1433T), H-PRDX4, serine/threonine-protein 
phosphatase-2A-catalytic subunit beta isoform PP2A (M-Ppp2cb), eukaryotic translation 
initiation factor 2-subunit 1  alpha-35kDa (H-eIF2), H-actinin-α1 (ACTN1 ), Annexin A1 (H-
A1), annexin A5 (H-A5), Mouse albumin 1 (M-Alb1),  dimethylarginine 
dimethylaminohydrolase 2 (H-DDAH2). In PC-3 xenografts, anti-apoptosis expression is 
lesser than those in GI-101A cells, however 3 anti-apoptosis associated proteins were down-
regulated such as ARP3 actin-related protein-3-homolog (H-ARP3), Human FLNA protein, 
Rho GDP dissociation inhibitor (GDI) alpha (H-GDIa). In contrast, in HT-29 xenografts, 
there are several anti-apoptosis-associated proteins that show even to be up-regulated; they 
mostly belong to peroxiredoxin proteins. Lesson from HT-29 had been given what various 
means the HT-29 cells use to escape their apoptosis fate. This suggests that VAVC GLV1h68 
infection may induce unbalance of unfolded protein response (UPR) but tending to anti-
apoptosis-mediated proteins and promote the destructive elements of UPR, including caspase-
12 cleavage and apoptosis. 
Taken together in this thesis research I have tried to compare protein profiles obtained 
from responder cell line and from regressing solid tumors colonized by VAVC GLV-1h68 
with that of non-responding tumors. I also compared these data with PC-3 prostate cell line 
and tumor data on intermediate responder which alter mouse protein profiling in tumors 
similarly to the highly efficacious GI-101A breast tumor cell line. From these comparisons I 
have deduced exciting protein pattern signature characteristic for a responder or distinctly 
different from non-responder system. Combining these few crucial genes involved with the 
transcriptional test data obtained by fellow graduate student at NIH a novel national designed 
VACV GLV-1h68 strains with enhanced efficacy in many today non-responder cancer cell 
lines will be available to be tested into ongoing clinical trials.  
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            1. INTRODUCTION 
 
 
1.1 Vaccinia virus as a representative oncolytic virus 
 
An oncolytic virus is a virus that is able to infect and lysis cancer cells, while leaving 
normal cells unharmed, making them potentially useful in cancer therapy. Replication of 
oncolytic viruses both facilitate tumor cell destruction and also produce dose 
amplification at the tumor site. They may also act as vectors for anticancer genes, 
allowing them to be specifically delivered to the tumor site. 
Tremendous advances have been made in developing oncolytic viruses in the last few 
years. By taking advantage of current knowledge in cancer biology and virology, specific 
oncolytic viruses have been genetically engineered to target-specific molecules or signal 
transduction pathways in cancer cells in order to achieve efficient and selective 
replication. Oncolytic viruses utilize multiple mechanisms of action to kill cancer cells, 
cell lysis, cell apoptosis, anti-angiogenesis and cell necrosis. Once the virus infects the 
tumor cell, it compromises the cell's natural defense mechanisms, giving the virus extra 
time to thrive. The virus then begins to replicate. The virus continues to replicate until 
finally the tumor cell can no longer contain the virus and "lyses" (bursts) the host cell's 
membrane. The tumor cell is destroyed and the newly created viruses are spread to 
neighboring cancer cells to continue the cycle. It is important to remember that all 
oncolytic viruses are intended to replicate only in cancer cells and to pass through normal 
tissue without causing harm. Hence, once all the tumor cells are eradicated, the oncolytic 
virus no longer has the ability to replicate and the immune system clears it from the body. 
 In other way, the viral infection and amplification eventually induce cancer cells into cell 
death pathways and elicit host antitumor immune responses to further help eliminate 
cancer cells. Specifically targeted molecules or signaling pathways (such as RB/E2F/p16, 
p53, IFN, PKR, EGFR, Ras, Wnt, anti-apoptosis or hypoxia) in cancer cells or tumor 
microenvironment have been studied and dissected with a variety of oncolytic viruses 
such as adenovirus, herpes simplex virus, poxvirus, vesicular stomatitis virus, measles 
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virus, Newcastle disease virus, influenza virus and reovirus, setting the molecular basis 
for further improvements in the near future.  
In one of the most successful stories in medical history, vaccinia virus (VV) was utilized 
as the vaccine for worldwide smallpox eradication. Recombinant VV and other related 
poxviruses have served as vectors for gene delivery and as vaccines for infectious disease 
and cancer (Guo ZS and Bartlet DL 2004). Despite the fact that it has been used as a 
vaccine and a gene expression vector for many years, it is only in the last decade that VV 
has been specifically genetically engineered and explored as an oncolytic virus 
(Timiryasova TM et al., 1999; Bartlett DL et al., 2001; Thorne SH et al., 2005).  
 
1.2 Vaccinia virus biology 
 
The biology of vaccine viruses makes them suitable for adaptation to oncolytic vectors, 
the extensive use of vaccinia virus for both clinical and research purposes has led to the 
emergence of multiple strains with unique properties. Their large genome size makes 
them ideal promising vectors as it allows insertion of large numbers gene for viral 
therapeutic approaches.  
 
1.2.1 Vaccinia virion structure and life cycle 
 
Vaccinia virus (VV) is a member of the Poxviridae family (Esposito JJ and Frenner F 
2001; Moss B 2001). The true origin of VV remains obscure. When Edward Jenner, an 
English country physician, used the material that he isolated from a milkmaid as a 
vaccine for smallpox, he was in fact using cowpox virus (Jenner E 1798).  In the 1930s, it 
became clear that the strain being used at that time for smallpox vaccination was distinct 
from the cowpox. Later, this strain was identified as vaccinia (Fentiman IS et al., 1986). 
The genome consists of 191,636 bp and encodes for 2063 proteins of 65 or more amino 
acids. These proteins are used to construct the mature virion, which includes a double 
membrane. The infectious mature virion or extracellular enveloped virus (EEV) is 
released from the cell by membrane fusion and is responsible for cell-to-cell spread of the 
virus. The intracellular mature virus (IMV) is released from the cell upon lysis, and is the 
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form of the virus that is produced under laboratory conditions. The EEV is too fragile to 
withstand the purification process. The mechanism of vaccinia attachment and uptake 
into cells is still under intense investigation. This process is likely to involve the A27L 
and D8L proteins, which are found in the IMV membrane and appear to bind heparin 
sulfate and chondroitin sulfate on the cell surface (Hsiao JC et al., 1999; Chung CS et al., 
1998) Fusion is quickly followed by release of viral-transported transcriptional enzymes 
that transcribe early viral mRNA. These early mRNA typically encode for proteins that 
are involved with uncoating of the viral DNA and transcriptional factors for intermediate 
mRNA production. Intermediate mRNA encodes for the late transactivators that lead to 
late mRNA synthesis. The late proteins include viral structural proteins and early 
transcriptional factors to be incorporated into the mature virion (Moss B and Earl PL 
1998). Viral DNA replication occurs, forming concatemers, which are then resolved into 
individual genomes and assembled into mature virions. The mature virus contains three 
membranes after assembly; the outer fuses with the cell membrane, resulting in release of 
a double-membrane viral particle (EEV). The EEV remains attached to the cell surface 
through the A34R gene product, allowing for cell-to-cell spread of the virus (McIntosh 
AAG and Smith GL 1996). The EEV form is resistant to antibody neutralization. It is 
interesting to note that the vaccinia virus, like the other poxviruses, spends its entire 
lifecycle in the cytoplasm and has never been shown to integrate into the genome (Moss 
B and Earl PL 1998). IMVs represent the most abundant form of the virus and are 
retained in the cell until lysis. CEVs and EEVs are important for virus dissemination 
(Payne LG 1980; Smit G-L 2002). 
  
1.2.2 Interactions with host cells 
 
In order to make the cell an ideal environment for virus survival and replication, the 
invading VV must alter the cell in several ways.  
To inhibit of host cell macromolecular synthesis, VV were found to inhibit DNA, RNA, 
and protein synthesis in the cells they have infected. Vaccinia has very few interactions 
with host cellular proteins, allowing for rapid, efficient replication without negative 
effects from host cell defenses (Stephen McCraith et al., 2000). The virus induces a 
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profound cytopathic effect very soon after viral entry, as early viral enzymes completely 
shut down host cell function. By 4–6 hours after infection, there is almost complete 
inhibition of host protein synthesis. This allows for very efficient expression of viral 
genes and viral replication (Avirup Bose et al., 1997). In fact, approximately 10,000 
copies of the viral genome are made within 12 hours of infection; half of these are 
incorporated into mature virions and released. The success of vaccinia as an oncolytic 
vector relies on its efficiency in vivo. This is dependent on the rapidity of replication and 
spread, and evasion of host defenses (Geoffrey L Smith 1999).  
To defend against host antiviral mechanisms, there are several ways. Firstly, VV encode 
virokines which are secreted from infected cells and mimic host cytokines and therefore 
attach to and block host cytokine receptors (Johnston JB and Grant McFadden 2003), 
encode viroceptors which are essentially cellular receptors that do not contain a 
transmembrane domain, they are secreted from infected cells and bind their ligands, 
preventing their normal activity (Johnston JB and Grant McFadden 2003), intracellular 
proteins which can block the cytokine or complement-induced pathways within the cell 
itself, and encode complement regulatory protein. These products of the VV infection 
cause combat the host's antiviral complement and cytokines. Secondly, following the 
interferon patways, VV produce a dsRNA-binding protein (E3L, K3L) that blocks the 
PKR-mediated cellular reponse to IFN (Garc MA et al., 2007). Thirdly, VV can induce 
interleukins (secreted protein that mimics the mammalian proteins cause sequesters and 
blocks its pathways) or tumor necrosis (Johnston JB and Grant McFadden 2003; Bruce T 
Seet et al., 2003). Fourthly, VV produces chemokine that binds chemokine receptors and 
prevents their normal ligand from binding or bind to the chemokines themselves and 
prevent leukocyte stimulation (Jens Y Humrich et al., 2007). The last, E3L protein of VV 
can block apoptosis pathway (John M Taylor and Michele Barry 2006). 
 
1.3 Genetic engineering for tumor-selective replication 
  
Vaccinia virus strains may possess a natural tumor tropism after systemic delivery in 
mouse models (Acres B et al., 1994; Peplinski GR et al., 1996; McCart JA et al., 2001). 
Part of the reason for this may be in the fact that VV activates cell-signaling pathways 
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and alters the progression of the cell cycle upon infection by inactivation of the tumor 
suppressors‟ p53 and pRb. This may contribute to more efficient replication of the virus 
in rapidly growing cells such as many cancer cells (Yoo NK et al., 2008). As a large 
virus, 250×350 nm in size, it may also require leaky vasculature for extravasations from 
circulation and into tissues. Tumor tissues are well documented for their vascular 
endothelial growth factor (VEGF) production and leaky vasculature. A number of 
strategies have been designed to further enhance viral replication in cancer cells and 
reduce replication in normal cells and thus maximize its safety. 
To determine the location of viral particles in the rodents with tumors, vaccinia virus 
carrying the firely luciferase expression cassette has been injected intravenously (Grant 
MFX et al., 1999). Subsequent luciferase assays of homogenates of excised individual 
organs and tumors reveal 3 to 500 fold enhancement of light emission in the tumor 
samples, showing the accumulation of viral particles. The Renilla reniformis luciferase-
Aequorea victoria green fluorescent (GFP) fusion protein (RUC-GFP) (Wang Y et al., 
1996; Wang Y et al., 2001) allows real-time monitoring of gene activation in the live 
animals base on luciferase activity and GFP fluorescence (Wang Y et al., 2002), the 
activity of the RUC-GFP expression cassette inserted into  vaccinia virus DNA (rVV-
RUC-GFP) has been imaged in both virus-infected mammalian cell  cultures and in virus-
infected live animals (Tymiryasova T et al., 2000). Interestingly, authors show that 
vaccinia virus survived and replicated in the tumors for weeks without causing viremia, 
this was observed in both immunocompromised and immunocompetent animals with 
allergenic and syngeneric tumors (Yu YA et al., 2004). Base on their “Tumor-finding” 
nature. Viruses may be designed to carry multiple genes for detection and treatment of 
cancer. 
 Aberrant epidermal growth factor receptor (EGFR) signaling is a major characteristic of 
a number of human malignancies including breast cancer, lung cancer, colon cancer, and 
head and neck cancer. Alterations in the functions of the EGFR signaling pathway are 
associated with oncogenic transformation and are associated with essentially all of the 
key features of cancer, such as autonomous cell growth, invasion, angiogenic potential, 
and development of distant metastases (Yarden Y 2001). Vaccinia growth factor (VGF), 
a 19-kD secreted glycoprotein encoded by the virus, shares sequence homology and 
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functional properties with cellular growth factors, EGF and TGF-α. Like EGF and TGF-
α, VGF binds and induces tyrosine phosphorylation of the EGF receptor. Early work by 
Moss and associates demonstrated that viral genes encoding both thymidine kinase (tk) 
and vaccinia growth factor (vgf) are virulence genes and are needed for efficient viral 
replication in normal cells in vivo (Buller RM et al., 1985; Buller RM et al., 1988). When 
the tk gene was deleted from the viral genome of the WR strain of VV, the resulting virus 
displayed reduced replication in normal cells and yet retained full capacity to replicate in 
cancer cells (McCart JA et al., 2001; Puhlmann M et al., 2000). When both viral genes 
for VGF and TK were deleted, the resulting virus (vvDD) retained its ability to target and 
replicate in cancer cells both in vitro and in vivo, and displayed significant oncolytic 
potency in multiple tumor models (McCart JA et al., 2001; Chalikonda S et al., 2008). 
This virus was found to be dependent on cellular TK for viral replication, which is 
expressed to high levels in cancer cells as a result of aberrant EGFR signaling leading to 
E2F-mediated TK expression. The additional deletion of the vgf gene prevented 
activation of EGFR signaling in noncancer cells, further restricting viral replication to 
cancer cells (Thorne SH et al., 2007). The addition of GM-CSF gene to this virus was 
further found to be very useful for combination oncolytic immunotherapy. Systemic 
administration of this virus (JX-963) led to systemic efficacy against both primary 
carcinomas and widespread metastases in immunocompetent hosts (Thorne SH et al., 
2007). In addition, by taking advantage of cancer cells' ability to evade apoptosis, the 
deletion of two viral genes (B22R and B13R) encoding anti-apoptotic proteins and 
serpins SPI-1 and SPI-2 was examined. The resulting virus, named vSP, displayed 
enhanced tumor targeting, yet significant oncolytic potency in a tumor model (Guo ZS et 
al., 2005). The tumor selectivity could be explained at least partly by the fact that normal 
cells infected with vSP die with faster kinetics and thus viral replication is limited, while 
viral replication in cancer cells is sustained. However, there is a limitation to the strategy 
of deleting nonessential viral genes as illustrated in a new VV (vSPT) with a triple 
deletion of viral genes, spi-1, spi-2 and tk. This virus showed remarkable tumor 
selectivity, yet lost significant oncolytic potency in tumor models in vivo (Yang ST et al., 
2007). Other strains of VV have also been explored as oncolytic virus which Szalay et al. 
have described an oncolytic VV based on insertion of reporter genes into three viral sites 
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[J2R (TK), A56R (HA) and F14.5L] in the LIVP strain (Zhang Q et al., 2007). This virus, 
GLV-1h68, replicated poorly in normal mouse cells yet replicates well in cancer cells. It 
was also found to cause tumor regression in a human breast cancer xenograft in nude 
mice. Gene expression profiling of regressing tumors revealed gene expression signatures 
consistent with immune defense activation. A replication-competent vaccinia virus has 
significant infectious and oncolytic activity against a panel of human anaplastic thyroid 
carcinoma (ATC), these results encourage future in vivo and clinical studies for this 
novel agent to treat this fatal cancer (Lin SF et al., 2007).  So far, genetic engineering 
may further enhance the oncolytic potency and safety of viruses. 
 
1.4 Mechanisms of tumor escape 
 
Understanding the escape immune mechanism of tumors help to manipulate and estimate 
effectively using oncolytic viruses for cancer therapy appropriately. Despite an active and 
apparently normal immune response by a healthy immune system, tumor cells can grow, 
invade and metastasize in the host (Pardoll D 2003). Tumor cells can escape or fail to 
elicit anti-tumor immune responses by various mechanisms. They are phenotypically and 
genetically less stable than normal cells and can rapidly change to escape immune 
destruction. One of these escape mechanism is production of inhibitory cytokines by the 
tumor. 
Targeting tumor-associated macrophages (TAMs) is a novel trategy against cancer 
(Yunping Luo et al., 2006). TAMs are known as factors associated with tumor 
progression and metastasis. Decreasing the number of TAMs in the tumor stroma 
effectively altered the tumor microenvironment involved in tumor angiogenesis and 
progression to markedly suppress tumor growth and metastasis. Gaining better insights 
into the mechanisms required for an effective intervention in tumor growth and 
metastasis may ultimately lead to new therapeutic targets and better anticancer strategies 
(Luo Y et al., 2006). In recent studies, anti-TAM effects induced by small molecule 
inhibitors contributed to tumor suppression (Lewis C and Murdoch C 2005; Mantovani A 
et al., 2004). For example, the anti-neoplastic agent Yondelis has a selective cytotoxic 
effect on TAMs, thereby significantly reducing their production CCL2/MCP-1 
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(Monocyte chemotactic protein-1), which, in turn, contribute to growth suppression of 
inflammation-associated human tumors (Allavena P et al., 2005). MCP-1, a specific 
chemotactic and activating signal for monocytes, is expressed mainly by tumor cells as 
well as by endothelial cells, fibroblasts, and macrophages in human tumors (Mantovani A 
1994). Some studies have suggested that MCP-1 may be the main determinant of the 
macrophage content in tumors (Graves DT et al., 1989). and it is highly expressed in a 
wide range of tumor types including glioma (Leung SY et al., 1997), meningioma (Sato 
K et al., 1995), ovarian carcinoma (Negus RP et al., 1995), and squamous cell carcinoma 
of uterine cervix (Riethdorf L et al., 1996). Indeed, in a study of the poorly differentiated 
lymphoepithelioma-like carcinoma of the lung, Wong et al. (Wong MP et al., 1998) 
identified a close association between the up-regulation of MCP-1 by tumor cells and 
TAM accumulation. Moreover, MCP-1 expression by both tumor cells and TAMs 
themselves was positively associated with TAM accumulation in breast carcinoma (Ueno 
T et al., 2000). It also correlated significantly with levels of the angiogenic factors 
vascular endothelial growth factor (VEGF), thymidine phosphorylase (TP), tumor 
necrosis factor alpha (TNFa), and interleukin-8 (IL-8). The authors also noted that 
increased expression of MCP-1 as well as VEGF was a significant indicator of early 
relapse and suggested that MCP-1 may play an important role in the regulation of 
angiogenesis. MCP-1 may therefore be considered a pro-tumorigenic protein. Moreover, 
in a study by Sica et al. (Sica A. et al., 2000), the chemokine receptor CCR2, to which 
MCP-1 binds, was found to have a potential pro-tumorogenic role. TAMs from solid 
ovarian carcinoma or ascites displayed defective CCR2 mRNA and surface expression 
and did not migrate in response to MCP-1. This suggested that receptor inhibition may 
serve as a mechanism to arrest and retain recruited TAMs at sites of tumor growth. As 
neutralizing antibodies for TNFa restored the CCR2 levels expressed by monocytes 
(cultured in the presence of ascitic fluid), the authors suggested that down-regulation of 
CCR2 expression by such pro-inflammatory molecules as TNFα may account for the 
defective migration of macrophages and their inability to mount an effective 
inflammatory response to the tumor.  
In a different experimental model, the chemokine CCL5/RANTEST (regulated upon 
activation, normal T-cell expressed and secreted) was shown to be key in the recruitment 
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of TAMs, and an antagonist of this chemokine reduced the tumor infiltrate and slowed 
tumor growth (Robinson SC et al., 2003). CCL5 (or RANTES) is an 8 kDa protein 
classified as a cytokinechemotactic or chemokine CCL5 is chemotactic for T cell, 
eosinophils and basophils, and plays an active role in recruiting leukocytes into 
inflammatory sites. To investigate the role of tumor-derived CCL5 (regulated upon 
activation, normal T cell expressed and secreted, RANTES) in tumor immunity, Adler et. 
al., 2003 indicate that tumor-derived CCL5 can inhibit the T cell response and enhance 
the in vivo growth of murine mammary carcinoma (Evan P Adler et al., 2003). 
Tumor immune escape is a critical trait of cancer but the mechanisms involved have to be 
fully described yet. VCAM-1, also known as CD106, is a molecule with a well-
characterized role in the human immune system. It contains six or seven immunoglobulin 
domains and is expressed by many different cell types, including activated endothelial 
cells, bone marrow stromal cells, spleen stromal cells, thymic epithelial cells, peripheral 
lymph node (LN) and mesenteric LN high endothelial venules, and some dendritic cells 
in the spleen. Up-regulation of VCAM-1 in endothelial cells is induced by the cytokines 
IL-1h, IL-4, tumor necrosis factor-a, and IFN-g. VCAM-1 is an endothelial ligand for 
very late antigen-1 (VLA-4; or a4h1 integrin) and a4h7 integrin. The interaction between 
VCAM-1 and VLA-4 or a4h7 integrin, expressed on leukocytes, is thought to be involved 
in the extravasation of leukocytes through the endothelium to sites of inflammation 
(Petruzzelli L et al., 1999; Kobayashi H et al., 2007). One recent study has shown that 
tumor cells can escape T cell immunity by overexpressing the endothelial cell adhesion 
molecule vascular cell adhesion molecule-1 (VCAM-1), which normally mediates 
leukocyte extravasion to sites of tissue inflammation. Renal cell carcinoma was identified 
as one tumor type where VCAM - 1 is commonly highly overexpressed (Wu T-C 2007). 
VCAM-1 expression by tumor cells led to decreased apoptosis of the tumor cells and a 
significant decrease in the number of tumor-infiltrating CD8+ T cells in the tumors 
expressing VCAM-1 (Wu T-C 2007). 
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1.5 Proteomic strategies and their application cancer research 
 
1.5.1 Cancers 
 
Cancer is a complex disease and represents the end product of a multistep biological 
process including growth and survival of neoplastic cells at the primary tumor site, 
invasion of the host tissue, angiogenesis, intravasation and survival in the circulatory 
system, arrest and extravasation into a new tissue and finally growth at the secondary site 
(Alessandro R and Kohn EC 2002; Fidler IJ 2003). Despite the knowledge of genetic 
mechanisms driving some of these events at the tissue level, biochemical endpoints are 
not fully characterized nor are treatments optimized. The ability to accurately profile 
cancer on a molecular level would have a profound effect on the quality of treatment. 
Research activities in cancer have focused on the genomic characteristics of cancer cells. 
Until now, the output from this strategy has not been enough in itself and needs to be 
paired with a conceptual return to proteins as the real key players in all physiological and 
pathological processes (Wiesner A 2004). 
 
1.5.2 Cancer proteomic 
 
The proteome is defined as complete set of proteins encoded by the genome, including 
splice variant and post translational modifications, for particular organism, tissue, cell or 
subcellular component (Wilkins MR et al., 1996). Proteomics represents technologies for 
analysis of the proteome under a given set of physiological or developmental conditions. 
The term “cancer proteome” refers to the collection of proteins expressed by a given 
cancer cell and should be considered as a highly dynamic entity within the cell, which 
affects a variety of cellular activities. The emerging proteomic analysis platforms 
including 2D-PAGE, mass spectrometry technologies, and protein microarrays represent 
powerful tools to study and understand cancer. These systems aim to not only identify, 
catalogue, and characterize cancer proteins, but also to unveil how they interact to affect 
overall tumor progression. In neoplastic cells, proteins encoded by oncogenes or tumor 
suppressor genes are the effecter molecules in malignancy since they are critical 
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components or regulate the multiple interconnected signaling pathways that drive the 
metastatic phenotype (McCormick F 1999; Blume-Jensen P and  Hunter T 2001). High-
throughput genomic techniques have facilitated a better understanding of gene expression 
in cancer but are not adequate for thorough dissection of such a complex disease as 
cancer at the molecular level. Genomic techniques suffer a limitation in their ability to 
monitor changes in protein levels, co- and post-translational modification events, protein-
protein interactions, topographical distribution and distribution of factors across the 
varied cellular compartments. Moreover, genomic techniques cannot predict the 
activation state of signaling molecules in important protein networks. Our understanding 
of the molecular basis of tumor progression and metastasis needs to be developed through 
a detailed study of the proteins themselves. Although cancer is a genetic disease, it is a 
disease of proteins from a functional point of view in where the phenotype is often the 
result of deranged signaling pathways. (Herrmann PC et al., 2001; Petricoin EF et al., 
2002). Therefore, cancer proteomics aims not only to identify, catalogue, and 
characterize relevant proteins, but also to understand how they interact to affect the 
overall initiation and metastatic progression.  
 
 
1.5.3 Principles and technological platforms 
 
At the beginning of proteomics, the field was mainly decribed by the use of two-
dimensional polyacrylamide gel electrophoresis (2D-PAGE), traditionally performed to 
separate complex mixtures of proteins. Although this technique has some limitations for 
generally research applications, it still represents a powerful tool to study the protein 
profile of cell lysates or biological fluids. A major advantage to the use of 2D gels was 
the ability to identify gel-separated proteins by mass-spectrometry techniques as matrix-
assisted laser desorption ionization time of flight (MALDI-TOF) and electrospray 
ionization tandem MS (ESI-MS/MS) (Pandey A and Mann M 2000). Another emerging 
technique in proteomic research is the on-line reversed phase liquid chromatography 
tandem mass spectrometry (LC/MS/MS) that permits the sequencing of thousands of 
peptides produced by trypsinization of proteins from a single sample (cell lysate or serum 
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sample) (Peng J and Gygi SP 2001). A refinement of MALDI, involving the spotting of 
the biological sample onto a treated surface, is the surface-enhanced laser desorption and 
ionization time-offlight (SELDI-TOF).  
 
1.5.3.1 Two-dimensional polyacrylamide gel electrophoresis (2-DE) 
 
This procedure is based on the use of immobilized pH gel gradients to separate proteins 
by their isoelectric points, followed by SDS PAGE to further separate the proteins on the 
basis of their molecular mass. A map of several hundred spots can be resolved in a single 
gel where each spot represents a different protein, different isoforms of the same protein, 
or its post-translational modifications (Sivakumar A 2002). Protein profiles can be 
scanned and quantified to search for changes in the levels of pre-existing proteins, for 
mutated proteins, or for other types of variants. The qualitative and quantitative analysis 
of 2D maps is supported by specific powerful software packages, such as 2D-
DECODON. However, a major limitation of 2-DE is the inability to resolve and quantify 
proteins of low abundance. Other disadvantages of this method are due to the complexity 
and time-consuming nature of the procedure, the difficulty in separating hydrophobic as 
well as very large or very small proteins, and the inability to distinguish changes due to 
modification of truly novel proteins (Riccardo Alessandro et al., 2005).  
 
1.5.3.2 Mass spectrometry 
 
Matrix-assisted laser desorption ionization time of flight (MALDI-TOF) is currently the 
most accessible technique for most researchers and is used to identify proteins by peptide 
mass fingerprinting (PMF). In this technique the masses of tryptic peptides, generated 
after enzymatic degradation of gel-separated proteins, are measured at high accuracy (100 
ppm or better). Molecular ions from the peptide samples are produced using a laser 
source and then introduced in an analyzer that resolves ionized fragments on the basis of 
their mass-to-charge (m/z) ratio. MALDI-TOF is extensively used to determine peptide 
mass fingerprinting, allowing the identification of proteins by matching the experimental 
calculated peptide masses with spectra predicted by a “theoretical” trypsin digest of a 
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protein database. MALDI-TOF data are relatively easy to interpret since most peptides 
carry only one charge and are present as single peaks in a spectrum (Henzel WJ et al., 
1993; Srinivas PR et al., 2000; Rowley A et al., 2000). The limitations of MALDI-TOF 
are that only about 60% of proteins can be identified. Furthermore, factors that alter 
peptide masses from those stored in the database (e.g. post-translational modifications) 
can invalidate the search method. Also small proteins do not often generate sufficient 
numbers of digestion products for identification. When MALDI-TOF fails to 
unequivocally identify a protein, it is necessary to employ electrospray ionization tandem 
MS (ESI-MS/MS) to generate partial sequence information for database searching. 
MS/MS is a powerful separation tool of great value because in the presence of many 
other co-detected peptides, a single peptide ion can be selected, isolated, fragmented and 
sequenced (Peng J and Gygi SP 2001; Srinivas PR et al., 2000; Rowley A et al., 2000). 
Today, mass spectrometry techniques (both MALDI-TOF and MS/MS) are employed as 
a technology base for the relatively fast identification of proteins separated by 2D gels. 
These technologies have allowed a notable accumulation of knowledge concerning the 
proteomic profiles of several tumors. Recently, Friedman et al. (Friedman DB et al., 
2004) used 2D-DIGE coupled with mass spectrometry to investigate tumor-specific 
changes in the proteome of human colorectal cancer and adjacent normal mucosa. This 
approach detected over 40 statistically significant changes in protein abundance levels 
across the paired samples including alterations in vinculin, vimentin, microtubule-
associated protein, F-actin capping protein, cathepsin, and calgranulin B expression. 
Comprehensive proteomic expression profiles of normal mucosa, polyps, primary tumors 
and metastases from the same patients were generated by the group of Roblick and 
colleagues (Roblick UJ et al., 2008) using 2D PAGE and MS/MS sequence analysis in 
order to trace modifications of the proteome pattern corresponding to colon cancer 
development and progression at both the intra- and inter-patient level. Tissue biopsies 
from 15 patients were used and a total of 72 protein spots were identified and shown to 
be differentially regulated. These proteins belonged to cell cycle (elongation factor 1, 
translation initiation factor), cytoskeleton (mainly cytokeratins) or metabolic pathways 
(succinate dehydrogenase, 5-lipooxygenase, heat shock family proteins) (Gygi SP et al., 
1999). However, this approach has several limitations, especially when whole cell lysates 
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are analyzed. In 2D gels, very acidic or basic proteins, extremely large or small proteins, 
and membrane proteins are often excluded or underrepresented. Moreover, proteins of 
low abundance cannot be detected by two-dimensional electrophoresis without some 
method of previous enrichment. However, fractionation of whole cell lysates by itself can 
alter the results of quantitative analysis because some proteins are disproportionately 
distributed into different fractions. For all these reasons 2D/MS may not represent the 
most appropriate approach for large-scale, global proteome analysis (Peng J and Gygi SP 
2001). An alternative separation technique used as a new proteome analysis platform is 
reversed-phase liquid chromatography (LC) coupled with tandem MS (LCMS/MS). This 
method offers the possibility to isolate and sequence hundreds of selected peptides from 
one sample without previous 2D separation.  
Recently, the differentially expressed transcripts of vaccinia virus-infected tumor cells 
were analyzed by cDNA microarrays which provide an overview of the mRNA 
expression profiles of infected cells (Susana Guerra et al., 2004; Krystyna W et al., 
2003). The mRNA abundance is not always consistent with the protein level (Gygi, S. P. 
et al., 1999) and viral infection involves in post-translational modifications of diverse 
proteins, such as ubiquitination (Shackelford J and Pagano JS 2005), phosphorylation and 
glycosylation (Meredith DM et al., 1991), without affecting their transcription rate. 
Therefore, the proteomic analysis of host cellular responses to virus infection is more 
promising to probe potential cellular factors involved directly or indirectly in viral 
infection and to identify potential drug targets of antiviral treatment. To date, a small but 
increasing number of studies have used proteomic approaches to reveal the effects of 
viral infection on the cellular proteome (Maxwell KL and Frappier L 2007). The 
comparative proteomic approaches coupling 2-DE and mass spectrometry (2-DE/MS) 
effectively help the study of the molecular profiles of virus-infected cells (Tang H et al., 
2000). In plant viruses, 2-DE/MS has been used to study the cellular changes in rice 
yellow mottle virus-infected cells in susceptible and partially resistant rice cultivars 
(Ventelon-Debout M et al., 2004) and in tobacco mosaic virus-infected tomato (Casado-
Vela J et al., 2006) In animal viruses, 2-DE/MS has been utilized to investigate the 
cellular changes in Vero cells infected with African swine fever virus (Alfonso P et al., 
2004), rhabdomyosarcoma cells infected with enterovirus 71 (Leong WF and Chow VT 
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2006), nuclear proteome changes in A549 alveolar type II-like epithelial cells infected 
with respiratory syncytial virus (Brasier AR et al., 2004), and expression changes in B 
cells infected with Epstein-Barr virus (EBV) or with EBV nuclear antigen EBNA-2 
(Schlee M et al., 2004). In addition, several studies have used distinct protein separation 
methods, including difference gel electrophoresis (DIGE), isotope-coded affinity tags 
(ICATs), or multidimensional liquid chromatographic separations followed by liquid 
chromatography/tandem mass spectrometry (LC-MS/MS) identification to investigate the 
cellular response to infection by severe acute respiratory syndrome-associated 
coronavirus (SARS-CoV), flock house virus (FHV) and hepatitis C virus (Xiaojuan 
Zheng et al., 2008; Alexander Rassmann et al., 2006; Alessandro R and Kohn EC 2002). 
Therefore, the proteomic strategies provide an overall understanding of the cellular 
factors involved in various stages of infection and give an insight into the alteration of 
signaling pathways to further understand viral pathogenesis. 
 
1.5.4 Proteome analysis of human cancer 
 
1.5.4.1 Proteome analysis of human breast cancer 
 
Interesting results have been obtained from comparisons between human breast ductal 
carcinoma and histologically normal tissue. Proteins which express highly in all 
carcinoma specimens and less expressed and occasionally undetectable in normal tissue 
are GRP94, GRP78, GRP75, mitochondrial HSP60, calreticulin, protein disulfide 
isomerase, peptidyl-prolyl cis-trans isomerase, collagen-binding protein 2, fructose 
bisphosphate aldolase, glyceraldehyde-3-phosphate dehydrogenase, thioredoxin, 
cytochrome c oxidase Va subunit, tubulin beta isoform and macrophage migration 
inhibitory factor (MIF) were identified (Bini L et al., 1997). Also specific contributions to 
the overall knowledge of breast cancer biology have been provided by the study of 
proteomic profiles of cancer cells in culture. For example, analysis of the proteomic map 
of the 8701-BC cell line, which is derived from a primary ductal infiltrating carcinoma, 
has shown the coexpression of several forms of cytokeratin 8, cytokeratin 18 and 
vimentin. These are cytoskeletal markers of lumenal mammary epithelium and of 
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mesenchymal cells, respectively. This study has demonstrated that many features related 
to cancer cells (e.g. loss of polarity, defective cell-cell contacts, increased motility) reflect 
an epithelial-mesenchymal transition, as postulated for many carcinomas of different 
origins (Pucci-Minafra I et al., 2002). In particular, among the proteins with higher 
relative expression levels in cancer cells, several glycolytic enzymes and their isoforms 
were identified (Pucci-Minafra I et al., 2002). A proteomic approach by means of 2D-
PAGE was also applied to investigate the effects on protein expression in breast cancer 
cells by specific collagen molecules. With the use of a multivariate statistical procedure it 
was demonstrated that chaperons and heat shock proteins contributed most to changes in 
the observed protein expression, suggesting that this class of proteins may be involved in 
cellular responses following substrate interactions (Fontana S et al., 2004). Protein 
expression data obtained by 2D-PAGE analyses are stored in databases available world-
wide that document protein expression in several cell lines and normal and tumoral 
tissues. These databases provide an important and unique resource for scientists to 
identify changes in known protein levels or in new proteins in specific cancer histotypes, 
and can be exemplified by the EXPASY server in Geneva (SWISS-2DPAGE). 
 
1.5.4.2 Proteome analysis of human colon cancer 
 
Colorectal cancer represents an ideal model system to study the development and 
progression of human tumors, because epithelial cells of the colon mucosa often follow a 
systematic process of cellular proliferation, differentiation, adenoma formation, and, 
eventually, cancer transformation (Roberto Mazzanti et al., 2006). The first data 
describing the alteration of protein expression in transformed colon mucosa were 
published in the beginning of the 1980s (Jellum E et al., 1984; Tracy RP et al., 1982). In 
1983, Anderson et al. (Anderson KM et al., 1983) described differential distribution of 
acidic proteins in normal colon mucosa, primary colon adenocarcinoma, and colon 
metastases to the liver. With the use of the two dimensional gel electrophoresis (2DE) 
approach, several differences in protein expression in the cytosol of colon cancer 
samples, at various differentiation levels, were observed (Nalty TJ et al., 1988). 
Unfortunately, none of these proteins were identified. Keesee et al. (Keesee SK et al., 
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1994) detected the tumor-specific expression of six nuclear matrix proteins that were also 
present in a panel of colon tumor cell lines. This study reinforced the concept of 
differential protein expression by cancerous tissue, and it raised the problem of accuracy 
at extrapolating results from cancer cell lines to in vivo scenarios (Zhang L et al., 1997; 
Ramaswamy S et al., 2003). Specific expression of several nuclear proteins was observed 
by Szymczyk et al. (Szymczyk P et al., 1996) in human colorectal cancer tissue compared 
with normal matched mucosa. One of these proteins was a 36-kDa polypeptide that was 
absent in the normal colonic epithelium but present in 83% of the studied carcinomas. 
This protein might have served as a potential marker for colon malignancy, but, 
unfortunately, it was not identified, thus limiting its use and understanding of its function. 
The data on specific cancer-related proteins or cancer-related protein expression down-
regulation are still controversial. Recently, a 2-D electrophoresis database for human 
colon crypts, colorectal cancer cell lines (i.e., LIM 1215 and HT29), and colonic polyps 
of multiple intestinal neoplasia and p53-null mice has been set up by the Ludwig Institute 
for Cancer Research (Ji H et al., 1997; Simpson RJ et al., 2000; Stulik J et al., 1999). 
Stulik et al. (Stulik J et al., 1999) identified proteins that exhibit differential expression 
by comparing normal and malignant colon tissues.  
The most important cytosolic glycolytic and mitochondrial tricarboxylic acid cycle 
enzymes are basic proteins as demonstrated by the proteomic analysis of human colon 
crypt (Li, X. M. et al., 2004). Glycolysis has been shown to be elevated in almost all 
cancers, the so-called “Warburg effect” (Warburg O 1956). And many cancers show 
dysfunction of mitochondria (Verma M et al., 2003; Warburg O 1956; Altenberg B and 
Greulich KO 2004). The increased aerobic glycolysis for ATP generation in cancer cells 
is frequently associated with mitochondrial respiration defects and hypoxia (Isidoro A. et 
al., 2004). A recent report showed that inhibition of glycolysis in colon cancer cells could 
overcome drug resistance (against common anticancer agents) associated with 
mitochondrial respiratory defect and hypoxia (Xu RH et al., 2005). The mitochondrial 
enzyme succinate dehydrogenase, which links tricarboxylic acid cycle dysfunction to 
oncogenesis via hypoxia-inducible factor (HIF)-1_ was also demonstrated recently (Selak 
MA et al., 2005). 2-DE data for colon protein analysis showed up-regulation of glycolytic 
enzymes such as aldolase A, enolase 1, GAPDH, etc., The 2-DE data also revealed an 
 18 
 
impaired tricarboxylic acid cycle in CRC as evidenced by down-regulation of enzymes at 
the early entrance steps such as aconitase and aconitate hydratase and up-regulation of 
malate dehydrogenase at the exit step. These findings suggested extensive alterations in 
metabolic pathways that have not been well defined before (Xuezhi Bi et al., 2006). A 
recent report using 2-D DIGE and MS with the pH range of 4–7 found that in colon 
cancer some proteins such as succinate dehydrogenase subunit A, succinyl-CoA 3-
ketoacid coenzyme A transferase, aldehyde dehydrogenase, and carbonic anhydrase I 
were down-regulated, whereas several other proteins such as triosephosphate isomerase 
and keratins 8 and 18 were up-regulated (Friedman DB et al., 2004). Some new proteins 
(aconitase, phosphoenolpyruvate carboxykinase, UGDH, and UDP-glucose 
pyrophosphorylase 2) that exhibited altered expression level that have not been reported 
in CRC previously (Xuezhi Bi et al., 2006). It will be interesting to see whether the 
mechanism proposed above is applicable to other cancers. 
 
1.5.4.3 Proteome analysis of human prostate cancer  
 
A recent 2-DE-based analysis of surgical prostate cancer specimens found that they 
contained significantly increased levels of proliferating cell nuclear antigen (PCNA), 
calreticulin, heat shock protein 90 (HSP), HSP 60, oncoprotein 18(v), elongation factor- 
2, glutathione-S-transferase pi (GST-pi), superoxide dismutase, and triose phosphate 
isomerase (Alaiya A et al., 2000) This study also reported lower amounts of 
tropomyosin-1 and -2 and cytokeratin 18 in prostate cancer than in BPH. The same group 
reported in a subsequent study that 23 proteins out of 800 were somewhat different in 
amount between BPH and prostate cancer specimens (Alaiya AA et al., 2001). 
In other study, forty tumor-specific changes were identifed, and they included proteins 
involved in cellular morphology (tropomyosin-b), metabolism (aldolase A, L-lactate 
dehydrogenase M chain), and signal transduction (laminin receptor-67 kDa, 
phosphoserine-threonine-tyrosine interaction protein). Among the identifed proteins were 
two novel gene products that were downregulated in prostate cancer. One spot contains a 
putative kinase domain homologous to ATP-binding proteins, and the other is 
homologous to the thioredoxin peroxidase family. Several of the tumor-deregulated 
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proteins have been reported previously [tropomyosin-b (Alaiya AA et al.,  2001, Wang 
FL. et al., 1996) laminin receptor-67K (Waltregny D et al., 1997), and lactate 
dehydrogenase (Vrubel F et al., 1979)].  
Transcription factor (nucleoside diphosphate kinase 1) and enzyms involved in gene 
silencing (chromobox protein), protein synthesis (39-ribosomal protein L12, BiP protein, 
protein disulfide isomerase), degradation (cytosol aminopeptidase, endopeptidase, 
isocitrate dehydrogenase, NADH-ubiquinone oxidoreductase, pyruvate dehydrogenase) 
are among overexpressed proteins in the study of differential proteins expression in 
anatomical zones of prostate cancer (Lexander H et al., 2005). Other overexpressed 
proteins were heat-shock proteins (60 and 70 kDa), structural proteins (cytokeratins) and 
membrane proteins (stomatin-like protein 2). Nucleotide diphosphate kinase 1 is the 
product of NM-23H1, a metastasis suppressor gene known to be upregulated in early 
stage of prostate cancer. (Jensen SL et al., 1996). Lysophospholipase is related to 
proliferation and migration in cells and has been found at increased levels in ovarian 
cancer (Xie Y and Meier KE 2004). 
 
1.5.5 Proteomics analysis the differentially expressed of cancer cells infected  
with viruses 
 
Proteomics is the large-scale, systematic study of proteins, particularly their interactions, 
modifications, localization, and functions. Usually, the tools of proteomics are used to 
analyze modifications induced during the course of cell activation, differentiation, or 
transformation. However, several shortcomings have been noted in the proteomic study 
of host–microorganism interactions. These restrictions are mainly due to technical 
challenges arising from the high complexity of these systems (Anna Walduck et al., 
2004). Nevertheless, infection by intracellular parasites is a privileged model for this type 
of study, as it permits one to have a precise experimental control (for example, a non-
infected cell or infected cell variants) to compare protein profiles during infection. 
Depending on the different levels of interaction between microoganism and host, 
proteomics is of particular use in the following aspects such as: firstly, comparison of 
microbial proteomes from the same family but presenting a high or low expression in 
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different cell lines. Secondly, study of the modifications of cell proteins induced by viral 
infections, the impact on the host proteome by selective expression of parasite proteins 
can be also analyzed to understand their function. Thirdly, analysis of post translation 
modifications caused by the infection, especially phosphorylation, which may result in 
the activation of transcription factors or induction of metabolic routes involved in 
apoptosis. Fourthly, study of interactions between parasite and host proteins at different 
levels: taking over the transcriptional and translational machinery, association with 
intracellular transport structures, generation of parasite protein production factories, or 
sequestering of cell factors involved in morphogenesis and cell exit processes. Fifthly, 
both viruses and more complex parasites incorporate proteins from the infected cell once 
they emerge from it, proteomic analysis can define which proteins are incorporated into 
the parasite and their function in the life cycle; Finally, by using proteomics, it might also 
be possible to study complex interactions such as those related to the host–vector–
microorganism interplay, not only from the viewpoint of the vector, but also from that of 
the host and of the microorganism. 
Modification of host cell by infection with intracellular microorganism: this can modify 
the host cell metabolic pathways for their own benefit. In fact, microorganism often 
requires the replacement of existing host cell signaling pathways or membrane traffic 
machinery. Therefore, microorganism exposure may elicit changes in host proteins that 
can be gathered in many categories, including cell signaling pathways, protein 
degradation, cytokine and growth factor production, phagocytosis, apoptosis, as well as 
cytoskeletal rearrangement. These effects may be exerted immediately after the binding 
of the microorganism to the receptor on the cell surface, either by a new protein encoded 
by modifying the activity of a cellular protein, or by a microbial protein mimicking a 
cellular protein. Some of the most important cellular pathways modified by intracellular 
pathogens are explained and are summarized (Margo H Furman and Hidde L Ploegh 
2002). 
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1.5.5.1 Modification of apoptotic pathways in the host cell 
In any case, the tumor cell is killed by the oncolytic virus as it takes over the cellular 
translational and transcriptional machinery, ultimately leading to an induction of cell 
necrosis or apoptosis (Figure 1). 
 
 
Figure 1. Infecting and killing tumor cells by an oncolytic virus. a. Viruses interact with specific 
cell-surface receptors. As these proteins are overexpressed by tumor cells (blue) compared 
with normal cells (yellow), the virus will probably infect the tumor cell. b. Following 
binding to the cell surface receptor, the virus is internalized by endocytosis or membrane 
fusion, and its genome is released into the cell. Depending on the type of virus, replication 
and viral gene expression can take place entirely in the cell cytoplasm (such as for vesicular 
stomatitis virus), or in the nucleus and cytoplasm (such as for adenovirus). In either case, the 
virus is largely dependent on cellular machinery for viral gene expression and synthesis of 
viral proteins. Viral gene expression and replication leads to the activation of cellular 
antiviral defenses, such as apoptosis, that are operational in normal cells but are often 
inactivated in tumor cells. Expression of viral proteins will eventually lead to immune-
mediated lysis of infected cells by CD8+ T cells, which recognize viral peptide epitopes that 
are presented by major histocompatability complex (MHC) class I molecules on the surface 
of the infected cell. Alternatively, cells might be lysed owing to an overwhelming amount of 
budding and release of progeny virions from the cell surface, or by the activation of 
apoptosis during the course of viral replication and gene expression (Kelley A Parato et 
al., 2005). 
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Induction of apoptosis is one of the mechanisms that infected normal cells use to prevent 
further spread of viruses. In turn, viruses often encode gene products that block this 
process (Lee CJ et al., 2005; Reboredo M et al 2004; Wright CW 2005). Tumor cells 
accumulate defects in apoptotic programmers, so another design strategy for oncolytic 
viruses would be to delete viral anti-apoptotic genes, creating mutants that only replicate 
in apoptosis deficient tumor cells.  
Understanding how cancer cells evade apoptosis is one approach to engineer oncolytic 
viruses. The concept of programmed cell death, termed apoptosis, was introduced above 
in terms of the role of p53 in eliminating cells that have either acquired activating 
oncogenes or excessive genomic damage. Because apoptosis is such an effective 
mechanism of eliminating cells progressing to malignancy, it is not surprising that in 
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addition to inhibiting p53 function by mutation, other p53 independent mechanisms are 
also utilized by many cancers as survival factors. Apoptosis is triggered by external 
plasma membrane associated receptors and internal sensors, principally involving the p53 
gene. Both these external and internal mechanisms are perturbed in diferent cancers. 
Regardless of initial stimulus, pathways of apoptosis all appear to converge on the 
mitochondria causing loss of membrane integrity and release of cytochrome C. 
Cytochrome C is a potent mediator of apoptosis and appears to directly stimulate activity 
of a family of intracellular proteases, called caspases, whose function is to rapidly 
degrade cellular organelles and chromatin so as to induce cell destruction without 
inflammatory responses that are typically seen after cell necrosis (Earnshaw WC et al., 
1999). In addition to protecting the host against developing cancer cells, apoptosis is 
widely utilized during embryogenesis to eliminate populations of cells such as those 
between the digits or in the tail of human embryos and to eliminate self-recognizing 
immune cells. Apoptosis is also utilized to destroy viral genetic material and the infected 
cell after viral infection. As a consequence, many viruses have evolved mechanisms to 
evade apoptosis and several viral gene products interfere with mammalian proteins 
involved in apoptotic pathways (Thompson CB 1995.) 
 
1.5.5.2 Modification in the cytoskeleton structure of the host cell 
 
Targeting the cytoskeleton of the host cell is a common strategy among organism and 
reflects the alteration of many cellular activities, recent evidence demonstrates that 
various viruses manipulate and utilize the host cytoskeleton to promote that viral 
infection. Viruses induce rearrangements of cytoskeletal filaments so that they can utilize 
them as tracks or shove them aside when they represent barriers. Viral particles recruit 
molecular motors in order to a hitchhike rides to different subcellular sites which provide 
the proper molecular environment for uncoating, replicating and packaging viral 
genomes. Interactions between subviral components and cytoskeletal tracks also help to 
orchestrate virus assembly, release and efficient cell-to-cell spread. There is probably not 
a single virus that does not use cytoskeletal and motor functions in its life cycle (Radtke 
K et al., 2006). The actin cytoskeleton mediates a variety of essential biological functions 
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in all eukaryotic cells. In addition to providing a structural framework around which cell 
shape and polarity are defined, its dynamic properties provide the driving force for cells 
to move and to divide. There are several proteins act as molecular switches such as Rho 
GTPases which induce coordinated changes in the organization of the actin cytoskeleton 
and in gene transcription to drive a large variety of biological responses including 
morphogenesis, chemotaxis, axonal guidance, and cell cycle progression. These proteins 
could be changed by virus infection. It can be predicted with some confidence that the 
biochemical and genetic analysis of the signaling pathways controlled by these proteins 
will lead to a better understanding of these fundamental processes (Alan Hall et al., 
1998). The actin cytoskeleton system is also crucial for active recruitment in cells such as 
lymphocytes and macrophages that rapidly have to move to the infection and 
inflammation sites (Gruenheid, S and Finlay BB 2003). 
 
1.5.5.3 Modification of cell host intracellular signaling pathways 
 
 Many viruses have evolved sophisticated mechanisms to imitate host proteins and to 
occupy intracellular signal transduction systems for their own benefit (Kahn RA et al., 
2002). In fact, the binding of viruses to target cells is known to be mediated by several 
intracellular signaling events.  
When eukaryotic cells encounter adverse physiological conditions that impact on protein 
folding in the endoplasmic reticulum, a signal-transduction cascade is activated; this is 
termed the unfolded protein response (UPR). A number of cellular stress conditions, such 
as perturbation in calcium homeostasis or redox status, elevated secretory protein 
synthesis, expression of misfolded proteins, sugar/glucose deprivation, altered 
glycosylation, and overloading of cholesterol can interfere with oxidative protein folding 
and subsequently lead to accumulation of unfolded or misfolded proteins in the 
endoplasmic reticulum (ER) lumen, which constitutes a fundamental threat to the cells. 
The ER has evolved highly specific signaling pathways to alter transcriptional and 
translational programs to cope with the accumulation of unfolded or misfolded proteins in 
the ER lumen (Lee AS 1992; Brodsky JL et al. 1999). The UPR is also induced in 
response to viral infection (Lee AS 2001), apparently because of the high volume of viral 
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proteins that are being synthesized in the ER, although it has not been established 
whether this contributes to or limits the disease. 
Inside the solid tumor themselves, there is evidence of ER stress which can activate of the 
UPR. Neoplastic progression requires several genetic alterations that allow the cell to 
ignore growth controls and disable apoptotic signalling. As the tumor becomes larger, it 
experiences increasing hypoxia, nutrient starvation and acidosis until the 
microenvironment becomes limiting. Cells respond by producing pro-angiogenic factors 
to initiate the formation and attraction of new blood vessels to the tumor.Although many 
studies have focused on the hypoxic state of tumors, the stabilization of hypoxia 
inducible factor-1α (HIF1α), and the activation of protective downstream responses, there 
is increasing evidence to show that the UPR can also be activated in tumors. Although no 
direct link between these two pathways has been established, they share several 
downstream targets, and it is conceivable that the two pathways could synergize in some 
cases and be antagonistic in others. The UPR normally acts as a short-term cytoprotective 
mechanism. Cells subjected to especially severe or prolonged microenvironmental stress 
normally undergo UPR mediated apoptosis by both mitochondria-dependent and 
mitochondria-independent pathways. It is unclear how UPR activation in solid tumors 
balances cell-survival and celldeath signals. Figure 2 illustrates how ER stress and 
subsequent activation of the UPR can lead to one of four outcomes: (Guo ZS and Bartlet 
DL, 2004) apoptosis and tumor resolution, (Timiryasova TM et al., 1999) tumor 
dormancy, (Bartlett DL et al., 2001) tumor growth and disease progression and (Thorne 
SH et al., 2005) altered chemotherapeutic sensitivity. 
 
Figure 2. ER stress and activation of the UPR might result in Ire1/TRAF2-mediated apoptosis and 
disease resolution, PERKmediated G1 arrest and dormancy or an anti-apoptotic, pro-
angiogenic drive, thereby resulting in disease progression via PERK/NF-κB and molecular 
chaperones (Peter Scriven et al., 2007). 
 
 
 26 
 
               
 
 
 
1.5.5.4 Modification of cell host metabolic pathways 
 
Some microorganisms modify their metabolism to adapt to their specific host. The 
interaction between host and microorganisms not only entails alteration of protein 
expression levels, but also post-translational processing of the specific proteins involved. 
This is the case of post-translation modifications in some proteins from bacteria and 
viruses, which are mediated by the cellular protein machinery. Such modifications are 
generally reversible and play key roles in protein functional regulation. Among many 
reported types of post translation modifications, phosphorylation in serine, threonine, and 
tyrosine residues has received significant attention, since this reversible modification is a 
key event in signaling processes (Pawson T and Scott J D 1997).  Phosphorylation is also 
common in virus proteins implicated in the control of virus replication, transcription, and 
assembly. This is the case for Rubella virus capsid protein (Ficarro SB et al., 2002), 
 27 
 
influenza virus nucleoprotein (Neumann G et al., 1997), and Rabies virus nucleoprotein 
(Wu X et al., 2002). Therefore, great effort has been directed towards developing 
methods for detecting and characterizing these modifications. However, identification of 
phosphorylated residues was a difficult task, involving direct labeling of proteins with 
32
P
 (Chalmers, M. et al., 2004). ESI is one of the softest ionization techniques for MS 
(Fenn JB et al., 1989) which allows the detection and characterization of numerous post-
translation modifications, as direct sequence information is obtained. Highly complex 
protein mixtures can be identified directly, and the possible PTM characterized by MS 
(Washburn M et al., 2001). For example, MudPIT coupled to MS has been used to study 
the nucleocapsid protein phosphorylation of transmissible gastroenteritis virus (TGEV) in 
infected cells (Calvo, E. et al., 2005) which led to the identification of at least four 
phosphorylations in the TGEV nucleocapsid protein. Interestingly, previous work had 
suggested that phosphorylation/dephosphorylation processes could play an important role 
in coronavirus assembly (Laude H et al., 1995). The phosphorylation state of the human 
respiratory syncytial virus (HRSV) phosphoprotein (P protein) has been also assessed by 
LC-MS (Asenjo A et al., 2006).  
Generally, results of studies analysis interactions of tumor cells infected with virus by 
proteomics are still unobtrusive. The differentially expressed transcripts of virus-infected 
tumor cells were analyzed by cDNA microarrays, which provide an overview of the 
mRNA expression profiles of infected cells (Susana Guerra et al., 2004; Krystyna W et 
al., 2003). However, the mRNA abundance is not always consistent with the protein level 
(Gygi SP et al., 1999) and viral infection involves in post-translational modifications of 
diverse proteins, such as ubiquitination (Shackelford J and Pagano JS 2005), 
phosphorylation and glycosylation (Meredith DM et al., 1991), without affecting their 
transcription rate. Therefore, the proteomic analysis of host cellular responses to virus 
infection is more promising to probe potential cellular factors involved directly or 
indirectly in viral infection and to identify potential drug targets of antiviral treatment. To 
date, increasing number of studies has used proteomic approaches to reveal the effects of 
viral infection on the cellular proteome (Maxwell KL and Frappier L 2007). For example,  
in animal viruses, 2-DE/MS has been utilized to investigate the cellular changes in Vero 
cells infected with African swine fever virus (Alfonso P et al., 2004), rhabdomyosarcoma 
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cells infected with enterovirus 71 (Leong WF and Chow VT 2006), nuclear proteome 
changes in A549 alveolar type II-like epithelial cells infected with respiratory syncytial 
virus (Brasier AR et al., 2004), expression changes in B cells infected with Epstein-Barr 
virus (EBV), proteome alterations in HeLa and HepG2 cells infected with coxsackievirus 
B3 (Alexander Rassmann et al., 2006),  and EBV nuclear antigen EBNA-2 (Schlee M et 
al., 2004) or characterized response of the chicken embryo fibroblasts to Bursal disease 
virus infection (Xiaojuan Zheng et al., 2008). In addition, several studies have used 
distinct protein separation methods, including difference gel electrophoresis (DIGE), 
isotope-coded affinity tags (ICATs), or multidimensional liquid chromatographic 
separations followed by liquid chromatography/tandem mass spectrometry (LC-MS/MS) 
identification to investigate the cellular response to infection by severe acute respiratory 
syndrome-associated coronavirus (SARS-CoV), flock house virus (FHV) and hepatitis C 
virus (Xiaojuan Zheng et al., 2008; Alexander Rassmann et al., 2006; Alessandro R and 
Kohn EC 2002). Therefore, the proteomic strategies provide an overall understanding of 
the cellular factors involved in various stages of infection and give an insight into the 
alteration of signaling pathways to further understand viral infection.  
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AIMS OF THE STUDY 
 
 
 
The purposes of this thesis are to determine protein dynamic upon oncolytic 
vaccinia virus infectious activity of cells and tumors. Specifically, the aims of the study 
are to characterize the infection of  attenuated vaccinia virus VACV GLV-1h68 which 
were generated and studied as a live vector engineering for tumor selective replication 
with oncolytic efficacies. 
 To characterize vaccinia virus VACV GLV-1h68 
 To estimate imaging of tumors based on light emission 
 To describe the proteome profile of the tumor cell and tumor xenograft 
in mice with and without VACV GLV-1h68 infection. To identify 
proteins which increase or decrease expression in the different tumor 
cell line and tumors, possibly contributing to the understanding ability 
oncolytic in the protein level of VACV GLV-1h68. 
 To compare the differential protein expression between the non-
regressing and regressing tumors xenograft in nude mice treated with 
VACV GLV-1h68. 
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2. MATERIALS AND METHODS 
 
 
 
2.1 MATERIALS 
 
2.1.1 Equipments 
 
Biophotometer Eppendorf, Hamburg 
Cell counting chamber Marienfeld, Lauda-Königshofen 
Cell culture bottles Greiner, Frichenhausen 
Cell culture incubator RS Biotech,UK-Irvine 
Cell culture scraper TPP, Schwerin 
Centrifuge Eppendorf, Hamburg 
CO2  incubator  Nunc
Tna
-GaluxyS-RS Biotech 
Cold centrifuge Heraeus, Hanau 
Cuvettes Sarstedt, Nümbrecht 
Electrophorstic vertical system  Hoefer DALT 
Ettan IPGphor Amersham 
Film Kodak 
Film cassette Hartenstein 
Flow-Hood Lamin Air Kendro, Langenselbold 
IPG strips Amersham 
Microscopes 
 Axiovert 40CFC 
 DMR 
 DMIRB 
 M2 16 FA 
 
Zeiss, Göttingen 
Leica, Wetzlar 
Leica, Wetzlar 
Leica, Wetzlar 
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Microscopes 
 Axiovert 40CFC 
 DMR 
 DMIRB 
 M2 16 FA 
 
 
Zeiss, Göttingen 
Leica, Wetzlar 
Leica, Wetzlar 
Leica, Wetzlar 
Model 1000/500 Power supply Bio-Rad 
Multi Temp III  Pharmacia-Biotech 
Nitrocellulose transfer  membrane Schneider & Schuell, Dassel 
PH Electrode SenTix 61 Hartenstein 
Power supply  Power Pac Bio-Rad & PEQLAB Biotechnology 
Refrigerator  Liebherr 
X-ray film Konica 
Scale KERNABS A-Hartenstein 
Semi-Dry Blot apparatus Peqlab, Erlangen 
Sonicator Branson 450 Heinemann 
Spectrophotometer Pharmacia Biotech-Novapec II 
Themomixer comfort Eppendorf, Hamburg 
Vertical Gel-electrophoresis Own construction, Biocentre University of Wuerzburg 
Vortex Hartenstein 
Whatman 3MM Filter paper Hartenstein 
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2.1.2 Reagents, solutions and media 
 
2.1.2.1 Reagents 
 
1 x BSS PAA, A- Pasching 
1 x BBS PAA, A- Pasching 
Acetic acid Merck 
Aceton Roth, Karlsruhe 
Acrylamide, Bisacrylamide BioRad, Munchen 
Agarose Roth, Karlsruhe 
Ammoniumperoxidisulphate  Merck, Darmstadt 
Bovin Serum Albumin  Applichem, Darmstadt 
Bromophenol blue Sigma, Steinheim 
Carboxymethylcellulose Sigma, Steinheim 
Cells chamber Hartenstein 
Coomassie brilliant blue G-250 Serva, Heidelberg 
Coomassie brilliant blue R-250 Serva, Heidelberg 
Crystal violet Sigma, Steinheim 
Dithiothreitol  Roth, Karlsruhe 
DMEM PAA, A- Pasching 
EDTA Serva, Heidelberg 
Ethanol 96% Chemical of Uni-Würzburg 
Formaldehyde 37% Sigma, Steinheim 
Glycerin Merck, Darmstadt 
Glycin Roth, Karlsruhe 
H2O2 Merck, Darmstadt 
Hepes PAA, A-Pasching 
Isopropanol Roth, Karlsruhe 
L-Glutamin PAA, A- Pasching 
  
  
 33 
 
Magenesiumchloirid Merck,Damstadt 
Magermilchpulver Roth, Karlsruhe 
Methanol Roth, Karlsruhe 
N,N,N‟,N‟-Tetramethlethylendiamin Fluka 
Na2CO3 Merck, Damstadt 
NaOH Merck, Damstadt 
Na-thiosulphate 43% Merck, Damstadt 
Natrium dedocylsulphate   Roth, Karlsruhe 
Natriumcarbonat  Roth, Karlsruhe 
Nonidet P-40 (Igepal) Sigma, Steinheim 
Ostradiol/Progesteron PAA, A- Pasching 
Penicillin/ Streptomycin PAA, A- Pasching 
Ponceau S Sigma, Steinheim 
Prestained protein marker Fermentas, St. Leon-Rot 
Protease inhibitor  Roch, US-Indianapolis 
RPMI- Medium 1640 PAA, A-Pasching 
Silver nitrat Riedel deHaen, Seelze 
Trichloressigsäure Roth, Karlsruhe 
Tris-Base Roth, Karlsruhe 
Tris-HCl Roth, Karlsruhe 
Trypan blue Fluka, CH-Buchs 
Trypsin-EDTA PAA, A-Pasching 
Tween 20 Roth, Karlsruhe 
Urea Roth, Karlsruhe 
β-mecaptoethanol Roth, Karlsruhe 
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2.1.2.2 Solutions and media 
 
10x TBT buffer 
890  mM Tris-base 
890 mM H3PO4 
25 mM Na2EDTA 
1x Towbin buffer pH 8,3 
0,025 M Tris-base 
0,192 M Glycin 
20%  MeOH 
 
1x SDS Probe buffer  
200 mM Tris-HCl pH 6,8 
5%  SDS 
1 mM Na2EDTA 
8 M Urea 
0,1 % (w/v) β-mecaptoethanol 
0,2 % Bromophenol 
 
 
 
Rehydration stock solution 
8 M Urea 
2 % CHAPS 
0.5 % or 2 % IPG buffer 
0.002  % Bromophenol blue 
Displacing Solution 
0.375 M Tris-HCl pH 8.8 
50%  Glycerol 
0.002 % Bromophenol blue 
SDS equilibration buffer  
50  mM Tris-HCl pH 8.8 
6 mM Urea 
30%  Glycerol 
2 % SDS 
0.002 % Bromophenol 
 
 
 
SDS electrophoresis Buffer  
25 mM Tris-HCL pH 8.8 
192 mM Glycine 
0.1 % SDS 
 
 
Lysis buffer 
150 mM  NaCl 
1 mM EDTA 
10 mM Hepes 
 
 
 
 
Bradford solution 
50 mg Coomassie Blue G250 
25 ml Ethanol 96% 
50 ml Phosphor acid 
25 ml Deionized H20 
 
10% SDS-PAGE gel                                  
12.5 ml  Deionized H20 
7.5 ml  1.5M Tris-HCl pH 8.8 
150 µl  20%SDS 
150 µl 10%APS 
15 µl TEMED 
5% staking-gel   
9.23 ml  Deionized H20 
1.95 ml  30 % Acrylamide/Bis 
3.75 ml  0.5 M Tris-HCl pH 6.8         
75 µl  20 % SDS 
75 µl  10 %APS 
15 µl TEMED 
Coomassie solution   
100 ml Deionized H20 
100 ml Phosphoric acid 
1.2 g Coomassie G250 
800 ml Deionized H20 
200 ml Methanol 
 
 
Solution for Silve staining 
 
Fixative  
38 % Ethanol 
12 % acetic acid 
50 % Deionized H20 
 
 
 
 
Wash-solution  
30 % Ethanol 
70 %  Deionized H20 
 
 
 
 
Thiosulfate reagent: (per gel) 
62.5 µl Na-thiosulphate 43 % 
84 µl Formaldehyde 37 %, 
125 ml  Deionized H20 
 
 
 
Silver nitrate reagent: (per gel) 
0.25 g AgN03 
84 µl Formaldehyde 37% 
125 ml  Deionized water 
Developer: (per gel) 
2.25µl Na-thiosulfate 43% 
62.5 µl Formaldehyde 37%, 
7.5g Na2CO3 
125 ml Deionized water 
 
 
Stop-reagent: (per gel) 
3,5 g EDTA 
250 ml Deionized water 
Cell culture medium   
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GI-101A cultivation   
500 ml RPMI 1640 
6 ml Glucose 
6 ml HEPES 
6 ml Natrium pyruvat 
5 ml Antibiotics (Pen/Strep) 
100 ml FKS 
300 µl BE2 (Oestradiol/Progesteron) 
 
 
 
CV-1 cultivation 
500 ml DMEM 
50 ml FKS 
5 ml Antibiotics (Pen/Strep) 
 
HT-29 cultivation 
500 ml RPMI 1640 
100 ml FCS 
5 ml Antibiotics (Pen/Strep) 
2,2 g/L Na-bicarbonate 
PC-3 cultivation 
500 ml RPMI 1640 
100 ml FCS 
5 ml Antibiotics (Pen/Strep) 
2,2 g/L Na-bicarbonate 
  
 
 
2.1.3 Cell lines 
 
1. CV-1, a kidney fibroblast of African green monkey 
2. GI-101, a human breast tumor cell line 
3. HT-29, a human colon tumor cell line 
4. PC-3, a human prostate tumor cell line 
                                              
2.1.4 Recombinant Vaccinia virus VACV GLV-1h68 
 
VACV GLV-1h68 is provided by Genelux-Corporation. A new recombinant 
Vaccinia virus strain VACV GLV-1h68 is constructed by carring triple insertion mutations 
of Renilla luciferase-green fluorescent protein (ruc-gfp) in the F14.5 gene, β-galactosidase 
into thymidine kinase (TK) gene, and β-glucuronidase into hemagglutinin (HA) gene of the 
LIVP genome. 
Recombinant virus VACV GLV-1h68 was constructed by insertional inactivation 
the LIVP at the location of three genes: F14.5 gene, TK gene, and HA gene. In the locus of 
thymidinkinase (TK), there is the reverse transferrin receptor (rtfr) gene and marker β-
galactosidase (lacZ) gene which are under the control of promoter p7.5. In the gene of 
F14.5L, a fusion of protein Renilla-luciferase (RUC) and Green Fluorescent Protein (GFP)  
gene expressed under the control of promoter E/L (early/late). A marker gene β-
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glucuronidase (gus) is inserted in the locus og hemaglutinin (HA) gene which is under the 
control of the promoter p11. 
 
Figure 3. Construction of VACV GLV 1h68 
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2.1.5 Antibodies  
 
Primary antibodies 
 Anti Beta-Actin α-mouse Abcam, Cambridge 
 RUC α-sheep AG Szalay, Uni-Würzburg 
 GFP α-rabbit Santa Cruz 
 Anti β-galactosidase α-rabbit Molecular Probes 
 Anti β-glucuronidase α-rabbit Santa Cruz 
 
Secondary antibodies 
 α-rabbit, HRP  Sigma, Steinheim 
 α-sheep, HRP  Sigma, Steinheim 
 α-mouse, HRP  Sigma, Steinheim 
 α-goat/sheep, HRP  Sigma, Steinheim 
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2.2 METHODS 
 
 
2.2.1 Cell biological method 
 
2.2.1.1 Cell culture  
 
To ensure that all cell culture procedures are performed to a standard that will prevent 
contamination from bacteria, fungi and mycoplasm and cross contamination with other 
cell lines, Chloros/Presept solution and 70% ethanol in water are used. Personal 
protective equipment (sterile gloves, laboratory coat, and safe visor) and microbiological 
safety cabinet at appropriate containment level are used. 
Adherent cell lines were growing in appropriate nutrients medium. At this point the cell 
lines were sub-cultured in order to prevent the culture dying. View cultures using an 
inverted microscope to assess the degree of confluence and confirm the absence of 
bacterial and fungal contaminants. Media was replaced by pre-warmed medium. The cell 
monolayer was washed with BSS without Ca
2+
/Mg
2+
. Flasks were rotated to cover the 
monolayer with 1xTrypsin. Decant the excess trypsin. Return flask to the incubator and 
leave for 5-10 minutes. Examine the cells using an inverted microscope to ensure that all 
the cells are detached and floating. The side of the flasks may be gently tapped to release 
any remaining attached cells. Resuspend the cells in a small volume of fresh serum-
containing medium to inactivate the trypsin. Centrifuge cell medium at 13.000 rpm/min, 
then remove medium, add fresh medium and perform a cell counting. Transfer the 
required number of cells to a new labeled flask containing pre-warmed medium. 
2.2.1.2 Cell quantification  
It is necessary to quantify the number of cells prior to use. Haemocytometer and inverted 
phase contrast microscope are used. Suspension using trypsin/EDTA as above and 
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resuspend in a volume of fresh medium at least equivalent to the volume of trypsin. For 
cells that grow in clumps centrifuge and resuspend in a small volume and gently pipette 
to break up clumps. Cell suspension is viewed under a light microscope using 20 x 
magnification. Then count the number of viable (seen as bright) cells. The central area of 
the counting chamber is subdivided into 4 smaller squares (1/25mm
2
). Each of these is 
subdivided into 16 smaller squares. Counting cell number in 4 smaller squares in each 
and multiply with 10
4
. This data is cell number/ml. 
Cell/ml = (The mean cell count per quare) x (the dilution factor) ÷ 10
-4
 ml                   
 
2.2.1.3 Virus infection 
CV-1, GI-101A, HT-29, PC-3 (3 x 10
5
) cells were seeded on 6 well plates. 3 ml of 
appropriate media was added into each well then placed into 5% CO2/ 37 
o
C condition. 
Cells were checked 2-3 days after seeding for confluence. Cell number in each well of the 
plate is counted and cells are infected with individual virus strain VACV GLV-1h68 at 
MOI 0.5 
Total cell number = (cell/ml) x (the original volume from which the cell sample was 
removed) 
 
culture cell of  volume
 MOInumber x  cell Total
  = number of plaque (pfu) 
 
Incubate plates for 1 hour in a humidified, 5% CO2 incubator at 37
o
C. Plates were rotated 
briefly every 20 to 30 minutes during incubation period to allow infection to occur. After 
1 hour, cells were incubated in the fresh growth medium for monitoring in real time at 0, 
2, 4, 6, 8, 10, 12, 24, 36, 48, 60, 72 hours post infection.  
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2.2.2 Gene expression    
 
2.2.2.1 Fluorescent microscopy 
 
Fluorescence illumination and observation is the most rapidly expanding microscopy 
technique employed today. 
 We are using fluorescence microscopy to detect proteins within the cells infected with 
VACV GLV-1h68 which is constructed by inserting Renilla luciferase Green 
Fluorescent protein including into the Vaccinia genome (ruc-gfp). Fluorescent molecules 
absorb light at one wavelength and emit light at another, longer wavelength.  
The expression of GFP in GI-101A, HT-29 and PC-3 cells, respectively, infected with 
VV-RVGL21 was monitored at 0, 2, 4, 6, 8, 10 12, 24, 36, 48, 60 hours post infection. 
GFP-images were visualized by a Zeiss Axicvert 40 CFL fluorescence microscope with 
UV light. Visible image and GFP image were overlaid by using Adobe PhotoShop 
version 7.0. 
 
2.2.2.2 Western blot 
 
Western blots were performed essentially by the method of Towbin et al., (1970). 15µg 
protein of the extract was separated using minigels (10% acrylamide). Proteins were 
transferred into nitrocellulose membrane. Gels, membranes and Whatmann papers were 
soaked in 1X Towbin buffer then placed following description underneath. Power supply 
is calculated at 0.8 mA/cm
2
 and electrical transfer in 2 hours at room temperature 
condition. Band signals on the nitrocellulose membrane were detected by staining 
membrane with Ponceau solution and then blocked by milk solution for 2 hours at room 
temperature. Membranes were incubated with primary monoclonal antibodies raised 
against ß-actin, RUC, GFP, ß-galactosidase, ß-glucuronidase, and then was washed with 
1x TBT in 5 minutes , repeated 4-5 times on the rocker. The membranes were then 
incubated with horseradish peroxidase (HRP)-conjugated anti-mouse, anti-rabbit, anti-
goat, anti-sheep respectively, and visualized by using ECL substrate. Bound antibodies 
were detected on the X-ray film chemiluminescence subtrate.  
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2.2.3 Trypan blue staining 
 
Trypan blue staining was vital recommended for use in estimating the proportion of 
visible cells. In case the chromophor is negatively charged it does not react with the cell 
unless cell membranes are damaged. Staining facilitates the visualization of cell 
morphology. Trypan blue is derived from toluidine, that is, any of several isometric 
bases, C14H16N2 derived from toluene. Trypan blue is a vital stain that colors dead tissue 
and cells. It is a diazo dye. Live cells or tissues with intact cell membranes will not be 
colored. Since cells are very selective in the compound that pass through the membrane, 
in a viable cell trypan blue is not absorbed; however, it traverses the membrane in the 
dead cell. Hence, dead cells are shown as a distinctive blue colour under a microscope. 
 Non-infected and infected GI-101A, HT-29 and PC-3 cell suspensions in BSS were 
prepared. 0.5 ml of 0.4% trypan blue solution is added in mixture of 0.3 ml of BSS and 
0.2 ml of the cell suspension. Allow the cell suspension –Trypan blue mixture to stand 
for 5-15 minutes. Finally, live cell and dead cells are quantified by using counting 
procedure as described above. 
 
 
 
 
3x Whatmann paper   
3x Whatmann paper   
Nitrocellulose membrane  
Gel 
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2.2.4 Titration of vaccinia virus by plaque assay 
 
The Plaque assay is a method for determine virus titer in cell lysate and suspension. 
Serial dilution of the virus samples at time point 0, 4, 8, 12, 24, 48, 60 hours post 
infection were used to infected the appropriate cell line, here CV1 cell line was used for 
this aim. After several days of growing, the medium was removed and the cells were 
stained with crystal violet. Plaques appear as 1-2 mm in diameter of diminished staining 
due to the retraction, rounding and detachment of infected cells. 
Seed 24 well plates with 2.5x10
5
 cells per well of CV1 cells in 2 ml complete DMEM-10. 
Place the plates in the humidified, 5% CO2 incubator at 37 
o
C for 2 days. After 2 days, 
prepare 7 tubes for dilutions by adding 1 ml of media to tube #1 and 900 ml media to 
tube #7. Infected cells were harvested in 1ml of PBS and 50 µl of suspension were 
collected for virus titer samples. Prepare the virus samples from cell lysates and 
suspension for titration by sonication 3 times for 30 seconds in the cold water. Make 7 
fold serial dilutions from 10
-2
 to 10
-8
 of the virus samples in DMEM. Add 10 µl of virus 
samples to the tube #1, mixing well by pipetting up and down. Then 100 µl of virus 
dilution was transferred to the tube #2 and so on. Aspirate of old media from cells, add 
250 µl of virus dilutions as assigned per well. The CMC (Carboxymethylcellulose) 
overlay media was warmed up and after virus samples were incubated in the humidified 
5% CO2 incubator at 37 
o
C for 1 hour, virus samples were overlaid by CMC in the 
humidified 5% CO2 incubator at 37 
o
C for 2 days. After 2 days of incubation, CMC was 
removed and 250 µl of crystal violet and incubated for 1-2 days at room temperature. 
Wash off crystal violet and determine the titer by counting plaque within the wells and 
multiplying by the dilution factor. 
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2.2.5 Protein analysis 
 
2.2.5.1 Sample preparation and protein solubilization 
 
To take advantage of the high resolution of 2-DE, proteins of the sample have to be 
denatured, disaggregated, reduced and solubilized to achieve complete disruption of 
molecular interactions and to ensure that each spot represents an individual polypeptide. 
For cell samples: at 12 , 24  and 48 h post-infection (hpi) the viral infected and non-
infected cells were washed in 1 ml washing buffer (1x PBS) and manually scraped in  400 
µl of 1x lysis buffer and transferred into a small screw-cap tube. Cells were lysed by 40 
times repeated suction pump using a tuberculin syringe system in the cold condition (all 
steps were carried out on ice). The lysates were then clarified by centrifugation at 13.000 
rpm/20 minutes at 4 °C. The supernatants were collected and stored in single-use aliquots 
at - 80 °C. 
For tumor tissue samples tumor tissue samples were collected as rapid as possible and 
freeze immediately in liquid nitrogen at –196 °C. Disrupt the samples while still deep-
frozen. Small tissue specimens were homogenized and solubilized in 1x lysis buffer. 
Keep the centrifuge tube at 4 °C, centrifuge at 13,000g for 20 minutes at 4°C, supernatant 
was collected and centrifuged again. The proteins were collected and frozen in liquid 
nitrogen for using in one and two dimension electrophoresis. 
 
2.2.5.2 Protein precipitation  
 
Proteins were mixed with 15% TCA and incubated for 2 hours on ice then centrifuged at 
13000 rpm for 20 min at 4 
o
C. The protein pellet was washed 3 times with cold aceton, 
centrifuged at 14000 rpm/ min for 10min again. Protein pellet is incubated in 2-5 min to 
dry for one dimensional gel and two dimensional gel electrophoresis. 
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2.2.5.3 Determination of protein concentration by Bradford assay 
 
The standard care was made by using 1, 2, 3, 5, 7, 10, 15 µl of BSA 1µg/µl stock 
solution in 20 µl buffer each. 1 ml Coomassie brilliant blue solution was added into each 
tuble and incubated for 10 minutes at room temperature. A standard curve was generated 
by plotting. The absorbance at 594 nm measured in 1 cm path length (1 ml) 
microcuvette. Standard curves is generated to representative concentrations, the samples 
were diluted, measured according to a generated standard curve and then calculated 
following dilution ratio diluted. 
 
2.2.5.4 Separation of proteins in one dimensional gel electrophoresis and two   
dimensional gel electrophoresis  
 
2.2.5.4.1 One dimensional gel electrophoresis 
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a very 
common method for separating proteins by electrophoresis uses a discontinuous 
polyacrylamide gel as a support medium and sodium dodecyl sulfate (SDS) to denature 
the proteins. Protein pellets precipitated from above steps were soaked in 1x SDS sample 
buffer in 3 µg/µl, vortexed at 750 rpm/ 24 
0
C for 10 min, incubated for 5 min at 95 
o
C. 
Then 15 µg proteins were placed in 10% separating SDS-PAGE gel and 5% stacking gel. 
Power supply is arranged at 100 Volt for 4-6 hours. 
 Proteins were detected by staining with Coomassie Blue for 24 hours or more. Gels were 
washed with SDS removing solution (30 % v/v methanol, 10 % v/v acetic acid) and 
finally soaked in fixing solution ( 10% v/v acetic acid) for storing up to scanning.   
 
2.2.5.4.2 Two dimensional gel electrophoresis 
 
High-resolution two-dimensional gelelectrophoresis (2-DE) for the separation of complex 
protein mixtures was introduced by O‟Farrell in 1975 by combining isoelectric focusing 
(IEF) in the first dimension in presence of urea, detergents and DTT, with sodium 
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dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) in the second 
dimension. Proteins are separated according to isoelectric point (pI) and molecular mass 
(Mr), and quantified according to relative abundance. Depending on the gel size and pH 
gradient used, 2-D PAGE can resolve more than 5,000 proteins simultaneously (~2,000 
proteins routinely), and can detect under 10 ng of protein per spot. Furthermore, it 
delivers a map of intact proteins, which reflects changes in protein expression level, 
isoforms or post-translational modifications.  
To prevent protein degradation that otherwise may result in artifactual spots and loss high 
molecular weight protein, protease inhibitors were added. TCA/acetone precipitation was 
used for minimizing protein degradation, for removing interfering compounds, such as 
salt, or polyphenols, and for the enrichment of very alkaline proteins such as ribosomal 
proteins from total cell lysates (Görg et al., 1999). 
In this work firstly, protein preparation and the linear immobilizing pH 3-10 IPG strip 
was applied for testing the distributions of proteins extracted from GI-101A cells infected 
with VACV GLV-1h68. Next, according to detections of protein separation on 2DE 
which tended to appear at the narrow pH range of the gel based on the test distribution of 
protein obtained with an immobilizing pH of 3-10, a linear gel with an immobilizing pH 
gradient of 4-7 and SDS 10% gel were chosen to be optimal for protein resolution-
particularly for major proteins. 
To minimize the analytical variation between gels, the 2-DE conditions suitable for the 
analysis of 36 gels were optimized by dividing 36 independent samples into 3 
independent sections for isoelectric focusing (IEF) under the same conditions, and then 
simultaneously applying the 36 isoelectric-focused samples to sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). 
 
Isoelectric focusing step 
 
Rehydration step: protein probes of 150 µg and 250 µg proteins, respectively, were 
mixed with 400 µl of rehydration solution. Add rehydration solution with protein onto pH 
3-10 IPG strips and pH 4-7 IPG strips, long 18 cm. These strips were rehydrated in 20 
o
C 
plate for overnight (18–20 h).  
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Then strips were place in the tray with the anodic (+) end of the strip resting on the 
appropriate mark etched on the bottom of the Manifold track with the gel side up. Pads 
were wetted with 150 µl deionized water and placed on the end of the IPG strip, overlay 
the IPG strip with 2 ml of dry strip cover fluid.  
 
Program for first dimensional gel electrophoresis 
 
Length pH Step and Voltage mode       Voltage Step duration 
18cm 3-10 Step and hold 300 V 3 h 
  Gradient  1000 V          6 h 
  Gradient   8000 V 6 h 
  Step and hold  8000 V Until to 50-60000 Volt-hours. 
 
Equilibration step: Prior to the second-dimension separation (SDS-PAGE), it is essential 
that the IPG strips are equilibrated to allow the separated proteins to fully interact with 
SDS. The IPG strips are equilibrated in presence of SDS, DTT, urea, glycerol and 
iodoacetamide (IAA), and then placed on top of a vertical SDS gel.  Dissolve 14 mg of 
DTT in 4 ml of equilibration buffer (= equilibration buffer I) for each strip. Take out the 
focused IPG gel strips from the freezer and place them into equilibration buffer I. Rock 
them for 15 min on a shaker and then pour equilibration buffer I off. 
 Dissolve 180 mg of iodoacetamide in 4 ml of equilibration buffer (= equilibration buffer 
II) for each strip. Equilibrate for another 15 min on a rocker. After the 2nd equilibration, 
place it on a piece of filter paper at one edge to drain off excess equilibration buffer. 
Cover the SDS-polyacrylamide gel with 1xSDS running buffer. Place the IPG trip on top 
of the 12% and 10% SDS-PAGE gels with the plastic back touching the behind glass 
plate. Discard the excess of 1x SDS running buffer and seal the IPG strip by 0.5% 
Agarose resolved in 1xSDS running buffer.  
Separation of IPG strips in vertical gels The equilibrated IPG strips were further resolved 
with 10% SDS-PAGE gels at 100 V until the dye front reached the bottom of the gels.  
 47 
 
Gel detection  
 
Coomassie Brilliant Blue (CBB) staining methods have found widespread use for the 
detection of proteins on 2-D gels, ease of use and compatibility with most subsequent 
protein analysis and characterization methods such as MS. However, in terms of the 
requirements for proteome analysis, the principal limitation of CBB stains lies in their 
insufficient sensitivity, which does not permit the detection of low abundance proteins 
(the detection limit of CBB stains is in the range of 200-500 ng protein per spot). Hence, 
typically no more than a few hundred protein spots can be visualized on a 2-D gel, even if 
milligram amounts of protein had been loaded onto the gel. 
Gels were fixed in 250 ml of fixation solution (50% Ethanol, 12% acetic acid , 0,5 ml per 
litre of 37% formaldehyde for 1-3 hours at room temperature. Then gels were washed 2 
times with deionised water. Then the detection is carried out by staining gels with 
Coomassie blue solution. Staining gels for 1-2 days then wash with deionised water until 
background is clear. 
Silver staining methods (Merril et al., 1981; Oakley et al., 1980) are far more sensitive 
than CBB or imidazole-zinc stains (detection limit is as low as 0.1 ng protein/spot). They 
provide a linear response with over a 10-40 fold range in protein concentration, which is 
slightly worse than with CBB staining. However, silver staining methods are far from 
stoichiometric, and are much less reproducible than CBB stains due to the subjective end-
point of the staining procedure which makes them less suitable for quantitative analysis.  
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Silver staining steps  
Fixing 50 % MetOH/12 % acetic acid/ 38% d2H20  > 1 h or over night 
Washing 30% EtOH 2 x 30 min 
Sensitizer Thiosulfate reagent 1 min 
Washing Deionized water 3 x 1 min 
Silver Silver nitrate >1h or over night 
Washing Deionized water 2 x 30 sec 
Development Developer 3-5 min 
Stopping Stop reagent > 20 mis or overnight 
 
The detected gels were scanned at a resolution of 200 dpi using the EPSON 
PERFECTION 4990 Scanner.  
However, the 2D technique has some limitations. Proteins expressed at low levels, so 
called low abundance proteins (transcription factors, and some cell-signalling proteins), 
hydrophobic membrane and nuclear proteins with extreme pI as well as very large or very 
small proteins are very difficult to separate and/or detected in 2D gels.     
 
2.2.5.5 Computerized 2-D image anylysis 
 
One of the key objectives of proteomics is to identify the differential expression between 
control and experimental samples run on a series of 2-DEs. Protein spots that have been 
inhibited (disappeared), induced (appeared) or have changed abundance (increased or 
decreased in size and intensity). Once these gel features have been found, the proteins of 
interest can be identified using MS. This goal is usually accomplished with the help of 
computerized image analysis systems (Dowsey et al., 2003; Dunn 1992 & 1993; Garrels 
1989).  
Spot detection, spot matching, and quantitative intensity analysis were performed using 
Delta2D of DECODON Company. 
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Working with Delta 2D  
 
Gels were organized into analysis projects. A project consists of 6 gel groups. 
Quantitation of results was analyzed on a gel-by-gel basis and aggregated by groups. 
Wrapping and visual comparison of 2-DE images 
Wrapping compensates for the differences in spot positions between gels. These 
differences are due to variations in running conditions and the gel casting process.  
Delta2D‟s warping algorithms generate dual channel images on which corresponding 
spots are perfectly overlaid. The same algorithm that is used in producing dual channel 
images was used in the subsequent quantitation step to obtain accurate and reliable spot 
matching information. 
 
 
Figure 4. A region 2D image, before and after exact wrapping. Corresponding spots are overlaid 
exactly, allowing for easy identification of spots with changed expression level. 
 
 
Working with quantitation table 
 
 Expression intensity ratios infected/uninfected larger than 2.0 (p ≤ 0.05) or smaller than 
0.5 (p ≤ 0.05) were set as a threshold indicating significant changes. The numerical 
expression ratio was used for analysis. The column shows the ratio as mathematical ratio 
or as fold change. Additionally it can contain colour coded representation of the ratio. 
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Figure 5. Part of quantitation tables. The quantitation tables gives access to data in three basic types 
of representation: Single gel tables show all available quantitive data to one single gel image. 
Multi gel tables show the same data as the above type plus data comparing the spots of the gel 
images to each other, whereas the Statistics table shows one selectable subset of the above 
data in a statistical evaluation for each group plus data comparing the spots groupwise. The 
single gel tables are labeled each with the name of the respective gel image. The multi gel 
tables are labeled with either the names of the gel images involved, or, if containing all gel 
images, simply with all gel images.  
 
 
2.2.5.6 Mass spectrometry for protein identification 
 
Preparation of peptide mixtures for MALDI-MS 
 
Mass spectrometry has its origins in the studies performed by J. J. Thomson and his 
student F. W. Aston around the turn of the last century (Griffiths WJ et al 2001). An 
advantage of mass spectrometers over other analytical instruments is that it affords a high 
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degree of accuracy (~0.01–0.001%) and sensitivity (detection of 10-9 – 10-18 mol of 
sample required) when determining the molecular weight of biological compounds 
(Poland GA et al 2001). A mass spectrometer is an instrument that produces ions from a 
sample, separates them according to their mass-to-charge ratio (m/z) and records the 
relative abundance of each of the ions to obtain a mass spectrum (Bonner PLR, Lill JR et 
al 2002). 
Proteins were excised from colloidal CBB-stained 2-D gels using a spot cutter (Proteome 
Works
TM
, Bio-Rad) with a picker head of 2 mm diameter and transferred into 96-well 
microplates loaded with 100 ml Lichrosolv water per well. Digestion with trypsin and 
subsequent spotting of peptide solutions onto the MALDI targets were performed 
automatically in the Ettan Spot Handling Workstation (Amersham Biosciences) using a 
modified standard protocol. Briefly, gel pieces were washed twice with 100 mL 50mM 
ammoniumbicarbonate/ 50% v/v methanol for 30 min and once with 100 ml 75% v/v 
ACN for 10 min. After 17 min drying 10 ml trypsin solution containing 20 ng/ml trypsin 
(Promega, Madison, WI, USA) in 20 mM ammoniumbicarbonate was added and 
incubated at 37
o
C for 120 min. For peptide extraction gel pieces were covered with 60 ml 
50% v/v ACN/0.1% w/v TFA and incubated for 30 min at 37
o
C. The peptide-containing 
supernatant was transferred into a new microplate and the extraction was repeated with 
40 mL of the same solution. The supernatants were dried at 40
o
C for 220 min completely. 
Peptides were dissolved in 2.2 ml of 0.5% w/v TFA/50% v/v ACN and 0.7 ml of this 
solution were directly spotted on the MALDI target. Then, 0.4 ml of matrix solution 
(50% v/v ACN/0.5% w/v TFA) saturated with a-cyano-4-hydroxycinnamic acid (CHCA) 
was added and mixed with the sample solution by aspirating the mixture five times. Prior 
to the measurement in the MALDI-TOF instrument the samples were allowed to dry on 
the target for 10–15 min. 
 
Peptide analysis and identification of proteins by using MALDI-TOF-MS 
 
The MALDI-TOF measurement of spotted peptide solutions was carried out on a 
Proteome-Analyzer 4700 (Applied Biosystems, Foster City, CA, USA). The spectra were 
recorded in reflector mode in a mass range from 900 to 3700 Da with a focus mass of 
 52 
 
2000 Da. For one main spectrum 25 subspectra with 100 shots per subspectrum were 
accumulated using a random search pattern. If the autolytical fragment of trypsin with the 
mono-isotopic (M+H)
+
 m/z at 2211.104 reached a signal-to-noise ratio (S/N) of at least 
10, an internal calibration was automatically performed using this peak for one-point-
calibration. The peptide search tolerance was 50 ppm but the actual standard deviation 
was between 10 and 20 ppm. Calibration was performed manually for the less than 1% 
samples for which the automatic calibration failed. After calibration the peak lists were 
created using the “peak to mascot” script of the 4700 ExplorerTM Software with the 
following settings: mass range from 900 to 3700 Da; peak density of 50 peaks per range 
of 200 Da; minimal area of 100 and maximal 200 peaks per protein spot and minimal S/N 
ratio of 6. Peak lists were compared with a specific Homo sapiens, Vaccinia virus and 
Mus musculus sequence database using the mascot search engine (Matrix Science, 
London, UK). Peptide mixtures that yielded at least twice a mowse score of at least 49 
and a sequence coverage of at least 30% were regarded as positive identifications. 
Proteins/peptide mixtures that failed to exceed the 30% sequence coverage cutoff level 
were subject to MALDI-MS/MS. MALDI-TOF analysis was performed for the three 
strongest peaks of the TOF spectrum. For one main spectrum 20 subspectra with 125 
shots per subspectrum were accumulated using a random search pattern. The internal 
calibration was automatically performed as one-point calibration if the mono-isotopic 
arginine (M+H)
+
 m/z at 175.119 or lysine (M+H)
+
 m/z at 147.107 reached an S/N of at 
least 5. The peak lists were created using the “peak to mascot” script of the 4700 
Explorer
TM
 Software with the following settings: mass range from 60 Da to a mass that 
was 20 Da lower than the precursor mass; peak density of 5 peaks per 200 Da; minimal 
area of 100 and maximal 20 peaks per precursor and a minimal S/N ratio of 5. Database 
searches employed the Homo sapiens, Vaccinia virus and Mus musculus specific 
database and the MASCOT search engine (Matrix Science) mentioned above. Proteins 
with a mowse score of at least 49 in the reflector mode that were confirmed by 
subsequent measurement of the strongest peaks (MS/ MS) were regarded as positive 
identification. MS/MS analysis was particularly useful for the identification of spots 
containing more than one component. 
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3. RESULTS 
 
 
 
3.1 Verification of marker expression of VACV GLV-1h68 
 
3.1.1 GFP-fluorescence microscopy study 
 
Here we are using  a  novel vaccinia virus strain VACV GLV-1h68 which is constructed 
by carring triple insertions of Renilla luciferase-green fluorescent protein (ruc-gfp) in the 
F14.5 gene, β-galactosidase into thymidine kinase (TK) gene, and β-glucuronidase into 
hemagglutinin (HA) gene of the LIVP genome.  
During the infection, viral infection in the cells was monitored in real time with different 
methods. The expression of ruc-gfp which is encoded by inserted gene in VACV GLV-
1h68 genome was confirmed by fluorescence microscopy.  
GI-101A, HT-29, PC-3 cell lines were seeded in 6 well plates. As cell growths achieve 
100% confluence, they were infected with VACV GLV-1h68 with MOI 0.5. The 
replication of VACV GLV-1h68 was monitored by GFP images at different time: 2, 4, 6, 
8, 12, 24, 36, 48 hpi. The first images of GFP expression were cycled to estimate the 
initial expression of GFP for each cell line infected with VACV GLV-1h68. The 
morphology of non-infected and infected cells was performed under both visible light and 
UV light. Addition, merge images were made by Photoshop 7.0 to determine position of 
GFP brighten in the field of cell cultivation. 
GI-101A cells infected with VACV GLV-1h68 exhibited initial distribution at 4 hours 
after infection with a dramatic increase of light emission in the cells in next time point of 
infection. We can see simultaneously the image of viral replication by emission of GFP 
in the culture and cell morphology image was changed by infection.  The cells in which 
they were infected eventually detach from the plastic cell culture plate. The more cell are 
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infected the more changes become visible. These changes include the rounding up and 
detachment of the cell from the plastic culture dish, cell lysis can be seen under the 
visible light of microscope (Figure 6) 
 
 
    
 
                     A                                                B                                                 C 
 
Figure 6. Morphology of infected cells. Uninfected PC-3 cells (A), at 12 hours after infection many 
cells round up (B), at 24 hours after infection more cells have rounded up and detached 
from the culture dish (C). 
 
 
To discover whether there is any difference in details of expression of RUC-GFP fusion 
protein encoded by inserted gene in the F14.5 of VACV GLV-1h68 genome which are 
monitored by promoter early/late in other tumor cell line we did experiments in the same 
model with a human colon cell line (HT-29) and a human prostate tumor cell line. Three 
times monitoring of GFP for each cell line were performed to investigate the rule of 
VACV GLV-1h68 replication. Surprisingly, there is no difference of the first GFP 
expression in infected cells between GI-101A, HT-29 and PC-3 cells.  All red cycles for 
beginning of GFP expression were marked at 4 hour post infection and being increased in 
the next time points of infection (Figure 7, 8, 9). The result show that VACV GLV-1h68 
can express GFP-independent in cell line indicating efficient replication of the virus at 
least in three cell lines in this study.  
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Figure 7. GFP expression in GI-101A cells infected with VACV GLV-1h68. Cells expressing GFP                  
protein show green fluorescence under a fluorescence microscope. The image was acquired       
using a microscope (Zeiss Axiovert) 
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Figure 8. GFP expression in HT-29 cells infected with VACV GLV-1h68. Cells expressing GFP                  
protein show green fluorescence under a fluorescence microscope. The image was acquired       
using a microscope (Zeiss Axiovert) 
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Figure 9. GFP expression in PC-3 cells infected with VACV GLV-1h68. Cells expressing GFP                  
protein show green fluorescence under a fluorescence microscope. The image was acquired       
using a microscope (Zeiss Axiovert) 
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3.1.2 Biochemical analysis of cell lysate 
 
Successful tumor-directed gene therapy is dependent upon a high percentage of tumor 
cells expressing a large quantity of gene product after systemic injection of a vector. To 
further confirm the dynamic alterations of protein expression during VACV GLV-1h68 
infection, 15 µg of protein extracted from GI-101A, HT-29, PC-3 cells infected with 
VACV GLV-1h68 at MOI of 0.5 were separated in one dimensional SDS-PAGE gels, 
lysates at 4, 6, 8, 10, 12, 24 and 48 hpi were examined, separated in the SDS-PAGE gels 
and the transferred onto nitrocellulose membrane (0.45 μm pore). These membranes were 
incubated with special antibodies against Green Fluorescent proteins, β-galactosidase, 
and β-glucuronidase for Western-blot analysis. 
Image of Ponceau S staining give first evidence that proteins were transferred to the 
cellulose membrane by using appropriated power supply (Figure 10), marker proteins 
were detected by incubating membranes with special antibodies. 
 
 
 
Figure 10.   Blotting of proteins lysates of un-infected and infected GI-101A, HT-29, PC-3 cells. 
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3.1.2.1 Expression of GFP-RUC fusion proteins encoded in the VACV GLV-
1h68 infected cells 
 
Figure 11 show a sign of the expression of GFP-RUC fusion protein in both three cell 
line GI-101A, HT-29 and PC-3 cells. 
The first fusion protein expression was produced in VACV GLV-1h68 infected GI-101A 
cells at 10 hpi, elevated at the next time point of infection and reached a peak in time 
series at 48 hpi. Early but not much distinguished from GI-101A cells, the expression of 
RUC-GFP fusion protein was produced in VACV GLV-1h68 infected HT-29 cells at 8 
hpi and reached a peak in time series at 36 hpi. For infected PC-3 cells, evidence of the 
RUC-GFP fusion protein can be seen latest compared with other cell line where it was 
coming up since 24 hours after infection and keeping a very weak signal. This result 
indicates that GFP expression by Western-blot was lesser sensitive than the expression 
changes shown by the GFP image analysis by microscope. 
                 
 
        
Figure 11. Western-blot with GFP of GI101 cell lysate (A), HT29 cell lysate (B), PC-3 cell lysate 
(C), 3 seconds exposure, 15 µg of proteins from lysate of cells infected with VACV GLV-
1h68 were separated in SDS-PAGE 10%. 
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3.1.2.2 Expression of β-galactosidase proteins in the VACV GLV-1h68 
infected cells 
 
To examine the level of the β-galactosidase protein produced in the VACV GLV-1h68 
infected cells, SDS-PAGE gels containing protein lysates extracted from VACV GLV-
1h68 infected GI-101A, HT-29, PC-3 cells were transferred to nitrocellulose membrane. 
β-galactosidase was detected by using anti-β-galactosidase antibody. As shown in Figure 
12, signal of β-galactosidase was manifested in VACV GLV-1h68 infected cells at a level 
that was beginning detected readily from the 24 hpi of infection in both three cell lines 
and the protein level reached a peak on the 48 hpi of infection, results is similar to HT-29 
cells and PC-3 cells. This study were supposed that β-galactosidase gene which was 
inserted in the thymidine kinase (TK) gene controlled by promoter early/late p7.5 could 
be strongly activated at the late phase of replication but not in the early infection phase 
or/and reason is might be of the Western-blot is not sufficient sensitive to detect β-
galactosidase earlier or protein was degraded by proteasome in the early time. However, 
this data can compare with RUC-GFP fusion protein expression by the same Western-
blot method and analysis, noteworthy. 
 
          
 
Figure 12. Western-blot with β-galactosidase GI101 cell lysate (A), HT29 cell lysate (B), PC-3 cell 
lysate (C), 3s exposure, 15 µg of proteins from lysate of cells infected with VACV GLV-
1h68 were separated in SDS-PAGE 10%. 
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3.1.2.3 Expression of β-glucuronidase proteins encoded by marker genes in 
the tumor cells 
 
As shown above, the first expression of RUC-GFP fusion protein was shown in different 
time point. For example, that is at 10 hpi in GI-101A cells, that is 8 hpi in HT-29 cells 
and 24 hpi in PC-3 cells. Besides, the first expression of β-galactosidase protein was 
shown in VACV GLV-1h68 infected GI-101A cells at 24 hpi, results shown is similar in 
HT-29, PC-3 cells. To examine expression of of β-galactosidase which were one of three 
genes which were inserted into LIVP genome then converted to VACV GLV-1h68 (β-
glucuronidase were encoded by GUS gene in the hemagglutinin (HA) gene which were 
controlled by promoter p11), antibody against β-glucuronidase was using for Western-
blot analysis. Three time of doing experiment in the same condition to confirm the data, 
that β-glucuronidase expression is also point out the first bands in the GI-101A cells, HT-
29 cells and PC-3 cells at 24 hpi (Figure 13). 
 
                                
Figure 13. Western-blot with β-glucuronidase of GI101 cell lysate (A), HT29 cell lysate (B), PC-3 
cell lysate (C), 3s exposure, 15 µg of proteins from lysate of cells infected with VACV 
GLV-1h68 were separated in SDS-PAGE 10%. 
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3.1.2.4 Expression of marker proteins of the tumor xenograft in mice  
 
To determine expression of marker proteins which are encoded by VACV GLV-1h68 
gene in the mice bearing tumor, the tumor xenografts in the mice with GI-101A, HT-29  
and PC3 cell lines were surgeries and homogenized in the lysis buffer, then supernatant 
were collected for Western-blot analysis. Result is shown in the figure 14 below point out 
the expression of almost proteins which were extracted from tumor tissue then were 
separated in the 10% SDS-PAGE gels, protein bands were detected by Coomassie blue 
staining. We would to compare how different between uninfected sample (control) with 
infected samples after mice were subcutaneously injected with VACV GLV-1h68 virus. 
In general, some bands were disappeared compared with control one. In contrast, there 
are some bands shown appearance which have no in the control sample or shown a sign 
of more intensive (Figure 14). These bands may be derived from viral proteins extracted 
in tumor cells where viruses using host factors to produce their own products or/and host 
proteins which were degraded or induced by host-virus interaction. 
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Figure 14. Protein analysis from tumor lysate by using SDS-PAGE electrophoresis and detection 
by Coomassie blue 
 
To determine in detail of the marker proteins expressed in the tumor from mice, Western-
blot analysis were necessary to detect protein expression level. We were also using 
antibodies against proteins green fluorescent, β-galactosidase, and β-glucuronidase. 
Figure 15 indicate that expression of the marker genes in the GI-101A tumor were 
obvious, relatively. Protein bands of both three markers have shown right first tumor 
growing phase where tumors were not yet regressed by infection. They also were keeping 
persistent during tumor progression. These results indicate that a recombinant VACV 
GLV-1h68 can replicate in the tumor, they use the home tumor to evade hunt of the host 
immune system. 
 
                     
                                           
Figure 15. Western-Blot detection of marker proteins of GI-101A tumor lysate. RUC-GFP fusion 
protein(A), β-galactosidase (B), β-glucuronidase (C), β-actin (D), 3s exposure, 15 µg of 
proteins from lysate of cells infected with VACV GLV-1h68 were separated in 10% SDS-
PAGE gels. 
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In comparison, RUC-GFP fusion protein, β-galactoside and β-glucuronidase could be 
found in HT-29 and PC-3 tumor but not equal levels (Figure 16). In HT-29 tumors, 
marker proteins could initially found at intermediate tumor phase and were present during 
to the late tumor phase. In PC-3 tumors only found at 21 day post infection were present. 
Evidence of marker gene expression in mice bearing tumors showed modifications in 
each of the tumors. 
 
 
 
 
Figure 16. Western-blot detection of marker proteins of GI101, HT-29, PC-3 tumor lysate. RUC-
GFP fusion protein(A), β-galactosidase (B), β-glucuronidase (C), β-actin (D), 3s exposure, 
15 µg of proteins from lysate of cells infected with VACV GLV-1h68 were separated in 
SDS-PAGE 10%. 
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3.2. Growing characteristic of tumor cells non-infected and   
       infected with VACV GLV-1h68 
 
GI-10 1A, PC-3, HT-29 non-infected and infected cells with VACV- 1h68 at MOI 0.5 in 
the 6-well plate were determine number staining cells with Trypan-blue. Experiment 
were examined at 0, 4, 8, 12, 24, 36, 48, 60 hpi.  With the help of counting chamber, a 
diagram of live cells and dead cells number was estimated.  Figure 17 (G-co) showed 
result of Trypan-blue staining of non-infected GI-101A cells and elucidate a minor part 
of dead cells. Whereas live cells number was induced following monitoring time. 
Thereby, the total cell line and the live cell line were closed identically. At 72 hours 
maximum of cells achieve 5x10
6
. The figure 17 (G-inf) shows results of Trypan Blue 
staining of GI-101A cells infected with VACV- 1h68. After infection at 12 hpi, a live cell 
number was start reduced and dead cell increased notably. Live cell number from 2.3x10
6 
at 24 hpi fall of 1.2 x10
5 
at 72 hpi. 
The figure 18 (H-co) shows result of Trypan Blue staining of non-infected HT-29 cells 
and determine a minor part of dead cells too. However,  live cell line was increased 
following time point of monitoring until 36 hours only and maximal cell number is 6,08 
x10
6 
. After that live cell curve start reducing from 6,08 x10
6 
and down to 1.74 x10
6
 at the 
72 hours, total cell number and the live cell number were resulted reducing identically, 
achieved 1,85 x10
6
 . Figure 18 (H-inf) is also results of Trypan Blue staining of HT-29 
cells infected with VACV GLV-1h68. After 24 hours of infection, a live cell number was 
start reduced and there are no cells anymore at 72 hours. The dead cell number was 
increasing unstable until 40 hpi then decreasing companied the live cell number.  
Finally, to determine survival state PC-3 cells with and without infection with VACV- 
1h68, experimental result gave a diagram of the total, live and dead PC-3 cell non-
infected in which they can also remain the maximal number at 36 hours, achieved 2.34 
x10
6 
cells [Figure 19 (P-co)]. Later, PC-3 cells continued to grow insecurely. Figure 19 
(P-inf) is results of Trypan Blue staining of PC-3 cells infected with VACV- 1h68. At 
12
th
 hours of infection, a live cell number was start reduced and there is nothing at 72 
hours. There is few dead cells in each real time of infection, their number was also 
decreased companied the live cell number.  
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Figure 17. Distribution of live and dead non-infected GI-101A cells (G-co) and infected GI-101A 
cells (G-inf) 
       
      
    
Figure 18. Distribution of live and dead non-infected HT-29 cells (H-co) and infected HT-29 cells 
(H-inf) 
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Figure 19. Distribution of live and dead non-infected PC-3 cells (P-co) and infected PC-3 cells (P-inf) 
 
In figure 20, shows the relation of live cell percentage of GI-101A cells, HT-29 
cells and PC-3 cells infected with VACV GLV-1h68. This study indicated that a curve of 
GI-101A cells infected with VACV- 1h68 was most decreased. This result was very 
different in comparison with HT-29 cells and PC-3 cells infected with VACV GLV-1h68. 
Therefore, it is evident that VACV- 1h68 virus had more effects on the GI-101A cells in 
culture than on HT-29 cells or on PC-3 cells. 
 
Figure 20. The relation of live cell percentage of cell lines infected with VACV GLV-1h68 
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3.3 Replication of VACV GLV-1h68 in cell cultures 
 
GI-101A cells, HT-29 cells, PC-3 cells were grown in 24-well plates flat surface until 
forming a monolayer of cells covering a plastic dish. They were then infected with 
VACV GLV-1h68 at MOI 0.5. The infection medium was removed, and cells were 
incubated in fresh growth medium until cell harvest at 0, 4, 8, 12, 24, 36, 48, and 60 h 
after infection. Viral particles from the infected cells were released by a quick freeze-
thaw cycle, and the titers determined as medium (pfu/ml) in duplicate by plaque assay in 
CV-1 cell monolayers. The liquid growth medium is replaced with a semi-solid one so 
that any virus particles produced as the result of an infection cannot move far from the 
site of their production. A plaque is produced when a virus particle infects a cell, 
replicates, and then kills that cell. Surrounding cells are infected by the newly replicated 
virus and they too are killed. This process may repeat several times. The cells are then 
stained with a dye which stains only living cells. The dead cells in the plaque do not stain 
and appear as unstained areas on a colored background. Each plaque is the result of 
infection of one cell by one virus followed by replication and spreading of viruses.  
However, viruses that do not kill cells may not produce plaques. 
 
 
 
Figure 24. A viral plaques. Serial dilutions of virus have 
been plated on confluent monolayer cultures of cells. The 
cells are stained after a period of time in which a single 
virus infects a cell, produces new virus particles and 
infects surrounding cells. The white areas show areas of 
the culture in which the cells have been killed. Each 
"plaque" is the result of the presence of one original 
infectious virus particle.  
 
VACV GLV-1h68 indicated its replication capacity in all three cell lines. Compared 
between GI-101A cell lysate, HT-29 and PC-3 cells infected by VACV GLV-1h68 
derivatives showed differential replication in confluent CV-1 cells. That were 
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approximately one-sixth as efficient at initial hour after virus inoculation for HT-29 cells 
(3000 plaques/17400 plaques, respectively) and one-second for PC-3 cells  (3000 
plaques/ 6200 plaques, respectively) (Figure 25). Compared with GI-101A cell 
supernatant, the infection and replication of VACV GLV-1h68 were very different one-
third from those of HT-29 (200 plaques/600 plaques, respectively) but similar to PC-3 
cell supernatants (the same 200 plaques), suggesting that the VACV GLV-1h68 affect the 
entry, replication and egression in PC-3 cells than GI-101A cells and HT-29 cells (Figure 
25 A-B-C). 
 
Figure 25. Viral titer of VACV GLV-1h68 in GI-101A infected cells (A), in HT-29 infected cells (B), 
in PC-3 infected cells (C). 
 
Tissue samples were collected, weighed, dissected and added to 9 times of volume of 
lysis buffer. The samples were homogenized (or the samples be frozen in liquid N2 and 
stored at - 80
o
C if not used immediately). Tumor homogenisates were centrifuged at 
13000rpm for 20 min, aspirate a supernatant for plaque assay. Experiments were 
performed under the same condition with viral titration of infected cells. Then plaques 
were calculated within weight of tumor. VACV GLV-1h68 indicated its replication 
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capacity quite well in all three tumors. After comparison of plaques data between infected 
GI-101A, HT-29 and PC-3 tumors we found differences in replication. VACV GLV-
1h68 replicated most strong in GI-101A tumors. This is shown in the second tumor state 
and remains stable in the last tumor state. HT-29 tumor does not seem to be a perfect 
environment for VACV GLV-1h68 compared with GI-101A tumor but virus replication 
still keeps increasing (Figure 26). 
 
 
 
 
 
 
Figure 26. Viral titer in VACV GLV-1h68 infected GI-101A, HT-29, PC-3 tumors    at 7, 21, 42 days 
post infection. 
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3.4 Enzyme linked immunoabsorbent assays (ELISAs) using a ‘two-site’ 
sandwich detection assay for CCL2/MCP-1, CCL5/RANTES and VCAM-1 
 
The growth and progression of tumor cells depend not only on their malignant potential, 
but also on the multidirectional interactions of secreted substances. Secreted substances 
are produced by all the cell types including tumor, stroma, endothelial cells, and immune 
system cells within the local microenvironment (Bonin-Debs et al., 2004). Secreted 
substances in tumor microenvironment including extracellular matrix are constituted by 
proteins, receptors, proteoglycans, and adhesive molecules as well as a milieu of secreted 
proteins including growth factors, angiogenesis factors, proteases cytokines, and 
chemokines (Wiseman BS and Werb Z 2002; Pupa et al., 2002). It implied that 
chemokines play a key role in the recruitment of TAMs, (Robinson SC et al., 2003; Leek 
RD and Harris AL 2002). It has been also established that TAMs have pleiotropic 
functions, which can influence tumor growth. This differential effect of TAMs is believed 
to be regulated by modulation of the host immune system (Mills CD et al., 1992; Elgert 
KD et al., 1998). The influence tumor growth is both in terms of progression and 
regression. In term of progression, contribute to cancer initiation, proliferation, metastasis 
due to the immune tolerance, or suppression associated with malignant disease, in this 
hand, there is convincing data for TAMs demonstrating tumor cell growth-promoting 
effects through release of various cytokines and prostanoids (Grabbe S et al., 1994; 
Blachere NE et al., 1997). In term of regression, such as cytotoxic to the tumor cells 
(Condeelis J 2006; Luo Y 2006)-tumor growth reduction by TAMs can be mediated by 
non-specific anti-tumor cytotoxic mechanisms or induction of specific cell lytic effects. 
(Sunderkotter C 1994; Parajuli P and Singh SM 1996). An understanding of the complex 
regulatory mechanisms, therefore, that control macrophage functions during tumor 
growth is critical to planning therapeutic approaches to achieving improvement of patient 
well being and control of the malignant process.  
To investigate differences of chemokines CCL2/MCP-1, CCL5/RANTES and VCAM-1 
between tumors in the mice untreated and treated with VACV GLV-1h68, we assayed 
ELISA. The tumor was surgically removed from mice and a tumor extract was prepared 
in lysis buffer supplemented with protease inhibitor cocktail. Supernatant was kept frozen 
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at -80 °C until analyzed. Chemokines were determined by using enzyme-linked 
immunoabsorbent assays (ELISAs). ELISAs is method using a „two-site‟ sandwich 
detection assay, that is, one antibody is used to capture cytokine antigen(s) and another 
detection antibody, is the most broadly used methods to quantify cytokines in biological 
matrices because of their acceptable specificity, sensitivity, rapid turnaround time, 
convenience, the ease of performance. However, a typical ELISA can only measure one 
cytokine at a time and requires at least 100 μl sample volumes. Quantification of 
cytokines and chemokines in tumor extract were determined. All experiments were done 
in, at least, triplicate was determined. We would to determine that how VACV GLV-
1h68 injection into mice bearing tumor could change the patterns of cytokines and 
chemokines within the tumor microenvironment. Results show that in GI- 101A tumor, 
CCL5 decrease at 7 day post infection nearly 6 folds, while CCL2 decrease at the 21 dpi. 
For VCAM-1, we did not see differential changes significantly. In the HT-29 tumor, 
infection effect changes CCL5 level at the last tumor state (2 folds). Variously, CCL2 is 
decreased at 7 dpi but coming up at 21 dpi 7 folds then notably decrease 9 folds at 42 dpi. 
For PC-3, CCL5 show decrease at 42dpi, CCL2 increase at 21 dpi. In general, CCL5 and 
CCL2 seems specific decrease for GI-101A (Table 7, 8, 9).   
 
Table 7. Chemokine RANTES/CCL5 change (ng/ml) in the tumor microenvironment of tumor-
bearing mice following treatment in control mice or VACV GLV-1h68 mice. 
GI101A Monitoring day 1h68(-) 1h68(+) Fold Increase 
 7 days 91-135 16-22 -5,7 
21 days 16-17 17-20 +1,1 
42 days 106-112 114-138 +1,1 
HT29     
 7 days 1,72-1,78 1,8-2,0 +1 
21 days 9,9-10,2 9,9-10,7 +1 
42 days 12,3-13,4 7-9 -1,8 
PC3     
 7 days nd nd nd 
21 days 10 10 +1 
42 days 12,5 1,7-2,0 -7,4 
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Table 8. Chemokine MCP-1/CCL2 change (ng/ml) in the tumor microenvironment of tumor-
bearing mice following treatment in control mice or VACV GLV-1h68 mice. 
 GI101A Monitoring day 1h68(-) 1h68(+) Fold Increase 
 7 days 0,94 0,94-0,97 +1,0 
21 days 1,15-1,28 0,5 -2,3 
42 days 1,47-1,75 1,7 +1,2 
HT29     
 7 days 0,41-0,48 0,16 -2,6 
21 days 0,1-0,3 0,7-0,8 +7 
42 days 1,57-1,64 0,2 -8,5 
PC3     
 7 days nd nd nd 
21 days 0,1 0,9 +9 
42 days nd nd nd 
 
 
 
Table 9. Chemokine VCAM-1 change (ng/ml) in the tumor microenvironment of tumor-bearing 
mice following treatment in control mice or VACV GLV-1h68 mice. 
GI101A Monitoring day 1h68(-) 1h68(+) Fold Increase 
 7 days 63,7 55,6 -1,2 
21 days 53 48 -1,1 
42 days 99 80 -1,2 
HT29     
 7 days 60 56 -1,1 
21 days 44 44 +1 
42 days 65 39 -1,7 
PC3     
 7 days nd nd nd 
21 days 53 41 -1,3 
42 days 68 65 -1,1 
 
3.5 Two-dimensional gel electrophoresis profiles of infected tumors/cells with     
      VACV GLV-1h68 
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Total cytosolic soluble protein including nuclear and organellar proteins from cells and 
tumor tissues were resolved by using 2-DE. During cell lysis, interfering compounds 
(e.g., proteolytic enzymes, salts, lipids, polysacarides, nucleic acids…) were removed. To 
prevent protein degradation that otherwise may result in artifactual spots and loss of high 
molecular weight protein, protease inhibitors was added. TCA/acetone precipitation was 
used for minimizing protein degradation, for removing interfering compounds, such as 
salt, or polyphenols, and for the enrichment of very alkaline proteins such as ribosomal 
proteins from total cell lysates (Görg A and Weiss W 2000). 
Initially, the simple method for protein preparation and the linear immobilizing gel pH 3-
10 was applied for testing the distributions of GI-101A cell protein, 150 µg of protein 
from GI-101A cells infected with VACV GLV-1h68 were separated in the first 
dimension on IPG strips pH 3-10 and in the second dimension on 12.5% SDS-PAGE 
gels. As show in figure 27 (A), proteins were incompletely separated in 2-DE gels 
following horizontal direction.  This may happen by many low molecular weight proteins 
extracted from infected cells accumulated in low pH charge field but other places. In this 
case, it will be difficult for analyse precisely when many proteins would be overlaid with 
others. Therefore, this would be not helpful within this study framework for first 
overview to investigate tumor cell protein profiling using the novel oncolytic virus 
VAVC GLV 1h68. 
To overcome overlapping obstacles of using IPG strip pH 3-7, 250 µg of protein were 
separated in the first dimension on IPG strip pH 4-7 and in the second dimension on 
12.5% SDS-PAGE gels, result in figure 27 (B) shows that protein extracted from GI-
101A infected with VACV GLV-1h68, detected by Coomassie blue G-250 staining, 
exhibited also incompletely separation following vertical direction. This might be caused 
by SDS-PAGE gradient. 12% SDS-PAGE gel might not be favourable for separating of 
high molecular proteins. Separation of GI-101A samples were further continued with 250 
µg of protein separated in the first dimension on an IPG strip at pH 4-7 and in the second 
dimension on softer SDS-PAGE gel of 10%, 2-DE gels were detected by Coomassie blue 
G-250 staining. Noteworthy, result indicated that protein separation reached higher 
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resolutions [figure 27 (C)]. Finally, a linear gel with an immobilizing pH gradient of 4-7 
and SDS 10% gel were chosen to be optimal for protein resolution particularly for the rest 
of project.  
 
 
Figure 27. Selection of optimal 2-DE condition. 2-DE of protein extracted from GI-101A tumor 
infected with VACV GLV-1h68. 150 µg of protein were separated in the first dimension on 
an IPG strip at pH 3-10 and in the second dimension on a 12.5% SDS-PAGE gels (A). 2-DE 
of protein extracted from GI-101A tumor infected with VACV GLV-1h68. 150 µg of protein 
were separated in the first dimension on an IPG strip at pH 4-7 and in the second dimension 
on a 12.5% SDS-PAGE gel (B). 2-DE of protein extracted from GI-101A tumor infected with 
VACV GLV 1h68. 250µg of protein were separated in the first dimension on an IPG strip at 
pH 4-7 and in the second dimension on a 10% SDS-PAGE gel. All gels were stained with 
Coomassie blue G-250 (C).  
 
 
Although silver staining methods are far more sensitive than Coomassie blue or 
imidazole-zinc stains (detection limit is as low as 0.1 ng protein/spot). They provide a 
linear response with over a 0-40 fold range in protein concentration, which is slightly 
worse than with CBB staining. However, silver staining methods are far from 
stoichiometric, and are much less reproducible than CBB stains due to the subjective end-
point of the staining procedure which makes them less suitable for quantitative analysis. 
Silver staining methods using aldehyde-based fixatives/sensitizer are the most sensitive 
ones, but prevent subsequent protein analysis (e.g., by MS) due to protein cross-linkage. 
Coomassie staining methods have found widespread use for the detection of protein on 2-
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DEs, ease of use and compatibility with most subsequent protein analysis and 
characterization methods such as mass spectrophometry (MS). However, in terms of the 
requirements for proteome analysis, the principal limitation of CBB stains lies in their 
insufficient sensitivity, which does not permit the detection of low abundance proteins 
[the detection limit of Coomassie stains is in the range of 1-10 ng protein per spot 
(Giovanni Candiano 2004; Brian D Wolf 2007)]. Hence, typically no more than a few 
hundred protein spots can be visualized on a 2-DE, even if milligram amounts of protein 
had been loaded onto the gel. For all the reasons, Coomassie staining is still the most 
appropriate chois of protein identification by MS. 
 
 
 
Figure 28. 2-DE of protein extracted from GI-101A cells (A), HT-29 cells (B), PC-3 cells (C)-
uninfected. 250 µg of total protein were separated in the first dimension on an IPG strip at 
pH 4-7 and in the second dimension on a 10% SDS-PAGE gel. Gel was stained with 
Coomassie blue G-250. 
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Figure 29. 2-DE of protein extracted from un-infected GI-101A tumor (A), HT-29 tumor (B), PC-3 
tumor (C). 250 µg of protein were separated in the first dimension on an IPG strip at pH 4-7 
and in the second dimension on a 10% SDS-PAGE gel. Gel was stained with Coomassie blue 
G-250. 
 
Around 700, 500, 800, 850, 900, 950 individual protein spots from GI-101A cells, HT-29 
cells, PC-3 cells, GI-101A tumor, HT-29 tumor, PC-3 tumor, respectively, were detected 
in 2-DE gels. All visible protein spots were excised by both automatically and manually 
and subjected to MS/MS analysis. Results of identification by MS/MS data were scored 
by the Mascot programs, and the top-scoring gene products were considered to be the 
corresponding proteins. 
By using Delta2D software which can match correlative spots between infected gels with 
infected gels of the same cell or tumor species, we showed analysis of proteomic 
differences between early and advanced stages of infection. Protein spots of uninfected 
cell/tumor were marked in green. Infected one with VACV GLV-1h68 was marked in 
red. The protein expression difference was illustrated by the dual channel images of 2-
DEs. Although recent modern 2-DE research often utilizes software-base image analysis 
tools. Incompletely separated (overlapping spots), less-defined and/or separated (weak 
spots/noise e.g., “ghost spots”), running differences between gels (e.g., protein migrates 
to different positions on different gels), differences in software algorithms and therefore 
affect the analysis tendencies. 
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Figure 30. Differential protein expression in infected cells. Row A1, A2, A3: The differences of 
protein pattern of the GI-101A uninfected cells (green) and infected cells with VACV GLV-
1h68 (red) at 12, 24, 48 hpi, respectively. Row B1, B2, B3 are those of HT-29 cell and C1, 
C2, C3 are those of PC-3 cell, respectively. 
 
1 2 3 
A 
B 
C 
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Figure 31. Differential protein expression in infected tumors. Row A1, A2, A3: The differences of 
protein pattern of the GI-101A uninfected tumor (green) and infected tumors with VACV 
GLV-1h68 (red) at 12, 24, 48 hpi, respectively. Row B1, B2, B3 are those of HT-29 and C1, 
C2, C3 are those of PC-3, respectively. 
 
 
There are 436 protein spots excised from GI-101A cell culture, 423 protein spots were 
excised from HT-29 culture, 591 protein spots were excised from PC-3 cell cultivation 
1 2 3 
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B 
C 
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project, 597 protein spots were excised from GI-101A tumor xenograft project, 615 
protein spots were excised from HT-29 tumor xenograft project, 542 protein spots were 
excised from PC-3 tumor xenograft project. The spots obtained were subjected to trypsin 
digestion for subsequent MALDI-TOF analysis. 
Infection of virus produces a general shut off of protein synthesis, for example affects to 
the Vero cells infected with African swine fever virus increased up to 65% of cellular 
proteins (314). To investigate cellular proteins whose synthesis and changes were 
enhanced by VACV GLV-1h68 infection, we focused on proteins that are probably 
significant to the cellular response to infection particularly in tumor cells. Several 
changes in the analyzed cellular protein patterns during the infection were observed by 2-
DE analysis.  
 
3.5.1 Comparison of differential protein expression 
 
           3.5.1.1 Comparison of differential protein expression in VACV GLV-1h68    
                        uninfected and infected GI-101A cells 
 
To obtain a detailed comparison of the differences in protein expression profiles, the 
protein lysates extracted from GI101-A cells infected with VACV GLV-1h68 at 12 h, 24 
h and 48 hpi and GI101-A control were separated on the 2-DE for analysis. Spot number 
was observed about 580 to 670. In this experiment, very little obvious changes were 
observed in the number of spots of the detectable proteins in controls compared with 
infected protein spots (from 539 to 611 spots at 12 hpi, 671 at 24 hpi and 583 at 48 hpi) 
(Figure 38). Total of 436 major protein spots among them were excised automatically and 
manually from gels and subjected to trypsin digestion for subsequence MALDI-TOF 
analysis, including 225 spots among them were labelled (Figure 32). Some proteins were 
separated in two or three spots on the 2-DE (called “multiple spots”), that why there are 
178 individual protein spots were counted (30 up-regulated, 38 down-regulated and 110 
equal protein spots). 
 On the basis of average intensity ratios of protein spots, a total of 76 protein spots were 
found to be dynamically changed by infection, including 30 significantly up-regulated 
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protein spots (ratio infection/control ≥ 2). Among this 30 up-regulated protein spots 
including spots shown increasing in one state of infection but decreasing in other states 
(Table 3). There are 38 significantly down-regulated protein spots (ratio infection/control 
≤ 0.5) (Table 3). As shown in table 1, 13 protein spots showed signs of up-regulation at 
12 hpi, there are more 17 protein spots were up-regulated at 24 hpi and remains 11 
protein spots were up-regulated at 24 hpi. There are 4 protein spots which remains were 
up- regulated at 48 hpi from 12 hpi and 24 hpi. 15 protein spots were remained up- 
regulated at 48 hpi from 24 hpi and 3 protein spots are observed up- regulated at 48 hpi 
only. 
Among 38 down regulated, 20 protein spots showed signs of decreasing at 12 hpi. There 
is no evidence showed about down-regulated protein spots at 24 hpi. That pointed out 
proteins identified at 24 hpi are equal and up-regulated proteins. Among that down-
regulated proteins at 12 hpi, 13 protein spots displayed continuously decrease at 48 hpi. 4 
spots almost completely inhibition at 48 hpi. In general, the majority of protein 
expression changes appeared at 48 hours post infection. 
 
            3.5.1.2 Comparison of differential protein expression in VACV GLV-1h68   
            infected GI-101A tumors 
 
To determine a difference in GI-101A tumor protein expression profile, subcutaneous GI-
101A tumors in nude mice with and without VACV GLV-1h68 treatment  were taken 7, 
21 and 42 days after virus intravenous injection. The protein lysate extracted from VACV 
GLV-1h68 infected GI101-A tumors was separated on the 2-DE for analysis. Spot 
number was observed about 449 to 861. In this study, obvious changes were observed at 
42 dpi. Remarkably, the spot number in infected samples about half of the control ones, 
(Figure 39). Total of 597 major protein spots were excised automatically and manually 
from GI-101A tumor gels and subjected to trypsin digestion for subsequence MALDI-
TOF analysis, 368 spots among them were labelled. Many of the same proteins were 
separated in two, three or four spots on the 2-DE, they may be results of post-
translational modification during infection. Therefore, 178 individual protein spots were 
identified from 368 labelled (Figure 33).  
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 In the same basis comparison of the average intensity ratios of protein spots analysis 
through the study, a total of 295 protein spots were found to be dynamically changed in 
GI101-A tissue tumors, including 103 significantly up-regulated protein spots, and 192 
significantly suppression protein spots showed in table 1.  
As shown in table 1, 49 protein spots showed signs of up-regulation at 7 dpi, including 20 
human protein and 29 mouse protein spots. There are more 17 protein spots were up-
regulated at 21 dpi and remains 10 protein spots were up-regulated at 42 dpi from 7 dpi 
and 21 dpi. They are all mouse protein spots, 6 spots are unknown proteins. All of them 
are shown most intensive at the last infection time point. 22 protein spots were coming at 
21 dpi. The rest 27 protein spots just up-regulated at 42 dpi only. In general, the majority 
of protein expression changes about enhancement appeared at 42 day post infection.  
Total 36 human up-regulated spots including 31 individual protein, and 53 individual 
mouse protein among 66 mouse protein spots were found. 
 Among 192 the down-regulated spots, 30 protein spots observed at 7 dpi (4 protein spots 
displayed decreasing at 21 and 42 dpi, 4 protein spots continue decreasing then stop 
down- regulation a 21 dpi. 16 other spots start their decreasing at 21 dpi and remains 
down- regulated at 42 dpi, including 12 human protein spots and 9 human protein spots. 
At 42 dpi, there are 184 of down-regulated proteins spots (observed 50% in total spots in 
GI-101A tumor profile), 130 human spots and 54 mouse spots.  
 
            3.5.1.3 Comparison of differential protein expression in VACV GLV-1h68  
            uninfected and infected HT-29 cells 
 
To investigate the effects of oncolytic VACV GLV-1h68 on different tumor cell lines we 
performed experiments in human tumor colon HT-29 cell line. In the 2-DE analysis, spot 
number observed were about 440 to 500. There were some changes were observed in 
number of spots in the controls compared with infected protein spots at 12 hpi (Figure 
38). Total of 423 major protein spots among them were excised automatically and 
manually from HT-29 cell gels and subjected to trypsin digestion for subsequence 
MALDI-TOF analysis, 238 spots were labelled (Figure 34). Some proteins were 
separated in two or three spots o the 2-DE and 176 individual protein spots were counted.  
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Table 5 shows total of 82 protein spots were found to be dynamically changed in HT-29 
cells infected with VACV GLV-1h68, including 25 significantly up-regulated protein 
spots (ratio infection/control ≥ 2) and 57 significantly down-regulated protein spots (ratio 
infection/control ≤ 0.5). As shown in table 5 of the up-regulated proteins in infected HT-
29, 18 protein spots showed signs of up-regulation at 12 hpi , there are 5 more protein 
spots up-regulated at 24 hpi but 5 spots do not change at 24 hpi. There are 12 protein 
spots which remained up- regulated at 48 hpi from 12 hpi and 24 hpi. 2 protein spots 
were observed up-regulated at 48 hpi only. 
 16 protein spots were found showing signs of down-regulation at 12 hpi, 12 spots 
continued to decrease at 48 hpi. 3 spots showed almost reduction at 48 hpi. Other 29 
showed signs of a decrease at 48 hpi only. 
 
            3.5.1.4 Comparison of differential protein expression in VACV GLV-1h68   
            infected HT-29 tumors 
 
To determine differences in HT-29 tumor protein expression profile, subcutaneous HT-29 
tumors were generated in nude mice with and without VACV GLV-1h68 treatment. 
Tumors were harvested at 7, 21 and 42 days after VACV GLV-1h68 intravenous 
injection. Spot number observed were about 662 to 881. In this study, obvious decrease 
changes were observed in the number of spots of the detectable protein in controls 
compared with infected tumor protein spots also at late tumor state (42 dpi) (Figure 39). 
About 615 major protein spots were excised from HT-29 tumor gels. 264 spots among 
them were identified and labelled (Figure 35). 
Table 2 shows that total of 129 protein spots were found to be dynamically changed in 
HT-29 tissue tumors. They include 57 human protein spots and 72 mouse spots.  Many of 
the same proteins were separated in two, three or four spots on the 2-DE, that explains 
why there are 92 individual protein spots counted. 62 protein spots showed signs of up-
regulation at 7 dpi, which included 33 human protein and 29 mouse protein spots. 16 
protein spots were up-regulated at 21 dpi and 15 protein spots remained up-regulated at 
24 dpi. 7 of them are human protein spots. There are only 9 protein spots which were 
coming up at 42 dpi. 4 spots just from 21 dpi and 5 other spots continued show a signs of 
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down-regulation from 7, 21 dpi. In general, the majority of protein expression changes 
occurred at 7 day post infection.  
Among the down- regulated proteins, 24 protein spots were observed at 7 dpi, 25 at 21 
dpi and 42 at 42 dpi. Among 42 down-regulated spots at 42 dpi, there were 8 spots that 
showed a signs of decrease very early at 7 dpi, 3 spots started a decrease at 21 dpi and 
remained their low concentration levels at 42 dpi. 
 
            3.5.1.5 Comparison of differential protein expression in VACV GLV-1h68  
            infected PC-3 cells 
 
The growth, development and function of the prostate gland are dependent of the 
presence of hormone, i.e. androgens. This hormone can be converted in the prostate by 
enzymes (i.e. 5α-reductase). Prostate cancers as well as prostate cells require the presence 
of androgens to survive. To determine how VACV GLV-1h68 interacts with prostate 
cancer cells, proteomic analysis was performed. Protein lysates extracted from infected 
and uninfected PC-3 cells at 12 h, 24 h and 48 hpi were separated in the 2-DE for 
analysis. Spot number observed to be about 530 to 780. A few obvious changes were 
determined at 48 hpi (Figure 38). Total of 591 major protein spots were excised 
automatically and manually from PC-3-3 cell gels and subjected to trypsin digestion for 
subsequence MALDI-TOF analysis, including 322 spots among them were ladled (Figure 
36). Some proteins were separated in two or three spots on the 2-DE and 268 individual 
protein spots counted.  
 On the basis of the average intensity ratios of protein spots, a total of 181 protein spots 
were found to be dynamically changed in PC-3 cells infected with VACV GLV-1h68 
(ratio infection/control ≥ 2) (Table 6). 29 spots showed signs of up-regulation at 12 hpi, 
there are 15 more protein spots up-regulated at 24 hpi but 6 spots slowed up-regulation at 
24 hpi. There are 16 protein spots which remained up-regulated at 48 hpi through 12 hpi 
and 24 hpi. 10 protein spots were observed to be up-regulated at 48 hpi only. 
There are 57 spots which showed a sign of down-regulation at 12 hpi, 57 at 24 hpi and 
107 at 48 hpi.  
 85 
 
Among 107 protein spots were signs of down-regulation at 48 hpi, 50 spots continued to 
decrease up to 48 hpi from 12 hpi and 24 hpi. 13 spots started to be inhibited at 24 hpi 
and continued to decrease at 48 hpi. 19 spots showed almost complete inhibition at 48 
hpi. Other 54 showed signs of a decrease at 48 hpi only.  In general, the majority of 
protein expression changes appeared at 48 hours post infection. 
 
            3.5.1.6 Comparison of differential protein expression in VACV GLV-1h68  
            infected PC-3 tumors 
 
In PC-3 tumor protein expression profile, spot number was observed about 553 to 945. In 
this study, decreasing changes were observed in each time point of infection (Figure 39). 
Total of 542 major protein spots were excised for trypsin digestion and for subsequence 
MALDI-TOF analysis, 162 spots among them were labelled (Figure 37). Total of 101 
protein spots were found to be dynamically changed in PC-3 tissue tumors (Table 3). 
Many the same proteins were separated in two, three even four spots on the 2-DE, that 
explains why there are 69 individual protein spots counted.  
In infected PC-3 tumors, at 7 dpi no evidence was shown in protein increase. We found 
15 proteins started to increase their amount at 21 dpi but stopped to be enhanced at 41 
dpi. While 30 protein spots were enhanced at the late of infection time (42 dpi), 19 spots 
of them gave evidence for equal or to be down-regulated at early infection time.  
19 protein spots showed down-regulation at 7 dpi, also 19 at 21 dpi and 52 at 42 dpi. 
There are 21 spots showed complete disappearance at 42 dpi. In general, the majority of 
protein expression was found to be down-regulated at 42 days post infection.  
 
 
           3.5.2 Comparison of regulated and modified reproducibly identified upon  
        VACV GLV-1h68 infection  
 
Proteins that reproducibly regulated differentially or modified upon VACV GLV-1h68 
infection of the indicate cells/tumor were sorted according to their cellular function, the 
identified cellular proteins were involved in the viral proteins, in cytoskeleton, in stress 
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response, in translation , in RNA processing, in ubiquitin-proteasome pathway (UPP), in 
signal transduction, and in metabolic enzymes (Table 1-6). 
 
In VACV GLV-1h68 infected GI-101A cells 
 
In GI-101A cell protein profiling, the percentage of up-regulated and down-regulated 
protein spots was 44% and 56%, respectively. Thirty-four up-regulated spots 
corresponded to the following 30 proteins: 10 viral proteins (33,3%), 3 cytoskeletal 
proteins (10,0%), 3 macromolecular biosynthesis proteins which including translation 
associated and RNA processing (10,0%), 10 metabolism associated and transport proteins 
(33,3%) and 2  signal transduction proteins (6,7%) (Figure 41, 42). Some obviously up-
regulated proteins are cytosolic malate dehydrogenase (H-MDH1), Rho GTPase 
activating protein 1 (H-Arhgap1) (Table 4)  
11 viral proteins were identified produced by VACV GLV-1h68 very clear during 
infection in infected GI-101A cells. As well as infected GI-101A cells, viral proteins 
were also identified produced in infected HT-29 and PC-3 cells. Surprisingly, in infected 
HT-29 cells, infected PC-3 cells, VACV GLV-1h68 replicate strongly with evidence of 
the protein differential expression almost over than 5 folds. Particularly, enzymes like a 
serine protease inhibitor-like SPI-1 (V-C12L) as known as enzymes belong to serpin 
family, this viral protein may be involved in the regulation of the complement cascade 
(315). This protein is strongly increasing in all three infected cell lines. Other protein, 
dsRNA-dependent PK inhibitor (V-E3L), found increase in GI-101A and HT-29 infected 
cells, this protein may inhibit protein synthesis by phosphorylating of eukaryotic cell for 
its own protein synthesis, using ribonucleotide reductase  [(Ribonucleoside-diphosphate 
reductase (V-I4L)] encoded by vaccinia virus as a model for the mammalian enzyme 
(316). In this study, V-I4L was found greatly increase in HT-29 and PC-3 infected cells. 
Vaccinia virus A6L (V-A6L) encodes a virion core protein required for formation of 
mature virion (317) shows up-regulated in three infected cells. We could not find viral 
proteins in infected tumors. Perhaps that viral protein amount was not enough for MS 
detection or they might be modificated and digested by host enzymes in tumor 
environmental. (Table 4, 5, 6 and figure 40A-B-C). 
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Fourty two down-regulated spots corresponded to the following 38 proteins: 4 
cytoskeletal proteins (10,5%), 8 stress response (21,1%), 5 macromolecular biosynthesis 
proteins which including translation associated and RNA processing (13,2%), 4 ubiquitin 
proteasome pathway (10,5%), 9 metabolism associated and transport proteins (23,7%) 
and 5  signal transduction proteins (13,2%). Strongly down-regulated proteins are heat 
shock 70kDa protein 1A variant (H-hsp701a), proteasome activator subunit 2 (H-
PSME2) (Figure 42).   
 
In VACV GLV-1h68 infected GI-101A tumors 
 
The percentage of up-regulated and down-regulated protein spots was 33% and 67%, 
respectively. 103 human and mouse up-regulated spots corresponded to the following 89 
individual proteins: 10 cytoskeletal proteins (11,2%), 8 macromolecular biosynthesis 
proteins which including translation associated and RNA processing (9%), 18 
metabolism associated and transport proteins (20,2%), 13  signal transduction proteins 
(14,6%) and 29,2% other proteins (Figure 41). 
Recently it was reported that adenylate kinase-1 (M-ADK1) knockout mice (AK-/-) 
exhibit elevated rates of glucose uptake following repeated contractions and hypoxia 
(318), it is interesting to find that M-ADK1 in infected GI-101A cells  strongly up-
regulated in the intermediate tumor phase. Or up-regulated mouse ferritin heavy chain M-
Fth1, this protein stores iron in a soluble, non-toxic, readily available form, important for 
iron homeostasis, has ferroxidase act, iron is taken up in the ferrous form and deposited 
as ferric hydroxides after oxidation. Some more other protein show strongly up-regulated 
in GI-101A infected cells  like as mouse vimentin (M-Vim), prolyl endopeptidase (H-
PREP)                             ceruloplasmin isoform b (M-Ceru), ferritin heavy chain 1 (M-
Fth1), Ferritin light chain 1  (M-Ftl1), cathepsin Z (M-Ctsz),  fibrinogen, B beta 
polypeptide (M-Fibrb), HMW kininogen-I variant (M-KngnI), serine (or cysteine) 
peptidase inhibitor, clade A, member 3K (M-SPIC3K), thrombospondin (M-Thbs). 
Otherwise, many unknown proteins strongly increasing in infected GI-101A tumor were 
identified. Most of them are proteins with molecular mass from 20 to 70 kD (Table 1).  
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191 human and mouse down-regulated spots corresponded to the following 181 proteins: 
19 cytoskeletal proteins (10,5%), 17 stress response (9,4%), 19 macromolecular 
biosynthesis proteins which including translation associated and RNA processing 
(10,5%), 8 ubiquitin proteasome pathway (4,4%), 48 metabolism associated and transport 
proteins (26,5%) and 14 signal transduction proteins (7,7%), 36 unknown proteins 
(19,9%) (Figure 42). In particular, many proteins were inhibited in the late stages of 
VACV GLV-1H68 infection such as 3-phosphoglycerate dehydrogenase (H-PHGDH), 
acetyl-Coenzyme A acetyltransferase 2 (H-Acat2), Acidic ribosomal phosphoprotein P0 (M-
ARPP0), Adenosine kinase (H-AK), aldehyde dehydrogenase 1A3 (H-ALD1A3), aspartyl-tRNA 
synthetase (H-AspS), brain glycogen phosphorylase (H-Pygb), chaperonin containing TCP1 (H-
CCT2, H-CCT6a, H-CCT8) (Table 1) 
 
In VACV GLV-1h68  infected HT-29 cells 
 
The percentage of up-regulated and down-regulated protein spots was 29% and 71%, 
respectively. 25 human up-regulated spots corresponded to the following 23 individual 
proteins: 10 viral proteins (43,5%), 3 cytoskeletal proteins (13,0%), 3 stress reponse 
(13,0%), 4 metabolism associated and transport proteins (17,4%) (Figure 41). 
Proteins show strongly up-regulated in HT-29 infected cells like as heat shock 70kDa 
protein 8 isoform 2 (H-hsp708), keratin 1 (H-Krt1), KRT8 protein (H-Krt8) (Table 5).  
57 down-regulated spots corresponded to the following 52 proteins: 2 cytoskeletal 
proteins (3,8%), 4 stress response (7,7%), 5 macromolecular biosynthesis proteins which 
including translation associated and RNA processing (9,6%),  23 metabolism associated 
and transport proteins (44,2%) and 7 signal transduction proteins (13,5%) (Figure 42). 
Some cytoskeleton proteins show obviously down-regulated such as actin, gamma 1 
propeptide (H-ACTG), ARP1 actin-related protein 1 homolog A, centractin alpha (H-
ARP1). Strongly decreased proteins are annexin A13 isoform b (H-A13B), hypothetical 
protein (H-Hyp) (Table 5). 
 
In VACV GLV-1h68 infected HT-29 tumors 
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The percentage of up-regulated and down-regulated protein spots was 69,3% and 30,7%, 
respectively. 82 human and mouse up-regulated spots corresponded to the following 70 
individual proteins: 1 viral proteins (1,4%), 9 cytoskeletal proteins (12,9%), 3 stress 
reponse (4,3%), 22 metabolism associated and transport proteins (31,4%), 8 signal 
transduction (11,4%) (Figure 41). 
Proteins show strongly up-regulated in HT-29 infected tumors like as keratin 20 (H-
Krt20), peroxiredoxin (H-PRDX2, H-PRDX3, H-PRDX4), RAB14, member RAS 
oncogene family (M-RAB), proteasome (M-PSMA1, M-PSMD7). In this profiling, 
elongation factor 2 (M-EF2), TALDO1 protein (H-Tal1), IDI1 protein (H-IDI1), 
Triosephosphate Isomerase (H-TPI1) shown significant increased in the first tumor state 
but strong down in the late tumor state (Table 2).  
42 down-regulated spots corresponded to the following 31 proteins: 4 cytoskeletal 
proteins (13,3%), 1 stress response (3,3%) 2 macromolecular biosynthesis proteins which 
including translation associated and RNA processing (6,6%),  8 metabolism associated 
and transport proteins (26,7%) and other proteins (20%) ( Figure 42). 
Protein show obviously down-regulated is albumin 1 (M-Alb1). While Elongation factor 
2 (M-EF2), M-ENO3, Ig gamma-1 chain C region (15C5) - mouse (fragment) (M-IgGc) 
express up-regulated in the early state and inhibited in the last state (Table 2). 
 
In VACV GLV-1h68 infected PC-3 cells 
 
The percentage of up-regulated and down-regulated protein spots was 30,8% and 69,2%, 
respectively. 54 human up-regulated spots corresponded to the following 49 individual 
proteins: 11 viral proteins (22,4%), 6 cytoskeletal proteins (12,2%), 2 stress reponse 
(4,1%), 8 macromolecular biosynthesis proteins which including translation associated 
and RNA processing (16,3%), 12 metabolism associated and transport proteins (24,5%), 
3 signal transduction (6,1%) (Figure 41). 
Proteins show strongly up-regulated in PC-3 infected cells like as tropomyosin 3 isoform 
2 (H-Tpm3), DNA replication licensing factor MCM4, CCT2 (H-TCP1 ), PPA1 protein 
(H-PPA1), many proteins in the RNA process, COMT protein (H-COMT). Keratin group 
shows up-regulated in the last infection time. (Table 6).  
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127 down-regulated spots corresponded to the following 110 proteins: 13 cytoskeletal 
proteins (11,8%), 11 stress response (10%), 13 macromolecular biosynthesis proteins 
which including translation associated and RNA processing (11,8%),  37 metabolism 
associated and transport proteins (33,6%) and 16 other proteins (14,5%) ( Figure 42). 
Proteins show obviously down-regulated are L-plastin variant (H-LCP1), group of actins 
(H-ActB, H-ActG, H-ACTN4), heat shock 70kDa proteins (H-Hsp704, H-hsp708, H-
HSP90), oxygen regulated protein precursor (H-Orp), eukaryotic translation initiation 
factor 4B (H-EIF4B), ubiquitin activating enzyme E1(H-UBE1), dipeptidylpeptidase 9 
(H-DPP9Ê) (Table 6). 
 
In VACV GLV-1h68 infected PC-3 tumors 
 
The percentage of up-regulated and down-regulated protein spots was 44% and 56%, 
respectively. 45 human and mouse up-regulated spots corresponded to the following 40 
individual proteins: 2 cytoskeletal proteins (5%), 3 stress reponse (7,5%), 10 
macromolecular biosynthesis proteins which including translation associated and RNA 
processing (10%), 8 metabolism associated and transport proteins (20%), 8 signal 
transduction (20%)  and 14 unknown proteins (35%) (Figure 41). 
Proteins show strongly up-regulated in PC-3 infected tumors like calreticulin (H-Calr), 
Chain A, Crystal Structure Of 14-3-3 Gamma In Complex With A Phosphoserine Peptide 
(H-1433G), apolipoprotein A-I (M-ApoA1) show up-regulated at 7dpi but down-
regulated at 42dpi (Table 3).  
56 down-regulated spots corresponded to the following 51 proteins: 6 cytoskeletal 
proteins (11,8%), 4 stress response (7,8%), 4 macromolecular biosynthesis proteins 
which including translation associated and RNA processing (7,8%),  12 metabolism 
associated and transport proteins (23,5%) and 16 unknown proteins (31,4%) (Figure 42). 
Proteins show obviously down-regulated are BiP protein  (H-BiP), HSP90AA1 protein 
(H-HSP90AA1), EBNA-2 co-activator variant (H-p100), enolase 1 variant (H-Eno1), 
epsilon subunit of coatomer protein complex isoform c (H-COPE), Ferritin light chain 1 
(M-Ftl1), Rho GDP dissociation inhibitor (GDI) alpha (H-GDIa), vinculin isoform meta-
VCL (H-mVCL), 3 unknown proteins with molecular mass of 50-70 kD (Table 3). 
 91 
 
 
 
 
Figure 32. The differences in protein patterns of GI-101A cell uninfected (green) and VACV GLV-
1h68 infected GI-101A cells (red) were illustrated by the Dual channel images of 2D-gels 
produced with Delta 2D Software. 
 
 
 
 92 
 
                        
            
 
Figure 33. The differences in protein patterns of GI-101A tumor uninfected (green) and the GI-101A 
tumor infected with VACV GLV-1h68 (red) were illustrated by the Dual channel images of 
2D-gels produced with Delta 2D Software. 
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Figure 34. The differences in protein patterns of uninfected HT-29 cells (green) and VACV GLV-
1h68 infected HT-29 cells (red) were illustrated by the Dual channel images of 2D-gels 
produced with Delta 2D Software. 
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Figure 35. The differences in protein patterns of HT-29 tumor uninfected (green) and the HT-29 
tumor infected  with VACV GLV-1h68 (red) were illustrated by the Dual channel images of 
2D-gels produced with Delta 2D Software. 
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Figure 36. The differences in protein pattern of PC-3 cells uninfected (green) and the PC-3 cells 
infected VACV GLV-1h68 (red) were illustrated by the Dual channel images of 2D-gels 
produced with Delta 2D Software. 
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Figure 37. The differences in protein patterns of PC-3 tumor uninfected (green) and the PC-3 tumor 
infected  with VACV GLV-1h68  (red) were illustrated by the Dual channel images of 2D-
gels produced with Delta 2D Software. 
 
 97 
 
 
 
Figure 38. Protein spots number in infected cells.  Protein spots number of VACV GLV-1h68 
infected GI101-A cells separated in 2-DE (A), infected HT-29 cells (B), infected PC-3 
cells (C). 
 
 
 
 
 
 
Figure 39. Protein spots number in infected tumors.  Protein spots number of VACV GLV-1h68 
infected GI101-A tumors separated in 2-DE (A), infected HT-29 tumors (B), infected 
PC-3 tumors (C). 
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              Figure 40A. Viral protein expression in the infected GI-101A cells separated in 2-DE 
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Figure 40B. Viral protein expression in the infected HT-29 cells separated in 2-DE 
 
 
Figure 40C. Viral protein expression in the infected PC-3 cells separated in 2-DE 
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Figure 
41. 
Functional classification of up-regulated proteins spots in the human 
tumor cells with and without VAVC GLV-1h68 treatment; time points 
were taken 12, 24 and 48 hours after virus infected cells and subcutaneous 
tumors in nude mice with and without VAVC GLV-1h68 treatment; time 
point were taken 7, 21 and 42 days after virus intravenous injection; >2 fold 
of enhancement of protein expression after virus treatment were considered. 
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Figure 
42. 
Functional classification of down-regulated proteins spots in the human 
tumor cell lines with and without VAVC GLV-1h68 treatment; time 
points were taken 12, 24 and 48 hours after virus infected cells and 
subcutaneous tumors in nude mice with and without VAVC GLV-1h68 
treatment; time point were taken 7, 21 and 42 days after virus intravenous 
injection; >2 fold of reduction of protein expression after virus treatment 
were considered. 
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DISCUSSION 
 
 
 
In this study, increasing evidence emphasizes comparative proteomics to screen 
the differentially expressed proteins associated with host tumor cellular responded 
processes of virus infection (Seet BT. and McFadden G. 2002). From the literature, it 
appears that very few studies have been performed to analyze the interplay between 
vaccinia virus and host cells using proteomic analysis. In our study, we obtained a 
dynamic overview of the altered protein expression of tumor cells responding to VACV 
GLV-1h68. The identified cellular proteins function in translational regulation, UPP, 
cytoskeleton organization, signal transduction, stress response, macromolecular 
biosynthesis, and as metabolic enzymes (Table 1, 2, 3, 4, 5, 6). In general, in the cell 
lines, the proteins found to be differentially regulated are most often associated with 
metabolic processes, in particular with primary energy metabolism (glucose catabolism, 
TCA and lactate production). In tumors, the responses cover a much broader panel of 
cellular processes, including signalling (e.g., cell death), transport (in particular of iron 
ions) and migration. A common pathway to be upregulated in both tumors and cell lines 
is the "unfolded protein response".  
 
4.1 VACV GLV-1h68 infection hijacking of the host translation apparatus 
 
In practical terms, it would be important to understand what is changed insight 
tumors where VACV GLV-1h68 replicate specifictly. Then some tumors could be 
eliminated through viral oncolysis, while others are resistant. It appears that the degree of 
viral replication in vivo is a key determinant. Protein data in this study indicated that 
protein profile changes associated with viral replication precede tumor destruction by a 
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substantial amount of time. For instance, viral replication was quite active at day 21 and 
keeping their growth before tumor shrinkage at day 42 for GI-101A xenografts 
(regressive tumors); at the same late time significant shut down of cancer cell metabolism 
and simultaneous activation of the mouse response (Table 1).  
Interestingly, homo sapiens eukaryotic translation initiation factor 2, subunit 1 
alpha, 36kDa (H-eIF2) is part of the heterotrimeric complex eIF2, which in a GTP-bound 
form binds methionyl-initiator tRNA (Met-tRNAMeti ) is a eukaryotic translation 
initiation factor that participates in cap-dependent translation by binding the initiator 
tRNA to the 40S ribosomal subunit (Merrick, W. C. 2004) and plays a central role in the 
maintenance of a rate-limiting step in cellular mRNA translation (Kimball, S. R. 1999). 
The reported data showed that the host translational machinery was turned off by down-
regulating EIF4A2 in cells infected with influenza virus type A, poliovirus, herpes 
simplex virus, and enterovirus 71 (Leong, P. W. et al., 2002; Kuyumcu-Martinez, N. M. 
et al., 2004). One of the best characterized mechanisms for regulating protein synthesis is 
the reversible phosphorylation of the a subunit of eukaryotic protein synthesis initiation 
factor 2, eIF2α (Hershey, J. W. B. 1993; Merrick, W. C. 1992). Phosphorylation of eIF2α 
increases the stability of complexes formed between eIF2α and eIF-2B (Safer, B. 1983). 
Since eIF-2B is required for the exchange of GDP for GTP in the recycling of eIF2 in the 
formation of the eIF2-GTP Met-tRNA ternary complex and exists in cells in relatively 
low molar quantities with respect to eIF2, phosphorylation of only a limited amount (i.e., 
20-25%) of eIF2α is sufficient to sequester virtually all of the eIF-2B, resulting in 
inhibition of protein synthesis (Safer, B. 1983). Interestingly, H-eIF2α was considerably 
down-regulated in VACV GLV-1h68 infected GI-101A cells and tumor xenografts 
(Table 1, 4). Hence, this may be inferred that VACV GLV-1h68 turns off the host 
translational machinery for initiating its viral translation in infected cells by down-
regulating eIF2α but not EIF4A2.  
A number of cellular stress conditions, such as perturbation in calcium 
homeostasis or redox status, elevated secretory protein synthesis, expression of misfolded 
proteins, sugar/glucose deprivation, altered glycosylation, and overloading of cholesterol 
can interfere with oxidative protein folding and subsequently lead to accumulation of 
unfolded or misfolded proteins in the ER lumen, which constitutes a fundamental threat 
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to the cells. The ER has evolved highly specific signaling pathways to alter 
transcriptional and translational programs to cope with the accumulation of unfolded or 
misfolded proteins in the ER lumen. This adaptive response, which couples the ER 
protein folding load with the ER protein folding capacity, is termed the unfolded protein 
response (UPR) (David Ron. 2002; Patil C. and Walter P. 2001). A transient inhibition of 
protein synthesis occurs during the unfold protein response (UPR), which is achieved by 
activation of PKR-like endoplasmic reticulum (ER) kinase (PERK) that phosphorylates 
eIF2α (Harding, H. P. et al., 1999; Shi, Y. et al. 1998). Among other things, this leads to 
the loss of cyclin D1 from cells (Brewer, J. W. and Diehl, J. A. 2000), causing a G1 arrest 
that prevents the propagation of cells experiencing ER stress. Paradoxically, the block in 
translation specifically allows the activating transcription factor 4 (ATF4) to be 
synthesized (Brewer, J. W. and Diehl, J. A. 2000) and transactivate downstream genes, 
like GADD34 (Ma, Y. and Hendershot, L. M. 2003), which is the regulatory subunit of 
the PP1 phosphatase that acts on eIF2α and reverses the translation arrest, and C/EBP-
homologous protein (CHOP) (Ma, Y. et al., 2002), which has been implicated in 
apoptosis. Evidence of down-regulated eIF2α could be explained for inhibiting tumor 
follow apoptosis branch which could contribute for GI-101A tumor regression. 
Among protein differentially expressed in the GI-101A xenografts from VACV 
GLV-1h68 infected animals, the large majority were down-regulated, particularly, in 
xenografts excised at day 42 suggesting that viral replication depresses cellular 
metabolism (Table 1).  
Comparison of GI-101A xenografts differential protein expression identified, 
which involve in anti-apoptosis mediate pathway in the tumor cells, they conclude 12 
proteins down regulated. Among them, including positive regulatiton NK-αB (H-PRDX3, 
H-PRDX4), signal transduction H-GDIa ( Rho GDP dissociation inhibitor (GDI) alpha), 
H-eIF2 ( Eukaryotic translation initiation factor 2, subunit 1  alpha, 35kDa), H-A1 ( 
Annexin A1), H-A5 (annexin A5), M-1433T (Ywhaq protein), other metabolism and 
transport proteins H-TPT1 (Tumor protein, translationally-controlled), M-Ppp2cb ( 
Similar to Serine/threonine-protein), phosphatase  2A catalytic subunit beta isoform 
(PP2A), H-ACTN1 ( Actinin, alpha 1), H-DDAH2 ( Dimethylarginine 
dimethylaminohydrolase 2), M-Alb1 ( Mouse albumin 1). In contrast, group of protease 
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inhibitors show up-regulated (M-KngnI, M-SPIA3K, H-SPIB5, M-Serp1c) (Table 1). 
What does role of protease inhibitor in tumor? In in vitro study demonstrate that 
combination of ER stress and proteasome inhibitors greatly promoted the destructive 
elements of the UPR, including CASPASE-12 cleavage and apoptosis. Proteasome 
inhibitors are being used to successfully treat patients with multiple myeloma (Adams, J. 
2004). Although proteasome inhibitors have a myriad of effects including a weak 
activation of the UPR, and it has not been demonstrated that the UPR is activated in 
myeloma cells, it is possible that an unbalanced stress response in these cells could 
contribute to tumor death. These studies would support for evidence of regressing in GI-
101A  xenografts by down regulated proteasome inhibitor level. Unfortunately, in the 
HT-29 xenografts (non-responding), proteins which involved in anti-apoptosis pathway 
and protease inhibitor group show to be actually opposite difference. In principle, ER 
stress has been implicated in, and could potentially have opposing roles during, several 
different stages of tumor development. During early tumorigenesis and before 
angiogenesis occurs, activation of UPR could activate the unfolded protein response 
(UPR) then induce a G1 arrest and activate p38, both of which would promote a dormant 
state. If the apoptotic branches of the UPR are also activated during this stage of tumor 
development, cancer cells will be selected that have mutated elements of the apoptotic 
machinery to evade the alternative fate of death. ER stress also induces anti-apoptotic 
NF-κB and inhibits p53-dependent apoptotic signals. If the balance of early cancer 
development tilts against cell death, ER stress can further promote the aggressive growth 
of these cancer cells by enhancing their angiogenic ability, for example through GRP170 
induction and increased vascular endothelial growth factor (VEGF) secretion. In HT-29 
xenografts situation, combination of high anti-apoptosis related proteins level and the low 
proteasome inhibition protein level with changing of cellular metabolism process which 
occurs in the early tumor phase (7 dpi).  VACV GLV-1h68 replication was even 
activated at 21 dpi but metabolism process changes insight infected tumors tend to 
adverse physiological condition. In PC-3 xenografts ( non regressing), where we could 
see the differential protein expression model of deceasing anti-apoptosis and increase of 
proteasome inhibitors seems similar to GI-101A xenogaft. This would be suggest that 
protein profile changes associated with viral replication precede tumor destruction slower 
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than GI-101A tumors, somehow PC-3 xenografts can resist longer from structural 
collapse.  It is appropriate that investigation on cytoskeletal proteins, there are 20 dow-
regulated cytoskeletal proteins in GI-101A tumor. On the contrary, only 7 cytoskeletal 
proteins were found to be dow-regulated express by HT-29 and PC-3 xenografts from 
infected compared to non-infected animals. 
 
 
4.2 Alteration of cytoskeleton networks 
 
Studied GI-101A tumors, revealed features on microfilament-associated and 
microtubule-associated proteins that  many actin and tubulin proteins were up-regulated 
(H-ACTB, H-Btub, H-FLNA, H-Krt2, H-Krt8, H-LRPPRC, M-Myl1, M-Vim) whereas 
Microfilament-associated proteins (H-ACTN1, H-ARP2, H-Glsln, H-Moe, H-Tpm2, H-
TUBB2C) were down-regulated (Table 1). Unlike microfilament-and microtubule-
associated cytoskeleton, Gelsolin isoform b (H-Glsln) was greatly decreased. Although 
these proteins may not be specific to VACV GLV-1h68, most of the cytoskeleton 
alterations detected in VACV GLV-1h68 infected tumors were caused by VACV GLV-
1h68. IFA clearly demonstrated that the β-tubulin networks collapse and disperse in 
IBDV-infected cells (Xiaojuan Zheng et al., 2008).The same result was obtained in this 
study in which human β-tubulin was down-regulated in the GI-101A infected cells (Table 
4), PC-3 infected cells (Table 6) and PC-3 infected tumors (Table 3). Hence, we 
speculate that cytoskeletal disruption may be a critical mechanism of VACV-GLV-1h68 
particle release from infected cells. Recent evidence demonstrates that various viruses 
manipulate and utilize the host cytoskeleton to promote that viral infection (Radtke, K. et 
al., 2006). Several studies have shown that human immunodeficiency virus (HIV) type 1 
protease cleaves the IF vimentin and induces the collapse of vimentin in infected cells 
(Xiaojuan Zheng et al., 2008; Alexander Rassmann et al., 2006). Further elucidation is 
required to determine if IBDV protease VP4 uses an HIV-like strategy to cleave 
vimentin, resulting in highly decreased expression and the collapse of the vimentin 
network. Here we found decreased expression human vimentin in PC-3 infected tumor 
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only (Table 3). However, human vimentin in PC-3 xenografts was dow-regulated 
dispersely at 21 dpi only then seems remodeled at 42 dpi by up-regulated expression.  
In this study, mouse Apolipoprotein A-I (M-Apoa1) expression was up-regulated 
in GI101-A and PC-3 infected tumors. In contrast, the signal transduction protein Rho-
GDP dissociation inhibitor beta (M-GDIa) was considerably down-regulated (Table 1, 3 
respectively). Primary reported that Apoa1, a major constituent of high-density 
lipoproteins, alters plasma membrane morphology by participating in the reverse 
transport of cholesterol binding with ATP-binding cassette transporter A1 (Wang, N. et 
al., 2000), and activates the small GTP-binding protein Cdc42-associated signaling 
including Apoa1-induced cholesterol efflux, protein kinases, and actin polymerization 
(Nofer, J. R. et al., 2006). Cumulative evidence also shows that the GTPases of the Rho 
family are key regulatory molecules of the actin cytoskeleton (Hall, A. 1998), and that 
Cdc42-activated GTPase induced the collapse of the vimentin network (Nofer, J. R. et al., 
2006). Rho-GDI was also reported to be members of the Rho-GTPase regulator family 
that regulate a wide variety of cellular functions by binding and inhibiting Rho GTPases 
(Van Aelst, L., and D'Souza-Schorey, C. 1997). Thus, the activity of GTPase regulating 
the cytoskeletal networks may have been interfered with by the high expression of Apoa1 
and down-regulation of Rho-GDI during infection. 
In 1989, a computer-based analysis of 2DE gels reported a total of 8 polypeptide 
differences between cancerous and normal breast epithelial cells in tissue culture (Patil C. 
and Walter P. 2001). More precise characterization of such polypeptide differences was 
published in the early 90‟s with the demonstration that normal breast epithelial cells 
produce keratins K5, K6, K7 and K17, whereas tumor cells produce mainly keratins K8, 
K18 and K19 (Giometti, C. S. et al., 1995). This distribution was secondarily confirmed 
in tumor samples (Daniel R. et al., 2005) and cytokeratin immunodetection is now 
eventually used to help discriminate benign from malignant cells on histopathological 
slides. In infected GI-101A tumors, Keratin 19 was dispersed and greatly decreased at 42 
dpi. 
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4.3 Ubiqitin proteasome pathway (UPP) disorders in VACV GLV-1h68  
infected tumor cells 
 
Ubiquitin was described as a heat shock protein playing an important role both 
during and after stress in chicken embryo fibroblast (Bond, U. et al., 1998). UPP, a major 
intracellular protein degradation pathway, has recently been implicated in viral infections, 
including avoidance of host immune surveillance, viral maturation, viral progeny release, 
efficient viral replication, and reactivation of virus from latency (Gao, G., and Luo, H. 
2006). One reports considered that the replication of pea seed-borne mosaic virus induces 
polyubiquitin and HSP70 expression (Aranda, M. A. et al., 1996). In this study, six UPP-
linked proteins were identified as differentially expressed cellular proteins following 
VACV GLV-1h68 the down-regulated [Proteasome alpha 3 subunit isoform 2 (H-
PSMA3), Proteasome (prosome, macropain) subunit, beta type, 7 (H-PSMB8), 
Proteasome activator subunit 1-PA28 alpha (H-PSME1), Ubiquitin activating enzyme E1 
(H-UBE1), Proteasome subunit, alpha type 6 (M-Psma6), Proteasome  subunit, beta type 
2 (M-Psmb2)] and one up-regulated Proteasome activator hPA28 subunit beta (H-
PA28b) (Table 1). 4 UPP-linked proteins in GI-101A cells [Proteasome activator subunit 
2 (H-PSME2, Chain B-Proteasome Activator Reg-α (H-PARegA), Proteasome beta-
subunit (H-PSMB), and Proteasome 26S non-ATPase subunit 5 (H-PSMD5)] (Table 4), 1 
in HT-29 cells is  otubain 1 (H-otub) (Table 5), 7 in PC-3 cells [ubiquitin activating 
enzyme E1 (H-UBE1), proteasome 26S ATPase subunit 4 isoform 1 (H-26S4), otubain 1 
(H-otub), proteasome subunit Y (H-PSMB6), Proteasome (prosome, macropain) 26S 
subunit, ATPase, 1 (H-PSMC1), human 26S proteasome subunit p97 (H-PSMD2) and 
proteasome 26S non-ATPase subunit 5 (H-PSMD5)] (Table 6) were all identified as 
differentially expressed cellular proteins following VACV GLV-1h68 the down-
regulated.  Notably, after VACV GLV-1h68 infection, most of the UPP-associated 
proteins involved in ubiquitination and deubiquitination were down-regulated, and H-
UBE1 was completely inhibited. These data indicate that VACV GLV-1h68 infection 
results in functional disorders of UPP system as a “cell cleaner” though the reason for 
this is unknown. Xiaojuan Zheng et al. (Xiaojuan Zheng et al., 2008) reported the down-
regulation of PSMA6, PSMA6, PSMB, PSMD5 in Infectious Bursal Disease virus-
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infected cells, suggesting that VACV GLV-1h68 resemble to Infectious Bursal Disease 
virus in how it disturbs cellular UPP. 
 
4.4 VACV GLV-1h68 alter stress response proteins 
 
Exposure of cells to conditions of environmental stress-including heat shock, 
oxidative stress, heavy metals, or pathologic conditions, such as ischemia and 
reperfusion, inflammation, tissue damage, infection, and mutant proteins associated with 
genetic diseases, results in the inducible expression of heat shock proteins that function as 
molecular chaperones or proteases. Molecular chaperones are a class of proteins that 
interact with diverse protein substrates to assist in their folding; with a critical role during 
cell stress to prevent the appearance of folding intermediates that lead to misfolded or 
otherwise damaged molecules. Consequently, heat shock proteins assist in the recovery 
from stress either by repairing damaged proteins (protein refolding) or by degrading 
them, thus restoring protein homeostasis and promoting cell survival. The events of cell 
stress and cell death are linked, such that molecular chaperones induced in response to 
stress appear to function at key regulatory points in the control of apoptosis. On the basis 
of these observations-and on the role of molecular chaperones in the regulation of steroid 
aporeceptors, kinases, caspases, and other protein remodeling events involved in 
chromosome replication and changes in cell structure-it is not surprising that the heat 
shock response and molecular chaperones have been implicated in the control of cell 
growth. Caroline Jolly et al. (Morimoto RI. 1991) addressed some of the molecular and 
cellular events initiated by cell stress, the interrelationships between stress signaling, cell 
death, and oncogenesis-and chaperones as potential targets for cancer diagnosis and 
treatment.  
Cells or tissues from a wide range of tumors have been shown to express atypical 
levels of one or more HSPs (Morimoto RI. 1991; Fuller KJ et al., 1994). HSPs are 
overexpressed in a wide range of human cancers and are implicated in tumor cell 
proliferation, differentiation, invasion, metastasis, death, and recognition by the immune 
system. Elevated expression of members of the Hsp70 family has also been reported in 
high-grade malignant tumors (Kaur J. and Ralhan R. 1995; Santarosa M et al., 1997). In 
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general, HSPs were found down-regulated in both three infected tumor cells. 
Interestingly, they were found with 12 different HSPs in GI-101A xenografts, in contrast 
there is only 3 in PC-3 xenografts and 2 HSPs in HT-2 xenografts. This indicated that 
stress response which was induced in primary tumor cells now changed with evidence of 
down-regulated HSPs in GI-101A tumors. HSPs what could contribute for tumor cell 
survival were inhibited at the time viral replication activation occurs. Cellular metabolism 
process responded to HSPs changing here may lead to disease resolution in GI-101A 
tumors. Why HSPs were little found in HT-29 and PC-3 xenografts while they were 
clearly found at in vitro? It is possible that at in vivo, HSPs might not induce stronger in 
HT-29 and PC-3 xenografts than GI-101A xenografts therefore observation of identified 
HSP set in these non-regressing is obstacle or HSPs might be inhibited by mouse protease 
inhibitors.  
In addition, another stress response protein, activator of Heat shock 90kDa protein 
(H-HSP90), was down-regulated or inhibited during VACV GLV-1h68 infections (Table 
1, 3, 4, 5, 6). Previous studies have shown that HSP90 was a co-chaperone that stimulates 
Hsp90 ATPase activity and may affect a step in the endoplasmic reticulum-to-Golgi 
trafficking, and that this Hsp90-associated ATP/GTPase may participate in the regulation 
of complex formation of Hsp90 (Panaretou, B. et al., 2002). Consequently, inhibiting H-
HSP90 in VACV GLV- 1h68 infected cells may lead to impairment of intracellular 
protein trafficking in infected cells what happened in GI-101A and PC-3 xenografts.  
 
4.5 Infection effect to anti-apoptosis pathways in cancer cells 
 
Apoptosis is an active cellular process of self-destruction defined by 
morphological and biological criteria (Kerr JF et al., 1972). Apoptosis protects an 
organism by ridding it of individual cells whose survival could be detrimental to the 
organism as a whole (Shen Y and Shenk TE. 1995; Williams GT. 1991). Viral infection 
often leads to an apoptotic response by a cell, thereby defending other cells from a similar 
fate (Teodoro JG and Branton PE. 1997) and limiting viral spread. Improving viral 
propagation in cancer cells is a potential approach to enhance efficacy of oncolytic viral 
therapy. Many cancer cells have evolved to evade apoptosis (D. Hanahan and R.A. 
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Weinberg 2000; T.C. Liu and D. Kirn 2005). During evolution of host–pathogen 
interactions, viruses have also evolved mechanisms to evade apoptosis in order to assist 
their replication. In the term of infection, the viral genes encoding anti-apoptosis 
functions or viral induce anti-apoptosis function proteins are therefore theoretically 
expendable in cancer cells but essential for viral replication in normal cells (E. White 
2006; F.H. Igney and P.H. Krammer 2002) illustrates the interactions of cellular 
apoptosis signaling pathways with a number of viral proteins derived from Ad, HSV and 
VV (F.H. Igney and P.H. Krammer 2002; W. Schneider-Brachert et al., 2006). Therefore, 
specific replicating of oncolytic viruses in tumor cell, spreading to others and finally 
being annihilated before cell die is success in using oncolytic viral therapy. 
As shown in table 1, evidence for using VACV GLV-1h68 to eradicate GI-101A 
xenografts in mice is 12 proteins associated with anti-apoptosis function were found 
down-regulated, including Tumor protein, translationally-controlled (H-TPT1), Rho 
GDP dissociation inhibitor (GDI) alpha (H-GDIa), Ywhaq protein (M-1433T), H-
PRDX4, Serine/threonine-protein phosphatase  2A catalytic subunit beta isoform PP2A 
(M-Ppp2cb), Eukaryotic translation initiation factor 2, subunit 1  alpha, 35kDa (H-eIF2), 
H- actinin-α1 (ACTN1 ), annexin A1 (H-A1), annexin A5 (H-A5), mouse albumin 1 (M-
Alb1),  Dimethylarginine dimethylaminohydrolase 2 (H-DDAH2). In PC-3 xenografts, 
anti-apoptosis expression is lesser than those in GI-101A cells, however 3 anti-apoptosis 
associated proteins were down-regulated such as ARP3 actin-related protein 3 homolog 
(H-ARP3), Human FLNA protein, Rho GDP dissociation inhibitor (GDI) alpha (H-
GDIa). In contrast, in HT-29 xenografts, there are several anti-apoptosis associated 
proteins show even up-regulated; they mostly belong to peroxiredoxin proteins. 
In mammalian cells, intracellular redox status has been linked to cellular 
differentiation, immune response, growth control, tumor promotion, and apoptosis, as 
well as activation of viruses, notably HIV-1 from latency (Schreck R. et al., 1991; 
Kalebic T. et al., 1991). One redox-regulated protein is NF-kB. The NF-kB transcription 
factor promotes cell survival in response to several apoptotic stimuli (figure 44). NF-kB 
is a member of the Rel family of transcription factors that exist ambiently in the 
cytoplasm via association with inhibitor protein, IkB (Verma I. M. 1995. Baeuerle P. A. 
1996). A wide variety of stimuli including tumor necrosis factor-a (TNF-a), phorbol 
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ester, bacterial lipopolysaccharide, and virus infection can activate NF-kB. One pathway 
of NF-kB activation involves site-specific phosphorylation of IkB-a on serine residues 32 
and 36. It has been suggested that serine phosphorylation targets IkB to the ubiquitin-
proteasome pathway for degradation (Palombella V. J. e al., 1994; Traenckner E. B. M. et 
al., 1995; Chen Z. J. 1996). IkB inactivation, without proteolytic degradation, has also 
been reported to occur as a consequence of tyrosine phosphorylation on residue 42 
(Imbert V. et al., 1996). In both instances, phosphorylation results in an unmasking of the 
NF-kB nuclear localization signal facilitating nuclear entry of proteins. Thus, for stimuli 
such as oxidative stress, which potently and rapidly modulates the nuclear activity of NF-
kB, IkB-a may represent a critical activation target (Schreck R. et al., 1991). Other hand, 
phosphorylation and activation of its positive regulator IkB kinase leads to 
phosphorylation and degradation of IkB, an inhibitor of NF-kB, promoting nuclear 
translocation of NF-kB and activation of its target genes (351). Dong-Yan et al., (1997) 
provide the first evidence that the AOE372 class of peroxiredoxins functions through 
cytoplasmic IkB-a to regulate nuclear activity of NF-kB, peroxiredoxins demonstrated as 
redox regulators of signal transduction (Baeuerle, P. A., 1996). Cells have multiple 
pathways to transduce extracellular signals into the nuclear compartment, these pathways 
are complex networks that ultimately modulate gene expression NF-kB is redox-
regulated (2, 50). Several peroxiredoxins were greatly increased in HT-29 tumor such as 
H-PRDX4, H-PRDX2, and H-PRDX3 suggesting that these peroxiredoxins may 
participate negative regulation IkB inhibitors to keep up NF-kB pathway activation that 
cause a continued cell survival. 
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Figure 43. mTOR pathway, which is one of the main tumor related pathway, describes inhibiting 
kappa kinase B (IkB) induces NF-kB release and activation that support cell survival ( in 
red cycle) 
 
 
4.6 Infection effect to activated EGFR or Ras pathways 
 
Epithelium growth factor (EGFR) is overexpressed in various tumor types, and its 
expression correlates with metastatic behavior and poor prognosis. Growth factor binding 
to EGFR induces receptor oligomerization and activation of tyrosine kinase signaling. In 
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tumor cells, high levels of EGFR lead to hyperactivation of the signaling pathways and 
activation of Ras signaling downstream. The Ras family of proteins consists of three 
isoforms, H-, K-, and N-Ras, which play critical roles in control of normal and 
transformed cell growth. Mutated K-ras is one of the most frequent genetic events in 
human cancer, with the highest incidences in pancreatic carcinomas (90%), colorectal 
tumors (50%), lung carcinomas (30%) and myeloid leukemia (25%) (Lexander H. et al., 
2005,Jensen, S.L. et al., 1996). Activated K-Ras may not only promote tumor initiation, 
but also tumor progression and metastasis formation (Xie,Y. and Meier, K.E. 2004; Anna 
Walduck et al., 2004). The human reovirus is a naturally occurring OV that specifically 
targets cancer cells with an activated Ras pathway (Roberto Mazzanti et al., 2006; Jellum 
E et al., 1984). A single intratumoral injection of virus resulted in regression of tumors in 
65 to 80% of mice in pre-clinical studies (Roberto Mazzanti et al., 2006). Systemic 
reovirus therapy of metastatic cancer has also been studied in immune-competent mice 
(Tracy RP. et al., 1982). In this study, Ras GTPase-activating-like protein IQGAP1 (H-
Iqgap1) and Guanine monophosphate synthetase variant (H-GMPS) were known as 
proteins activate Ras which were down regulated in GI-101A regressive tumor phase but 
did not find in HT-29 and PC-3 xenografts. This result supports for shrinking of GI-101A 
xenografts by effect onto Ras pathways.  
 
4.7 Infection effect to the hypoxic tumor environment 
 
About evidence for activation of the UPR, in principle, neoplastic progression 
requires several genetic alterations that allow the cell to ignore growth controls and 
disable apoptotic signalling. As the tumor becomes larger, it experiences increasing 
hypoxia, nutrient starvation and acidosis until the microenvironment becomes limiting. 
Cells respond by producing pro-angiogenic factors to initiate the formation and attraction 
of new blood vessels to the tumor. Although many studies have focused on the hypoxic 
state of tumors, the stabilization of hypoxia inducible factor-1α (HIF1α), and the 
activation of protective downstream responses, there is increasing evidence to show that 
the UPRs can also be activated in tumors. Although no direct link between these two 
pathways has been established, they share several downstream targets, and it is 
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conceivable that the two pathways could synergize in some cases and be antagonistic in 
others (Yanjun Ma and Linda M.Hendershot. 2004).  
HIF-1a has a dual role in that it is important for tumor growth but also apoptosis. 
HIF-1a may exert its proapoptotic effects through stabilisation of p53 or upregulation of 
BNIP3 (Greijer AE and van der Wall E. 2004). Hypoxia-induced HIF-1-mediated 
apoptosis might promote the survival of cells that express mutations in tumor suppressor 
genes and so contribute to their selection. Such a mechanism is supported by evidence 
that p53-null tumor cells are clonally selected and overgrow similar cells expressing 
wild-type p53 in hypoxic tumor regions (Graeber et al., 1996). In addition, group of 
genes induced by HIF-1 was reported (Shalini Patiar and Adrian L Harris 2006) such as 
iron metabolism associated proteins (ceruloplasmin, transferrin), glucose metabolism 
associated protein (triosephosphate isomerase). Proteins encoded by these genes were 
found up-regulated in GI-101A xenografts, only triosephosphate isomerase was found in 
HT-29, only transferrin was found in PC-3 xenografts, all of them derived from mice. 
This expression different between different types of tumors suggests that effect may be 
specific for GI-101A tumor that related to hypoxia-induced HIF-1-mediated apoptosis.  
 
 4.8 Chemokines in cell homing to cancer 
 
In order to develop efficient cellular vehicles for oncolytic viruses as well as 
effective cancer immunotherapy, it is extremely important to develop a systematic 
understanding of the molecular basis of cell trafficking and biodistribution of candidate 
carrier cells. Two classes of molecules, chemokines and adhesion molecules such as 
integrins, have been shown to be important for cell trafficking within immune systems 
and into tumors (L.M. Ebert et al., 2005; T. Kinashi 2007). Chemokines are a large 
family of small, generally secreted polypeptides which guide lymphocyte movement 
throughout the body by controlling integrin avidity and inducing migration. Cancer cells 
express a number of chemokines which may attract certain types of cells to tumor (F. 
Balkwill 2004). Host‟s involvement-derived chemokine RANTES (CCL5) in tumor may 
play dual roles in tumor growth. In fact that the host‟s involvement in the tumor phases of 
the oncolytic process are still intriguing. Here GI-101A, HT-29 and PC-3 xenografts were 
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further analysis by using enzyme linked immunoabsorbent assay using a “two-site” 
sandwich detection assay to determine chemokines such as CCL2/MCP-1 (Macrophage 
chemotactic protein-1), CCL5/RANTES (Regulated upon activation, normal T-cell 
expressed and secreted) and VCAM-1.  
In the breast cancer, elevated levels of the chemokine CCL5/RANTES (regulated 
upon activation, normal T cell expressed and secreted) have been frequently observed in 
advanced stage breast carcinoma (Riethdorf L. et al., 1996) and this potentiates the 
invasiveness of the breast cancer cells. The reciprocal interactions between breast tumor 
cells and TAMs through soluble mediators such as inflammatory cytokines, MMPs and 
angiogenic factors form a vicious cycle. For example, TNF-a released from TAMs can 
stimulate the expression of the chemokines CCL2 and CCL5 in breast cancer cells which 
attracts even more TAMs, thus completing the vicious cycle (Wong MP. et al., 1998). 
Also, the mRNA for the chemokine CCL5 has been shown to be expressed in the human 
prostate cancer cell lines including PC-3, DU-145 and LNCaP and also in primary 
prostate adenocarcinoma cells (Jensen, S.L. et al., 1996). CCL5 induces proliferation and 
stimulation of invasive power of prostate cancer cells and this effect is inhibited by the 
CCR5 antagonist TAK-779 (Jensen, S.L. et al., 1996).  In this study, interstingly, CCL5 
level was shown greatly decrease in GI-101A tumor in the first state, greatly decrease in 
PC-3 tumors  but in the late state and insignificant decreased in HT-29 tumors. This can 
refer that infection by VACV GLV-1h68 may activate expression of antagonist TAK-779 
to inhibits CCL5 which induces proliferation and stimulation of invasive. However, this 
result may be a significant effect when inhibition of CCL5 occur in early tumor phase.  
The chemokine CCL2/MCP-1 is highly expressed in breast tumor (Virchow R. 
1863) and stromal cells. Tumor-associated macrophages (TAM) in the tumor stroma 
exhibit elevated expression of CCL2 and high TAM accumulation correlates with disease 
recurrence and poor prognosis (Van Ravenswaay et al., 1992, Stephens TC et al., 1978). 
Further, neutralizing antibodies to CCL2 prevented the formation of the lung metastases 
in mice bearing CCL2-expressing MDAMB-231 human breast carcinoma xenografts 
(McBride WH. 1986). This suggests that CCL2 contributes to the metastasis of breast 
carcinoma cells. In estrogen receptor (ER)-negative breast tumor cells, the cancer-
associated membrane glycoprotein, dysadherin, promotes invasion of tumor cells into the 
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matrigel through regulation of CCL2 expression in vitro and lung metastasis in an in vivo 
animal model (Mantovani A. 1994). Thus, increased CCL2 expression as a result of 
overexpression of dysadherin may facilitate breast tumor progression and metastasis. 
Similar to CCL5, CCL2 is also involved in proliferation and migration of prostate cancer 
cells by acting in an autocrine and paracrine manner and this effect can be abrogated by 
directing neutralizing antibodies against CCL2 (Roberto Mazzanti et al., 2006). In colon 
cancer, genes reported to be up-regulated include chemokines (CCL2 and CXCL1), 
cyclooxygenase-2 (COX-2), growth factors (VEGF and TGF-b2), and cytokines (IL-6) 
(Hsiao JC et al., 1999,Wang, Y. et al., 2001–Yu YA. et al., 2004). In a mouse model of 
colitis-associated cancer, IKKb3, an upstream activator of NF-jB, has been reported to 
link inflammation with tumorigenesis as the conditional knockout of IKKb in colonic 
epithelial cells significantly attenuated the tumor incidence and deletion in myeloid cells 
significantly reduced the tumor size (Stephen McCraith et al., 2000). NF-jB activation 
transcriptionally up-regulates many chemokines involved in tumor progression and 
metastasis. In this study, CCL2 level shows decreased at the second state of GI-101A. 
For HT-29 tumor, CCL2 decreases at the first and late state whereas significant increases 
at second state. For PC-3 tumors, CCL2 shows significant increase at second tumor 
phase. A similar model of increasing CCL2 in HT-29 and PC-3 xenografts seems to be 
adverse factor to cancer therapeutic experiment by using oncolytic virus VACV GLV-
1h68. For VCAM-1, there is no change remarkably. In summary, role of chemokines and 
their receptors in tumor pathophysiology is still complex such as some chemokines favor 
tumor growth and metastasis, while others may enhance anti-tumor immunity. These 
diverse functions of chemokines establish them as key mediators between the tumor cells 
and their microenvironment.  
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 Table 1-p1 
 
Table 1. Differential expression proteins in GI-101A tumors (Protein profiling using 2-DE; Delta2D software; MALDI-TOF). 
(Subcutaneous GI-101A tumors in nude mice with and without VAVC GLV-1h68 treatment; time points were taken 7, 21 and 42 days after 
intravenous injection of the virus; fold of enhancement or reduction of protein expression after virus injection are shown; highly expression 
in red and  down-regulated in blue)  
 
Fold of enhancement Fold of suppression 
>5 >5 
3 to 5 3 to 5 
2 to3 2 to 3 
 
Protein name Abbr Accession MW pI 
7dpi 
(+)fold 
21dpi 
(+)fold 
42dpi 
(+)fold 
7dpi 
(-)fold 
21dpi 
(-)fold 
42dpi 
(-)fold 
 
Cytoskeleton proteins 
 
ACTB protein  H-ACTB gi|15277503 40194,07031 5,55  1,54 5,21 0,93   
ACTB protein  H-ACTB gi|15277503 40194,07031 5,55    0,40 0,72 0,59 
actin-like  M-Actl gi|8850209 43572,48047 5,11 1,16    0,32 0,40 
ARP2 actin-related protein 2 homolog   H-ARP2 gi|15778930 44732,25 6,3    0,87 0,99 0,26 
capping protein alpha 1 subunit  M-CAPZA1 gi|595917 32731,24023 5,34 1,40    0,92 0,27 
capping protein alpha 1 subunit  M-CAPZA1 gi|595917 32731,24023 5,34 1,46 1,55    0,56 
dynein, cytoplasmic, intermediate chain 2  M-DYNC1I2 gi|6753658 68351,65625 5,16  1,13  0,76  0,40 
fascin homolog 1, actin bundling protein  M-Fscn1 gi|113680348 54473,92969 6,44 1,07 1,05    0,22 
fascin homolog 1, actin bundling protein  M-Fscn1 gi|113680348 54473,92969 6,44 1,52 1,22    0,34 
FLNA protein  H-FLNA gi|15779184 88534,4063 5,93 2,06 1,22    0,36 
gamma-actin  M-ActG gi|809561 40992,46875 5,56 3,25 1,43 2,13    
 Table 1-p2 
 
gamma-actin  M-ActG gi|809561 40992,46875 5,56    0,64 0,67 0,06 
gamma-actin  M-ActG gi|809561 40992,46875 5,56  1,14  0,78  0,07 
gelsolin isoform b  H-Glsln gi|38044288 80590,50781 5,58 1,12    0,43 0,13 
gelsolin-like capping protein  M-GDIb gi|110227377 38744,67188 6,47   1,64  0,31  
gsn protein  M-Gsn gi|18606238 80712,38281 5,52 1,45    0,83 0,58 
actinin, alpha 1 H-ACTN1 gi|30585329 103105,711 5,25  1,03  0,68  0,49 
keratin 19  H-Krt19 gi|34783124 45586,96875 5,11 2,11 1,76 1,84    
keratin 19  H-Krt19 gi|34783124 45586,96875 5,11 2,76 2,14 1,89    
keratin 2  H-Krt2 gi|47132620 65393,21094 8,07 2,73 1,83    0,33 
keratin, type I cytoskeletal 19 (Cytokeratin-19)  H-Krt19 gi|75041620 44038,07813 5,04    0,81 0,98 0,07 
keratin, type I cytoskeletal 19 (Cytokeratin-19)  H-Krt19 gi|75041620 44038,07813 5,04 1,09 1,10    0,39 
KRT19 protein  H-Krt19 gi|39644709 45870,17188 5,16     0,89 0,00 
KRT19 protein  H-Krt19 gi|45709960 46179,37109 5,16  1,06  0,99  0,26 
KRT8 protein  H-Krt8 gi|33875698 55787,17188 5,62 7,06 1,47    0,23 
leucine-rich PPR motif-containing protein  H-LRPPRC gi|31621305 157805,1094 5,81 1,34 2,05 3,97    
moesin  H-Moe gi|4505257 67777,78906 6,08 1,20    0,98 0,32 
myosin, light polypeptide 1  M-Myl1 gi|29789016 20581,41016 4,98  1,22 8,37 0,48   
put. beta-actin (aa 27-375)  M-ActA gi|49868 39160,64063 5,78  1,35  0,70  0,08 
tropomyosin 2 (beta) isoform 1  H-Tpm2 gi|42476296 32830,57031 4,66  1,12 1,65 0,57   
TUBB protein  H-TUBB gi|16198437 30339,59961 4,77 1,20 1,35    0,38 
TUBB2C protein  H-TUBB2C gi|14124960 25858,39063 4,95 1,13 1,09    0,05 
TUBB2C protein  H-TUBB2C gi|14124960 25858,39063 4,95 1,14 1,47    0,05 
tubulin, beta, 2  H-Btub gi|5174735 49799 4,79  2,16  0,82  0,90 
vimentin  M-Vim gi|2078001 51533,08984 4,96 4,53  12,82  0,80  
vimentin  M-Vim gi|2078001 51533,08984 4,96 1,33  2,39  0,44  
WD repeat domain 1  M-Wdr1 gi|29144967 72068,32031 8,66 1,17 1,18    0,46 
 Table 1-p3 
 
WD repeat-containing protein 1 isoform 1 variant  H-WDR1 gi|62897087 66185,85156 6,17  1,71    0,25 
 
Stress response 
 
chaperonin (HSP60) H-Hsp60 gi|306890 60986,3711 5,7    0,73 0,97 0,29 
chaperonin containing TCP1, subunit 2 (beta) H-CCT2 gi|54696792 57565,21094 6,01  1,39  0,90  0,17 
chaperonin containing TCP1, subunit 3 (gamma)  H-CCT3 gi|55960506 57935,03125 6,46  2,84  0,94  0,13 
chaperonin containing TCP1, subunit 5 (epsilon)  H-CCT5 gi|24307939 59632,80859 5,45  1,10  0,60  0,52 
chaperonin containing TCP1, subunit 6A isoform a 
variant  H-CCT6a gi|62089036 57725,46094 6,25  1,40  0,91  0,20 
chaperonin containing TCP1, subunit 8 (theta)  H-CCT8 gi|48762932 59582,5 5,42  1,49  0,60  0,00 
heat shock 70kDa protein 4 isoform a  H-Hsp704 gi|38327039 94271,24219 5,11  1,57  0,73  0,14 
heat shock 70kDa protein 4 isoform a  H-Hsp704 gi|38327039    1,20  0,36  0,07 
heat shock 70kDa protein 8 isoform 1  H-Hsp708 gi|5729877 70854,21875 5,37    0,22 0,16 0,36 
heat shock protein 60  H-Hsp60 gi|77702086 61174,4492 5,7 1,04 1,26    0,33 
heat shock protein 70 - human H-Hsp70 gi|2135328 78945,29688 5,13 2,25  1,43  0,88  
HSP90AA1 protein  H-HSP90 gi|83318444 68328,78125 5,11    0,87 0,53 0,36 
HSP90AA1 protein  H-HSP90 gi|83318444 68328,78125 5,11 1,15    0,95 0,37 
Hspd1 protein  M-Hspd1 gi|76779273 59387,98828 8,09 1,54 1,05    0,24 
KIAA0002  H-KI002 gi|1136741 58465,14844 5,75    0,87 0,99 0,26 
peroxiredoxin 3 H-PRDX3 gi|54696872 27788,2598 7,67  1,98  0,88  0,40 
PRDX4  H-PRDX4 gi|49456297 30570,8496 5,86 1,28 1,12    0,40 
protein disulfide isomerase associated 4  M-PDIa4 gi|86198316 72324,64063 5,08 1,40 1,31 2,44    
protein disulfide isomerase associated 6  M-PDIa gi|60502437 48626,60156 5,05    0,84 0,85 0,55 
stress-induced-phosphoprotein1 (Hsp70/Hsp90-
organizing protein)  H-STIP1 gi|5803181 62599,39844 6,4 1,00 1,00    0,26 
t-complex polypeptide 1  H-TCP1 gi|36796 60355,75 6,03 2,01 2,07    0,55 
t-complex polypeptide 1  H-TCP1 gi|36796 60355,75 6,03 1,22 1,87    0,31 
 Table 1-p4 
 
 
Translation associated proteins 
 
acidic ribosomal phosphoprotein P0  M-ARPP0 gi|13277927 34164,73828 5,91  1,49  0,84  0,05 
ATP-dependent DNA helicase II  H-Ku70 gi|10863945 82652,27344 5,55 1,22 2,10 2,26    
ATP-dependent DNA helicase II  H-Ku70 gi|10863945 82652,27344 5,55 1,11    0,95 0,05 
ATP-dependent DNA helicase II, 70 kDa subunit  H-Ku70 gi|4503841 69799,04688 6,23 1,17 1,17    0,34 
endothelial cell growth factor 1 (platelet-derived)  H-Ecgf1 gi|4503445 49924,17188 5,36  1,03  0,98  0,41 
eukaryotic translation initiation factor 3, subunit 2 
(beta)  M-Eif3s2 gi|9055370 36437,58984 5,38  1,71  0,98  0,51 
eukaryotic translation initiation factor 3, subunit 3 
gamma H-Eif3s3 gi|60825606 40018,14063 6,09    0,90 0,84 0,10 
 eukaryotic translation initiation factor 2, subunit 1 
alpha, 35kDa  H-eIF2 gi|30584065 36202,4609 5,01 1,22 1,24    0,15 
human elongation factor-1-delta  H-EEF1D gi|38522 31201,8594 4,95 2,55 1,14    0,08 
KIAA0111  H-KI111 gi|40788956 46954,26172 6,33  1,05  0,69  0,21 
PPA1 protein  H-PPA1 gi|38181963 35859,91016 6,28 2,43 1,18    0,01 
pyrophosphatase 1  H-PP1 gi|11056044 32639,15039 5,54 1,18 1,21    0,03 
tu translation elongation factor, mitochondrial  H-TUFM gi|34147630 49843,32031 7,26  1,30  0,75  0,13 
 
RNA processing 
 
asparaginyl-tRNA synthetase variant  H-AsnS gi|62897229 62870,53906 5,9 4,85 2,01    0,14 
aspartyl-tRNA synthetase  H-AspS gi|45439306 57100,03125 6,11    0,83 0,70 0,12 
aspartyl-tRNA synthetase  H-AspS gi|78394948 57088 6,11 1,08    0,78 0,17 
Chromosome 17 open reading frame 25  H-GLOD4 gi|16198390 33193,57813 5,4 1,83 1,09    0,25 
glycyl-tRNA synthetase  H-GlyS gi|493066 77463,34375 5,88    0,66 0,52 0,15 
heme binding protein 2  H-HEBP2 gi|7657603 22861,18945 4,58 1,05    0,91 0,08 
heterogeneous nuclear ribonucleoprotein D-like  M-HnrpdlÊ gi|7710036 33538,08984 6,85 1,29 2,02    0,35 
 Table 1-p5 
 
HLA-B-associated transcript 1A  M-Bat1a gi|9790069 49003,96875 5,44 1,01    0,91 0,39 
HLA-B-associated transcript 1A  M-Bat1a gi|9790069 49003,96875 5,44 1,08 1,06    0,43 
PA2G4 protein  H-PA2G4 gi|33879698 41654,28125 7,14    0,99 0,88 0,41 
prolyl endopeptidase  H-PREP gi|41349456 80648,03125 5,53 1,27 1,47 5,61    
PRP19/PSO4 pre-mRNA processing factor 19 
homolog  H-PRPF19 gi|7657381 55146,33984 6,14    0,84 0,81 0,31 
TARS protein  H-TARS gi|56789234 78555,42969 6,45 1,11 2,01    0,19 
tryptophanyl-tRNA synthetase isoform b  H-TrpS gi|47419918 48820,39844 6,03  1,14    0,21 
 
Ubiquitin proteasome pathway 
 
 proteasome (prosome, macropain) subunit, beta type, 
7 H-PSMB8 gi|30585303 30112,40039 8,19 1,19 1,00    0,14 
proteasome (prosome, macropain) subunit, beta type 2  M-Psmb2 gi|31981327 22851,73047 6,43 1,50    0,88 0,07 
proteasome activator hPA28 suunit beta  H-PA28b gi|1008915 27331,31055 5,44 2,26 1,48    0,16 
proteasome alpha 3 subunit isoform 2  H-PSMA3 gi|23110939 27629,74023 5,19    0,69 0,79 0,23 
ubiquitin activating enzyme E1  H-UBE1 gi|35830 117715,3438 5,57    0,59 0,93 0,07 
ubiquitin activating enzyme E1  H-UBE1 gi|35830 117715,3438 5,57    0,62 0,98 0,15 
ubiquitin activating enzyme E1  H-UBE1 gi|35830 117715,3438 5,57  1,04  0,67  0,17 
ubiquitin activating enzyme E1  H-UBE1 gi|35830 117715,3438 5,57  1,25  0,80  0,40 
ubiquitin carboxyl-terminal hydrolase 5 H-USP5         0,92 0,47 
 
Metabolism associated and transport proteins 
 
3-phosphoglycerate dehydrogenase  H-PHGDH gi|5771523 56628,42188 6,29 1,05    0,87 0,09 
acetyl-Coenzyme A acetyltransferase 2  H-Acat2 gi|5174389 41269,30859 6,27    0,43 0,69 0,09 
Adenosine kinase  H-AK gi|13097732 38712,60156 6,23  1,01  0,86  0,01 
adenylate kinase 1  M-ADK1 gi|10946936 23101,78906 5,7  1,85 10,97 0,73   
aldehyde dehydrogenase 1A3  H-ALD1A3 gi|4502041 55973,73828 6,64 1,48    0,61 0,11 
 Table 1-p6 
 
aldo-keto reductase family 1, member B8  M-Akr1b8 gi|6679791 36097,60938 5,97 4,16 1,36    0,28 
aminopeptidase puromycin sensitive  H-NPEPPS gi|15451907 98440,95313 5,23    0,54 0,93 0,51 
annexin A1 H-A1 gi|54696610 38803,0586 6,57 1,46 1,22    0,48 
apoa1 protein  M-ApoA1 gi|61402210 23007,91016 7    0,25 0,85 0,33 
apolipoprotein A-I  M-ApoA1 gi|2145135 30497,60938 5,64 1,84 1,01 2,38    
asparaginyl-tRNA synthetase variant  H-Nars gi|62897229 62870,53906 5,9 2,82 1,29    0,15 
brain glycogen phosphorylase  H-Pygb gi|21361370 96634,52344 6,4 1,76 1,89    0,12 
branched chain ketoacid dehydrogenase E1, beta 
polypeptide  M-BCKDHB gi|40353220 35481,98047 5,33  2,36  0,97  0,50 
calpain, small subunit 1  H-CSS1 gi|4502565 28297,73047 5,05 1,11    0,99 0,25 
ceruloplasmin isoform b M-Ceru 
  
gi|110347564 121074,1875 5,53 1,53  2,28  0,76  
ceruloplasmin isoform b  M-Ceru gi|110347564 121074,1875 5,53 1,67  2,55  0,77  
ceruloplasmin isoform b  M-Ceru gi|110347564 121074,1875 5,53 1,97  2,60  0,95  
dihydropyrimidinase-like 2  H-DPYSL2 gi|4503377 62254,57031 5,95 1,13 1,09    0,08 
dimethylarginine dimethylaminohydrolase 2  H-DDAH2 gi|7524354 29625,4492 5,66 1,66 1,55    0,17 
eno3  M-Eno3 gi|71059715 46968,21875 6,29   4,26 0,99 0,72  
enolase 1 variant  H-Eno1 gi|62896593 47111,28906 7,01 1,15    0,71 0,32 
enoyl Coenzyme A hydratase 1, peroxisomal  H-ECH1 gi|16924265 35735,37891 8,47  1,40  0,85  0,37 
ferritin heavy chain 1  M-Fth1 gi|6753912 21053,25977 5,53  1,37 5,22 0,80   
ferritin light chain 1  M-Ftl1 gi|18044716 20745,4707 5,66 2,38 1,11 5,41    
glucosidase II  H-Glu2 gi|2274968 106832,6484 5,71  1,20  0,71  0,13 
glutamate carboxypeptidase  H-GCP gi|15620780 52818,91016 5,71  1,22  0,73  0,02 
glutathione S-transferase  H-GST gi|2204207 23367,03906 5,43 1,08 1,09    0,14 
glutathione S-transferase M3  H-GSTM3 gi|23065552 26542,14063 5,37    0,88 0,83 0,08 
glutathione synthetase  H-GS gi|4504169 52352,26172 5,67  1,26  0,87  0,36 
guanine monophosphate synthetase variant  H-GMPS gi|62898359 76647,90625 6,24 1,17    0,54 0,05 
 Table 1-p7 
 
guanine nucleotide binding protein (G protein), alpha 
inhibiting activity polypeptide 3  H-GNAI3 gi|5729850 40506,26953 5,5 1,05 2,17    0,05 
 cathepsin D (lysosomal aspartyl protease) H-Ctsd gi|30584113 44636,71094 6,1 1,20 1,04    0,40 
 glucose-6-phosphate dehydrogenase H-G6PD gi|30584817 59332,07031 6,39 1,37    0,41 0,23 
hypothetical protein  H-hyp gi|21740140 27244,63086 5,66    0,98 0,55 0,17 
inosine monophosphate dehydrogenase 2  H-IMPDH2 gi|66933016 55769,64844 6,44 1,32    0,43 0,09 
LAP3 protein  H-LAP3 gi|37588925 54354,73828 6,8    0,64 0,58 0,14 
LAP3 protein  H-LAP3 gi|37588925 54354,73828 6,8 1,18    0,84 0,20 
leukotriene A4 hydrolase  H-LTA4H gi|4505029 69241,24219 5,8    0,68 0,95 0,56 
major vault protein  M-MVP gi|13879460 95865,17188 5,43    0,72 0,83 0,28 
mitochondrial ATP synthase, H+ transporting F1 
complex beta subunit  H-ATPF1 gi|89574029 48083,03906 4,95  1,24 1,18 0,57   
mKIAA0573 protein  M-KI573 gi|50510531 49685,71875 5  1,72  0,73  0,50 
N-acetylneuraminic acid phosphate synthase  H-NANS gi|12056473 40281,44922 6,29 1,09    0,44 0,18 
NAPRT1 protein  H-NARP gi|33991172 54958,73828 5,74    0,81 0,75 0,26 
oxidized protein hydrolase  H-OPH gi|7144648 81200,64063 5,29    0,73 0,92 0,00 
peroxiredoxin 6  H-PRDX6 gi|4758638 25019,18945 6 1,07 1,22    0,08 
peroxiredoxin 6  M-PRDX6 gi|6671549 24810,98047 5,98 3,66    0,76 0,87 
Pgm2 protein  M-Pgm2 gi|33416468 63414,58984 6,02   1,92 0,87 0,54  
Ppp2cb protein  M-PPP2CB  gi|17512397 32037,6797 5,48 2,42 1,68    0,30 
similar to Serine/threonine-protein phosphatase 2A 
catalytic subunit beta isoform (PP2A- M-Ppp2cb gi|94383336 34903,0703 5,45 1,48 1,64    0,04 
proteasome (prosome, macropain) activator subunit 1 
(PA28 alpha) H-PSME1 gi|54695540 28818,09961 5,78    0,89 0,86 0,17 
proteasome (prosome, macropain) subunit, alpha type 
6  M-Psma6 gi|6755198 27354,80078 6,34 1,10 1,44    0,51 
protein disulfide isomerase-associated 4  H-PDIa4 gi|4758304 72886,96875 4,96 1,09 2,40 2,74    
purine nucleoside phosphorylase M-PNP gi|388921 32253,10938 5,93 1,23 2,16    0,78 
pyridoxal kinase  H-PDXK gi|4505701 35079,91016 5,75 1,29 1,25    0,15 
 Table 1-p8 
 
ribonuclease/angiogenin inhibitor variant  H-RNH1      1,11  0,91  0,29 
ribonuclease/angiogenin inhibitor variant  H-RNH1 gi|62087972 34524,33984 4,83 1,52 1,14    0,50 
selenium binding protein 1  H-SBP1 gi|16306550 52357,62109 5,93    0,89 0,89 0,25 
sulfotransferase family, cytosolic, 1A, phenol-
preferring, member 4  H-SULT1A4 gi|84040296 34303,14063 5,68 1,91 2,36    0,37 
TALDO1 protein  H-TALDO gi|48257056 37385,42188 6,35 2,13    0,96 0,28 
TALDO1 protein  H-TALDO gi|48257056 37385,42188 6,35 1,31    0,79 0,14 
thioredoxin peroxidase 1-like H-PRDX1l gi|62901916 24796,53906 6,05 1,02 1,04    0,29 
transferrin  M-Trf gi|20330802 76673,71875 6,94 3,37 1,10 2,13    
 triosephosphate isomerase M-TPI1  gi|1864018 22491,6308 5,62    0,93 0,43 0,42 
triosephosphate isomerase  M-TPI1 gi|1864018 22491,63086 5,62 1,87  2,81  0,99  
triosephosphate isomerase 1  H-TPI1 gi|4507645 26652,74023 6,45 1,19 1,33    0,22 
tumor protein, translationally-controlled 1  H-TPT1 gi|15214610 19644,5996 4,84  1,12  0,65  0,17 
TXNDC5 protein  H-TXDC5 gi|12654715 36155 5,32  1,09  0,82  0,15 
Ublcp1 protein  M-Ublcp1 gi|34784378 24285,68945 9,19  1,17  0,97  0,06 
UMP-CMP kinase 2, mitochondrial M-Tyki     1,20    0,77 0,33 
vitamin D-binding protein  M-DBP gi|193446 53050,69141 5,26 1,24 1,01 2,35    
 
Signal transduction 
 
annexin A3  H-A3 gi|4826643 36352,66016 5,63  2,43  0,83  0,01 
annexin A5 H-A5 gi|60824338 35932,3594 4,94 2,49 1,51    0,40 
annexin A5 H-A5 gi|60833746 36029,4297 4,89 1,17    0,85 0,02 
arhgap1 protein  M-Arhgap1 gi|13879250 50393,10156 5,97  3,15  0,95  0,66 
cathepsin Z  M-Ctsz gi|11066226 34153,21875 6,13 7,76 2,54 1,39    
chain B, Cathepsin B (E.C.3.4.22.1)  H-Ctsb gi|999909 22401,3301 5,2 1,94 2,09    0,25 
chloride intracellular channel 1  H-CLIC1 gi|55961458 26167,26953 4,95 1,14 1,25    0,37 
ER-60 protein  H-ER-60 gi|2245365 56747,73047 5,88  1,03  0,88  0,12 
 Table 1-p9 
 
fibrinogen, B beta polypeptide  M-Fibrb gi|33859809 54717,69141 6,68 14,42 1,65 4,92    
haptoglobin  M-Hpgn gi|8850219 38727,48047 5,88 1,80 1,15 2,04    
HMW kininogen-I variant  M_KngnI gi|40715900 53171,87109 4,88   8,00 0,68 0,88  
HMW kininogen-I variant  M_KngnI       1,78 0,54 0,53  
HMW kininogen-I variant  M-KngnI       8,00 0,68 0,88  
HMW kininogen-I variant  M-KngnI        1,78 0,54 0,53 
 serine (or cysteine) proteinase inhibitor, clade B 
(ovalbumin), member 1  H-SPIB1 gi|30584099 42827,78906 5,9 1,53    0,97 0,31 
IQGAP1 protein  H-Iqgap1 gi|40674640 107472,1406 5,64    0,99 0,98 0,00 
IQGAP1 protein  H-Iqgap1 gi|40674640 107472,1406 5,64 1,08 1,31    0,00 
iqgap1 protein  M-Iqgap1 gi|27370648 106421,3906 5,61  1,44  0,86  0,26 
kininogen 1  M-Kngn gi|12963497 47867,60156 5,74   3,45 0,51 0,59  
kininogen 1  M-Kngn gi|12963497 47867,60156 5,74   4,42 0,55 0,69  
kininogen 1  M-Kngn gi|12963497 47867,60156 5,74   4,98 0,77 0,89  
kininogen 1  M-Kngn        0,18 0,55 0,75 
kininogen 1 M-Kngn       1,94 0,19 0,58  
rho GDP dissociation inhibitor (GDI) alpha  H-GDIa gi|4757768 23192,6992 5,02  1,12  0,92  0,59 
serine (or cysteine) peptidase inhibitor, clade A, 
member 3K  M_SPIC3K gi|16741103 46869,96094 5,05 2,67 2,60 2,23    
serine (or cysteine) peptidase inhibitor, clade A, 
member 3K  M-SPIA3K gi|16741103   5,36  2,56  0,86  
serine (or cysteine) peptidase inhibitor, clade A, 
member 3K  M-SPIA3K gi|16741103   6,49 1,15 3,41    
serine (or cysteine) peptidase inhibitor, clade A, 
member 3K  M-SPIA3K gi|16741103 46869,96094 5,05 6,95 2,23 8,25    
serine (or cysteine) peptidase inhibitor, clade A, 
member 3K  M-SPIA3K     3,18    0,39 0,12 
serine (or cysteine) peptidase inhibitor, clade A, 
member 3K  M-SPIA3K     4,14  1,20  0,70  
serine or cysteine proteinase inhibitor clade B member H-SPIB5 gi|60817455 42083,42188 5,72  2,07  0,73  0,13 
 Table 1-p10 
 
5 
serpina1c protein  M-Serp1c gi|15929675 45593,39844 5,31 3,88 2,84 5,56    
serpina1c protein  M-Serp1c     2,33 1,60    0,60 
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, beta polypeptide  M-1433e gi|31543974 28068,85938 4,77  1,19  0,79  0,54 
ywhaq protein  M-1433T gi|51593617 29920,93945 4,87  1,33  0,81  0,33 
 
Other proteins 
 
albumin 1  M-Alb1 gi|33859506 68677,71875 5,75 1,27  1,16  0,31  
annexin A8 H-A8 gi|60652779 36970,73047 5,56 1,85 1,01    0,56 
chain A, crystal Structure of Fkbp52 C-Terminal 
domain H-FKBP gi|50513270 38216,17188 6,38  1,03 2,17 0,96   
chain A, crystal structure of murine coronin-1 M-Coro1 gi|83754025 44317,33984 6,03  1,08  0,62  0,56 
complement C3 precursor (HSE-MSF)  M-C3 gi|1352102 186364,6875 6,39 3,85 2,05 1,95    
complement C3 precursor (HSE-MSF)  M-C3        0,76 0,66 0,34 
crocalbin-like protein  H-CALUL gi|8515718 34968,32031 4,39  5,07    0,22 
FK506-binding protein 4  H-Fkbp4 gi|4503729 51772,07031 5,35    0,95 0,96 0,51 
HP95  H-HP95 gi|13375569 95936,1094 6,13    0,72 0,54 0,19 
hypothetical protein FLJ41407 variant  H-Hyp41407 gi|62088022 59575,87109 8,54    0,60 0,86 0,04 
KIAA0158  H-KI158 gi|40788885 42119,53906 6,05  1,61  0,66  0,31 
mFLJ00343 protein  M-FLJ gi|47847514 205197,625 5,6 1,22    0,84 0,39 
mFLJ00343 protein  M-FLJ343 gi|47847514 205197,625 5,6 6,12 2,22    0,73 
 mFLJ00343 protein M-FLJ343     3,54 1,15    0,57 
otubain 1  M-otub gi|19527388 31250,40039 4,85 1,85 1,21    0,45 
serum amyloid P-component precursor (SAP) M-SAP gi|134198 26230,26953 5,98 2,43 1,39 3,54    
SET  M-SET gi|3953617 24348,0293 4,97    0,90 0,41 0,09 
SET  M-SET gi|3953617 24348,0293 4,97 1,81 1,24    0,57 
 Table 1-p11 
 
stress-induced phosphoprotein 1  M-Stip1 gi|13277819 62528,37891 6,4 1,33    0,96 0,29 
thrombospondin  M-Thbs gi|554390 53810,44922 6,16 7,68 1,15 4,47    
TPMsk1  H-TPMsk1 gi|19072647 23740,13086 4,72   2,70 0,49 0,92  
villin 2  H-Vil2 gi|21614499 69369,74219 5,94 1,16    0,81 0,19 
villin 2 H-Vil2 gi|46249758 69198,63281 5,94 10,53 25,08    0,48 
villin 2 H-Vil2 gi|46249758 69198,63281 5,94 4,16 1,40    0,45 
villin 2 H-Vil2 gi|46249758 69198,63281 5,94    0,16 0,64 0,01 
villin 2 H-Vil2 gi|46249758 69198,63281 5,94    0,44 0,68 0,03 
villin 2 H-Vil2 gi|46249758 69198,63281 5,94    0,61 0,71 0,17 
villin 2 H-Vil2 gi|46249758 69198,63281 5,94 1,75    0,90 0,25 
vinculin H-VCL gi|60812071 116776,4219 5,83 1,21 1,30    0,26 
vinculin  M-VCL gi|31543942 116644,2969 5,77 2,01 3,74 3,06    
vinculin  M-VCL gi|31543942 116644,2969 5,77 1,99 1,03    0,25 
 
Unknown proteins 
 
unknown  H-unkn gi|63991119 36035,26953 5,96 2,36    0,82 0,38 
unknown  H-unkn gi|63991119 36035,26953 5,96 2,39 1,24 2,07    
unknown H-unkn gi|62288384 64990,55078 5,59 2,65 1,44 2,19    
unknown (protein for IMAGE:5068183)  H-unkn gi|116283668 106891,7188 5,69 1,31    0,64 0,02 
unknown (protein for IMAGE:3529287)  H-unkn gi|52790434 37696,98047 8,56 1,38    0,79 0,31 
unknown (protein for IMAGE:3592890)  H-unkn gi|14250269 69103,8125 6,38    0,55 0,63 0,01 
unknown (protein for IMAGE:3592890)  H-unmd gi|14250269 69103,8125 6,38 2,55 1,31    0,57 
unnamed protein product  H-unmd gi|7022978 91550,79688 5,22    0,86 0,60 0,09 
unnamed protein product  H-unmd gi|10435669 26938,83008 5,34    0,97 0,73 0,43 
unknown (protein for IMAGE:3592890)  H-unmd gi|14250269 69103,8125 6,38 1,15 1,21    0,43 
unknown (protein for IMAGE:3592890)  M-unkn gi|14250269 69103,8125 6,38 5,86 2,02 5,34    
 Table 1-p12 
 
unnamed protein product  M-unkn gi|74151835 35893,12109 5,43 1,20    0,63 0,25 
unknown (protein for IMAGE:2650358)  M-unkn gi|116283288 51882,26172 8,84 1,24    0,77 0,45 
unnamed protein product  M-unmd gi|74198890 22130,38086 8,26 8,59 14,15 11,16    
unnamed protein product  M-unmd gi|53141 3842,189941 9,78 3,27 4,21 9,30    
unnamed protein product  M-unmd gi|74198200 47292,98047 5,61 2,24 2,58 7,57    
unnamed protein product  M-unmd gi|12845061 43003,78125 6,58 2,61 2,64 8,52    
unnamed protein product  M-unmd gi|12845061 43003,78125 6,58 2,98 3,03 8,96    
unnamed protein product  M-unmd gi|74204932 26277,78906 5,16 1,21 1,43 2,07    
unnamed protein product  M-unmd gi|26344461 22933,64063 5,2 1,22 1,43 2,09    
unnamed protein product  M-unmd gi|26341410 20290,49023 9,8 1,27 1,44 2,11    
unnamed protein product  M-unmd gi|12851441 33155,16016 5,22 1,27 1,48 2,13    
unnamed protein product  M-unmd gi|74224797 36487,08984 6,47 1,32 1,51 2,22    
unnamed protein product  M-unmd gi|74214038 34524,53906 6,06 1,37 1,52 2,29    
unnamed protein product  M-unmd gi|74222627 33100,94141 5,83 1,38 1,59 2,29    
unnamed protein product  M-unmd gi|12845061 43003,78125 6,58 1,44 1,73 2,40    
unnamed protein product  M-unmd gi|74197204 19477,58008 4,76 1,44 1,80 2,46    
unnamed protein product  M-unmd gi|74178174 92418,25 4,74 1,51 2,09 2,68    
unnamed protein product  M-unmd gi|74219251 51285,17969 7,92 1,59 2,14 2,85    
unnamed protein product  M-unmd gi|74224797 36487,08984 6,47 1,70 2,30 2,90    
unnamed protein product  M-unmd gi|26346108 47145,35938 5,67 1,74 2,35 3,08    
unnamed protein product  M-unmd gi|74139792 56517,78125 7,53 1,75 2,49 3,50    
unnamed protein product  M-unmd gi|74139792 56517,78125 7,53 1,82 2,52 3,74    
unnamed protein product  M-unmd gi|74194251 46717,28125 5,09 1,94 2,53 6,37    
unnamed protein product  M-unmd gi|12847394 33036,17969 4,91    0,61 0,64 0,18 
unnamed protein product  M-unmd gi|74204185 46256,64844 5,49    0,63 0,64 0,21 
unnamed protein product  M-unmd gi|74185120 42704,23047 5,4    0,63 0,75 0,22 
unnamed protein product  M-unmd gi|74185796 42541,16016 5,53    0,63 0,78 0,22 
 Table 1-p13 
 
unnamed protein product  M-unmd gi|74185796 42541,16016 5,53    0,64 0,80 0,24 
unnamed protein product  M-unmd gi|74183311 42983,17188 5,08    0,66 0,82 0,25 
unnamed protein product  M-unmd gi|74194251 46717,28125 5,09    0,66 0,84 0,27 
unnamed protein product  M-unmd gi|50815 42157,89844 6,56    0,69 0,85 0,29 
unnamed protein product  M-unmd gi|12850141 38331,92188 5,01    0,73 0,85 0,29 
unnamed protein product  M-unmd gi|50815 42157,89844 6,56    0,73 0,85 0,31 
unnamed protein product  M-unmd gi|12846758 49607,96094 4,78    0,74 0,89 0,35 
unnamed protein product  M-unmd gi|74147276 48647,14063 5,72    0,77 0,92 0,37 
unnamed protein product  M-unmd gi|12846039 12923,26953 4,82    0,79 0,93 0,38 
unnamed protein product  M-unmd gi|74141821 49667,01172 4,82    0,82 0,93 0,39 
unnamed protein product  M-unmd gi|74138546 59225,75 5,97    0,82 0,94 0,45 
unnamed protein product  M-unmd gi|74138891 56950,75 4,79    0,83 0,95 0,51 
unnamed protein product  M-unmd gi|26353794 56589,58984 5,78    0,85 0,97 0,51 
unnamed protein product  M-unmd gi|26341396 64960,71094 5,49    0,88 0,98 0,53 
unnamed protein product  M-unmd gi|74219490 59645,98047 5,72  1,00  0,91  0,59 
unnamed protein product  M-unmd gi|74200069 42169,55078 4,57  1,01  0,94  0,60 
unnamed protein product  M-unmd gi|74184034 29177,75 6,14 1,19    0,32 0,00 
unnamed protein product  M-unmd gi|74197204 19477,58008 4,76    0,19 0,44 0,06 
unnamed protein product  M-unmd gi|74181386 26518,15039 4,69    0,45 0,45 0,07 
unnamed protein product  M-unmd gi|74137638 26380,18945 4,74    0,46 0,52 0,07 
unnamed protein product  M-unmd gi|74151976 35760,21875 4,83    0,51 0,56 0,11 
unnamed protein product  M-unmd gi|74142393 35716,14844 4,79    0,55 0,60 0,12 
unnamed protein product  M-unmd gi|74151784 32887,64844 5,69    0,59 0,61 0,15 
unnamed protein product  M-unmd gi|12834035 31441,7793 5,7    0,59 0,61 0,15 
 
 
 
 Table 2-p1 
 
Table 2.  Differential expression proteins in HT-29 tumors (Protein profiling using 2-DE; Delta2D software; MALDI-TOF). 
(Subcutaneous HT-29 tumors in nude mice with and without VAVC GLV-1h68 treatment; time points were taken 7, 21 and 42 days after 
intravenous injection of the virus; fold of enhancement or reduction of protein expression after virus injection are shown; highly expression 
in red and down-regulated in blue)  
 
Fold of enhancement Fold of suppression 
>5 >5 
3 to 5 3 to 5 
2 to3 2 to 3 
 
Protein name Abbr Accession MW pI 
12hpi 
(+)fold 
24hpi 
(+)fold 
48hpi 
(+)fold 
12hpi 
(-)fold 
24hpi 
(-)fold 
48hpi 
(-)fold 
 
Viral proteins  
  
GUS23  V-Gus gi|8515916 68346,70313 5,29 ∞  1,51  0,94  
 
Cytoskeleton proteins  
  
Actr2 protein  H-Actr2 gi|29126784 44601,19141 6,31 2,41  1,03  0,92  
keratin 1  H-Krt1 gi|17318569 66027 8,16  2,37 1,50 0,89   
keratin 18  H-Krt18 gi|12653819 48002,53125 5,39 2,50    0,37 0,89 
keratin 2  H-Krt2 gi|47132620 65393,21094 8,07 3,32 1,30 1,74    
keratin 20  H-Krt20 gi|60811060 48570 5,52 ∞  1,50  0,72  
keratin 8  H-Krt8 gi|60826349 53784,21875 5,52  2,70 1,74 0,48   
keratin 8  H-Krt8 gi|4504919 53671,12891 5,52  2,95 2,14 0,44   
gelsolin-like capping protein  M-GlsCap gi|110227377 38744,67188 6,47 2,98    0,86 0,63 
myosin A1 catalytic light chain, skeletal muscle - mouse M-MyoA1      2,32 1,28    0,41 
myosin A1 catalytic light chain, skeletal muscle - mouse M-MyoA1 gi|91114 20580,44922 4,98  70,32 2,48 0,89   
 Table 2-p2 
 
alpha actinin  H-Actna gi|3157976 105158,6797 5,47 1,36 1,10    0,49 
keratin, type II cytoskeletal 1 (Cytokeratin-1) (CK-1) 
(Keratin-1) (K1) (67 kDa cytokeratin) (Hair  H-Krt1 gi|1346343 65977,97656 8,16 ∞    0,55 0,35 
keratin 1  H-Krt1 gi|17318569 66027 8,16 13,04    0,68 0,56 
keratin 1  H-Krt1 gi|17318569 66027 8,16 35,16    0,63 0,46 
KRT8 protein  H-Krt8 gi|39645331 55874,19922 5,62    0,88 0,60 0,55 
KRT8 protein  H-Krt8 gi|33875698 55787,17188 5,62    0,87 0,74 0,57 
65-kDa macrophage protein  M-LCP-1 gi|984636 70156,8125 5,28 1,58 1,17    0,56 
 
Stress response  
  
chaperonin containing TCP1, subunit 2  H-CCT2 gi|5453603 57452,12891 6,01  1,12 2,24 0,54   
Hspd1 protein  M-Hspd gi|76779273 59387,98828 8,09  2,29  0,60  0,35 
T-complex protein 1 subunit beta (TCP-1-beta) (CCT-beta) M-TCP1 gi|22654291 57441,10938 5,97 1,12    0,78 0,47 
 
Translation associated proteins 
   
eukaryotic translation elongation factor 1 gamma  H-EEF1g gi|15530265 50115,17188 6,25 2,68  1,74  0,85  
elongation factor 2[Mus musculus M-EF2 gi|192989 29870,07031 6,2 ∞    0,23 0,25 
acidic ribosomal phosphoprotein P0  M-ARPP0 gi|13277927 34164,73828 5,91 2,27 1,33 1,45    
PP856  H-PP856 gi|10834730 43805,32813 6,05 1,08  1,10  0,59  
 
RNA processing  
  
asparaginyl-tRNA synthetase  H-AsnS gi|4758762 62902,51172 5,9 60,87    0,61 0,92 
PREDICTED: similar to zinc finger protein 658B  H-ZNF658B gi|113421082 94170,64063 8,86 1,05  1,57  0,50  
 
Metabolism associated and transport proteins 
  
peroxiredoxin 2 isoform a  H-PRDX2 gi|32189392 21878,24023 5,66 ∞ ∞ ∞    
peroxiredoxin 3  H-PRDX3 gi|14250063 27705,15039 7,11 ∞ 18,18 14,29    
peroxiredoxin 3  H-PRDX3 gi|14250063 27705,15039 7,11 2,14 6,64    0,77 
peroxiredoxin 4  H-PRDX4 gi|60834541 30635,83984 5,74 2,36 1,16 1,27    
 Table 2-p3 
 
peroxiredoxin 4  H-PRDX4 gi|60834541 30635,83984 5,74 2,27  1,01  0,99  
TALDO1 protein  H-Tal1 gi|48257056 37385,42188 6,35 2,01    0,76 0,84 
TALDO1 protein  H-Tal1 gi|48257056 37385,42188 6,35 2,36    0,73 0,79 
TALDO1 protein  H-Tal1      3,72    0,69 0,71 
TALDO1 protein  H-Tal1 gi|16307182 35306,44922 9,07 ∞    0,31 0,70 
annexin A13 isoform a variant  H-A13 gi|62898309 35321,16016 5,59 2,22  1,25  0,37  
acetyl-CoA acetyltransferase, cytosolic variant  H-Acat gi|62087566 42108,78906 7,2 2,35    0,69 0,78 
dihydropyrimidinase-like 2 variant  H-DPYSL2 gi|62087970 68141,52344 5,85 2,03  1,12  0,94  
glutathione-S-transferase omega 1  H-GSTo1 gi|4758484 27548,03906 6,23 2,04    0,83 0,94 
IDI1 protein  H-IDI1 gi|48257312 27585,17969 6,02 ∞  1,31  0,30  
chain A, Structure Of Importin Beta Bound To The Ibb 
Domain Of Importin Alpha H-Imp gi|5107666 97172,07031 4,71 3,38 1,14    0,98 
peroxiredoxin 1  H-Mccc2 gi|55959887 18963,66992 6,41 ∞    0,81 0,44 
peroxiredoxin 1  H-Mccc2 gi|6754976 22162,34961 8,26 1,58 211,68 1,66    
malate dehydrogenase (EC 1.1.1.37), cytosolic - human H-MDH gi|7431153 36391,94922 5,92 6,36 1,57 1,11    
protein disulfide isomerase-associated 4  H-PDIa4 gi|4758304 72886,96875 4,96 3,73 1,16 1,13    
chain A, triosephosphate Isomerase (Tim) (E.C.5.3.1.1) 
Complexed With 2-Phosphoglycolic Acid  H-TPI1 gi|999892 26521,69922 6,51 ∞ 110,01    0,24 
abhydrolase domain containing 14B  M-Abhd gi|14249382 22331,56055 5,94 24,90 3,30 1,01    
adenylate kinase 1  M-ADK1 gi|10946936 23101,78906 5,7  2,55  0,60  0,72 
alpha-fetoprotein M-AFP gi|191765 47194,94922 5,47  55,97  0,67  0,46 
apolipoprotein A-I  M-Apoa1 gi|2145135 30497,60938 5,64 3,89  1,22  0,74  
Apoa1 protein  M-ApoA1 gi|61402210 23007,91016 7 5,81 3,12 1,92    
Eno3  M-ENO3 gi|71059715 46968,21875 6,29 605,22 2,36    0,04 
Eno3  M-Eno3 gi|71059715 46968,21875 6,29  6,23  0,13  0,12 
rho, GDP dissociation inhibitor (GDI) beta  M-GDIa gi|33563236 22836,49023 4,97 2,19 1,17    0,88 
Purine nucleoside phosphorylase (Inosine phosphorylase) 
(PNP) M-PNP gi|1346738 32256,06055 5,78 4,46 1,01 2,22    
RAB14, member RAS oncogene family  M-RAB gi|18390323 23881,92969 5,85 ∞ 113,87 3,17    
annexin A13 isoform a variant  H-A13 gi|62898309 35321,16016 5,59 1,36  1,41  0,50  
S-adenosylhomocysteine hydrolase Human H-AHCY gi|178277 47684,21875 6,03 1,86  1,33  0,52  
aldo-keto reductase family 7, member A2  H-akrf7 gi|41327764 39563,69922 6,7 1,47    0,56 0,73 
 Table 2-p4 
 
aldehyde dehydrogenase 9A1  H-ALDH9 gi|115387104 56255,42969 6,23 1,68  1,46  0,50  
clusterin  H-Clu gi|61365285 52575,03906 5,73  1,21  0,80  0,58 
glycerol-3-phosphate dehydrogenase 1  H-GPD1 gi|60810758 37656,39844 5,81 1,95  1,23  0,55  
AICAR formyltransferase/IMP cyclohydrolase bifunctional 
enzyme (Homo sapiens) M-AICAR gi|1263196 64425,26172 6,39    0,72 0,97 0,45 
chromatin modifying protein 4B  M-CMP4B gi|28077049 24920,56055 4,76 1,13    0,38 0,81 
 
Signal transduction  
 
  
DJ-1 protein  H-DJ-1 gi|31543380 19878,49023 6,33 2,32 5,69 1,23    
PREDICTED: similar to Proteasome subunit alpha type 6 
(Proteasome iota chain)  H-PSMA6 gi|109083331 28129,24023 6,35 2,32  2,82  0,81  
fibrinogen, B beta polypeptide  M-Fibrg gi|33859809 54717,69141 6,68 2,58 1,27    0,78 
haptoglobin  M-Hpgn gi|8850219 38727,48047 5,88 1,00 2,42    0,65 
proteasome (prosome, macropain) subunit, alpha type 1  M-PSMA1 gi|33563282 29527,82031 6 11,17    0,66 0,74 
proteasome (prosome, macropain) 26S subunit, non-
ATPase, 7  M-PSMD7 gi|6754724 36517,21094 6,29 12,78 1,05    0,89 
serine (or cysteine) peptidase inhibitor, clade A, member 
3K  M-SPIA3K      2,15 1,10    0,31 
serine (or cysteine) peptidase inhibitor, clade A, member 
3K  M-SPIA3K gi|15079234 46835,96875 5,05 ∞    0,59 0,09 
serine (or cysteine) peptidase inhibitor, clade A, member 
3K  M-SPIA3K gi|16741103 46869,96094 5,05  2,04  0,38  0,91 
serine (or cysteine) peptidase inhibitor, clade A, member 
3K  M-SPIA3K gi|15079234 46835,96875 5,05  3,81 1,00 0,07   
HMW kininogen-I variant  M-KngnI gi|40715900 53171,87109 4,88  1,35 2,17 0,56   
serine (or cysteine) proteinase inhibitor, clade B 
(ovalbumin), member 6  H-SPIB6 gi|41152086 42594,05859 5,18  1,16  0,54  0,82 
fibrinogen gamma-chain  M-Fibrg gi|15593267 20752,91016 5,17  1,29 1,07 0,57   
fibrinogen gamma-chain  M-Fibrg gi|15593267 20752,91016 5,17  1,32 1,10 0,57   
haptoglobin  M-Hpgn gi|8850219 38727,48047 5,88 1,14 1,08    0,53 
LMW K-kininogen precursor M-Kng gi|205077 35672,78906 7,21  1,97 1,67 0,59   
kininogen 1  M-KngnI gi|12963497 47867,60156 5,74  1,15 1,44 0,58   
 Table 2-p5 
 
HMW kininogen-I variant  M-KngnI      1,48    0,59 0,42 
pregnancy zone protein  M-PZP gi|110347469 165747,7969 6,24 1,59 1,29    0,52 
serine (or cysteine) peptidase inhibitor, clade A, member 
3K  M-SPIA3K gi|16741103 46869,96094 5,05  1,69  0,57  0,87 
HMW kininogen-I variant  M-SPIA3K      1,01 1,15    0,45 
HMW kininogen-I variant  M-SPIA3K       1,28  0,87  0,47 
 
Others  
  
Ig gamma-1 chain C region (15C5) - mouse (fragment) M-IgGc gi|110077 17304,51953 8,76 6,90    0,23 0,20 
albumin 1  M-Alb1 gi|33859506 68677,71875 5,75  2,39 1,10 0,59   
albumin 1  M-Alb1 gi|33859506 68677,71875 5,75  23,40 1,15 0,39   
tumor rejection antigen (gp96) 1 variant  H-gp96       1,11  0,67  0,56 
tumor rejection antigen (gp96) 1 variant  H-gp96 gi|62088648 65912,28906 5,08  1,22 1,28 0,27   
PAP-inositol-1,4-phosphatase  H-PIP gi|6688197 33401,21094 5,46 1,23  1,02  0,60  
thioredoxin reductase  H-PRDX5 gi|2832346 54511,85156 6,07 1,55 1,14    0,42 
albumin 1  M-Alb1 gi|33859506 68677,71875 5,75 1,16 1,11    0,12 
albumin 1  M-Alb1 gi|33859506 68677,71875 5,75 1,11 1,12    0,39 
albumin 1  M-Alb1 gi|33859506 68677,71875 5,75  1,17  0,94  0,44 
complement component 3  M-CompC3 gi|23956044 186363,7031 6,44  1,44  0,77  0,51 
complement component 3  M-CompC3 gi|23956044 186363,7031 6,44    0,95 0,78 0,45 
otub1 protein  M-Otub gi|32484336 30977,28906 4,85    0,60 0,87 0,48 
 
Unknown   proteins 
  
  
unnamed protein product  H-unmd gi|10434142 65265,12109 8,96  1,34 1,70 0,51   
unknown (protein for IMAGE:3832468)  H-3832468 gi|33988037 38802,42969 9,37 2,65    0,97 0,58 
unnamed protein product  H-unmd gi|28317 59491,87109 5,17 43,13  1,02  0,77  
  H-unmd      ∞    0,35 0,93 
unknown (protein for IMAGE:3592890)  M-3592890 gi|14250269 69103,8125 6,38 ∞    0,21 0,26 
unknown (protein for IMAGE:3592890)  M-3592890 gi|14250269 69103,8125 6,38  8,89 2,56 0,16   
unnamed protein product  M-unmd gi|26345182 30596,64063 5,51 2,18    0,84 0,66 
 Table 2-p6 
 
unnamed protein product  M-unmd gi|26354961 60505,82813 7,63 5,05    0,84 0,63 
unnamed protein product  M-unmd gi|74219251 51285,17969 7,92 10,98    0,83 0,59 
unnamed protein product  M-unmd gi|26354961 60505,82813 7,63 12,06    0,77 0,59 
unnamed protein product  M-unmd gi|26361821 22151,18945 7,11 16,66    0,75 0,52 
unnamed protein product  M-unmd gi|26361821 22151,18945 7,11 21,61    0,72 0,52 
unnamed protein product  M-unmd gi|26345182 30596,64063 5,51 129,63    0,72 0,52 
unnamed protein product  M-unmd gi|26364516 12070,15039 6,28 323,36    0,60 0,44 
unnamed protein product  M-unmd gi|52181 25730,48047 7,59 568,02    0,57 0,40 
unnamed protein product  M-unmd gi|26341410 20290,49023 9,8 759,74    0,53 0,38 
  M-unmd      ∞    0,01 0,11 
unnamed protein product  M-unmd gi|74216905 16492,63086 6,14 ∞    0,21 0,22 
unnamed protein product  M-unmd gi|26344461 22933,64063 5,2  2,72 1,47 0,56   
unnamed protein product  M-unmd gi|74139512 36303,55859 5,61  3,07 1,55 0,55   
unnamed protein product  M-unmd gi|12845061 43003,78125 6,58  5,52 1,86 0,53   
unnamed protein product  M-unmd gi|26341396 64960,71094 5,49  9,32 2,34 0,26   
unnamed protein product  H-unmd gi|34039 44079,12109 5,04   1,69 0,59 0,95  
unknown (protein for IMAGE:3529287)  H-3529287 gi|52790434 37696,98047 8,56   1,05 0,44 0,98  
 
 
 
 Table 3-p1 
 
Table 3. Differential expression proteins in PC-3 tumors (Protein profiling using 2-DE; Delta2D software; MALDI-TOF). 
(Subcutaneous PC-3 tumors in nude mice with and without VAVC GLV-1h68 treatment; time points were taken 7, 21 and 42 days after 
intravenous injection of the virus; fold of enhancement or reduction of protein expression after virus injection are shown; highly expression 
in red and down-regulated in blue)  
 
Fold of enhancement Fold of suppression 
>5 >5 
3 to 5 3 to 5 
2 to3 2 to 3 
 
 
Protein name Abbr Accession MW pI 
7dpi 
(+)fold 
21dpi 
(+)fold 
42dpi 
(+)fold 
7dpi 
(-)fold 
21dpi 
(-)fold 
42dpi 
(-)fold 
 
Cytoskeleton proteins 
 
ACTB protein  H-ACTB gi|15277503 40194,07031 5,55  1,82    0,36 
ARP3 actin-related protein 3 homolog  H-ARP3 gi|5031573 47340,98047 5,61    0,86 0,47 0,97 
FLNA protein  H-FLNA gi|15779184 88534,4063 5,93 1,01    0,60 0,41 
moesin  M-Msn gi|199765 66440,10938 5,94   1,57 0,46 0,57  
tubulin, beta, 4 variant  H-Btub gi|62897639 50340,19922 4,83 1,23    0,66 0,24 
VIM  H-Vim gi|47115317 53547,05859 5,09 1,79 2,39    0,33 
vimentin  M-Vim gi|2078001 51533,08984 4,96   8,94  0,15  
vimentin  H-Vim gi|37852 53653,05859 5,06   ### 0,86 0,50  
vimentin  H-Vim gi|37852 53653,05859 5,06 1,79  3,59  0,78  
vimentin  H-Vim gi|62414289 53619,07813 5,06   1,53 0,84 0,00  
 
Stress response 
 
 Table 3-p2 
 
CCT2  H-TCP1 gi|48146259 57424,05859 6,01  1,57    0,24 
heat shock protein 1, beta  M-HSP1b gi|40556608 83229,10938 4,97   3,12 0,44 0,72  
HSP90AA1 protein  H-HSP90AA1 gi|83318444 68328,78125 5,11    0,92 0,82 0,14 
 T-complex protein 1 subunit beta (TCP-1-beta) (CCT-β) H-TCP1         2,32 0,81 0,77  
 
Translation associated proteins 
 
ATP-dependent DNA helicase II  H-Ku70 gi|10863945 82652,27344 5,55  2,44    0,88 
BiP protein  H-BiP gi|6470150 70887,52344 5,23  1,57  0,21  0,21 
Ribosomal protein, large, P0  H-RPLP0 gi|12654583 34252,73828 5,42 1,73 2,63    0,95 
stress-induced-phosphoprotein 1 (Hsp70/Hsp90)  H-STIP1 gi|5803181 62599,39844 6,4   4,35 0,70 0,23  
 
RNA processing 
 
  H-p100         3,82 0,93 0,81  
alpha isoform of regulatory subunit A, protein phosphatase 
2  H-Ppp2r1a gi|21361399 65266,9102 5    0,84 0,93 0,51 
calreticulin=calcium binding protein [human, placenta, 
Peptide Partial, 31 aa, segment 1 of 5] H-Calr gi|913149 3736,72998 6,86   5,29 0,87 0,95  
calreticulin=calcium binding protein [human, placenta, 
Peptide Partial, 31 aa, segment 1 of 5] H-Calr gi|913148 3736,72998 6,86 1,18 1,13    0,17 
heterogeneous nuclear ribonucleoprotein C  M-hnRNPC gi|8393544 34363,85938 4,92 1,15    0,85 0,23 
Hnrpc protein  M-hnRNPC gi|13435678 32256,88086 5,01   1,35 0,93 0,53  
tRNA nucleotidyl transferase, CCA-adding, 1 isoform 1  H-TRNT1 gi|7705763 46329,14063 6,3     0,90 0,22 
 
Metabolism associated and transport proteins 
 
aldehyde dehydrogenase family 1, subfamily A2  M-Aldh1a2 gi|6677665 54690,87109 5,83  1,29 4,05    
apolipoprotein A-I  M-ApoA1 gi|2145139 30525,60938 5,51 1,66    0,35 0,00 
apolipoprotein A-I  M-ApoA1 gi|2145139 30525,60938 5,51 ∞ 2,70    0,00 
copg protein  M-COPG gi|14250257 70573,60938 4,78     0,78 0,40 
EBNA-2 co-activator variant  H-p100 gi|62088600 107366,2734 7,36  1,07    0,15 
 Table 3-p3 
 
enolase 1 variant  H-Eno1 gi|62897945 47167,32031 7,01    0,70 0,65 0,09 
enolase 1 variant  H-Eno1 gi|62897945 47167,32031 7,01    0,87 0,76 0,43 
epsilon subunit of coatomer protein complex isoform c  H-COPE gi|40805827 28754,59961 5,11    0,32 0,51 0,00 
epsilon subunit of coatomer protein complex isoform c  H-COPE gi|40805827 28754,59961 5,11  1,01    0,02 
ferritin light chain 1  M-Ftl1 gi|18044716 20745,4707 5,66    0,96 0,81 0,19 
glycogen phosphorylase  H-PYG gi|3170407 97061,86719 6,31 1,11    0,67 0,32 
LAP3 protein  H-LAP3 gi|37588925 54354,73828 6,8   3,70 0,44 0,38  
LAP3 protein  H-LAP3 gi|37588925 54354,73828 6,8    0,88 0,80 0,23 
liver transferrin Musculus M-Trf gi|198848 14644,24023 4,94   2,50 0,57 0,83  
liver transferrin Musculus M-Trf gi|198848 14644,24023 4,94  1,02  0,99  0,04 
liver transferrin Musculus M-Trf gi|198848 14644,24023 4,94   9,48 0,52 0,72  
mitochondrial ATP synthase, H+ transporting F1 complex 
beta subunit  H-ATPF1 gi|89574029 48083,03906 4,95   4,54 0,84 0,58  
Pgm2 protein  M-Pgm2 gi|33416468 63414,58984 6,02  2,20 1,53    
Phosphorylase, glycogen; liver (Hers disease, glycogen 
storage disease type VI)  H-PYGL gi|112180335 96955,97656 6,71 1,44    0,46 0,28 
PREDICTED: similar to Transitional endoplasmic 
reticulum ATPase (TER ATPase) (15S Mg(2+)-ATPase 
p97 Mouse M-TERA gi|94408013 58740,21875 5,62    0,98 0,96 0,58 
rab GDP dissociation inhibitor alpha  M-GDIa gi|13936441 50494,07031 4,96   4,49  0,72  
rho GDP dissociation inhibitor (GDI) alpha  M-GDIa gi|31982030 23392,81055 5,12 1,27    0,92 0,00 
transferrin  M-Trf gi|20330802 76673,71875 6,94  1,19  0,96  0,06 
twinfilin-like protein  H-TWFl gi|6005846 39523,26953 6,37  1,10  0,78  0,55 
 ubiquitin activating enzyme E1 H-UBE1  gi|35830  117715,34375  5,57    0,36 0,67 0,68 
uroporphyrinogen decarboxylase  H-UROD gi|71051616 40760,82813 5,77   2,54 0,98 0,59  
 
signal transduction 
 
  M-SHP-1         2,17 0,62 0,75  
alpha-1 protease inhibitor 2  M-A1AT2 gi|191844 44746,85938 5,33 2,12 1,13 1,83    
alpha-1-antitrypsin  M-A1AT gi|192094 22826,7793 5,98 1,08    0,95 0,46 
 Table 3-p4 
 
chain A, Crystal Structure Of 14-3-3 Gamma In Complex 
With A Phosphoserine Peptide Human H-1433G gi|82407948 28153,8691 4,8 ###  ###  0,68  
chain A, crystal Structure Of 14-3-3 gamma in complex 
with a phosphoserine peptide  H-1433G gi|82407948 28153,8691 4,8 1,17    0,00 0,11 
nuclear chloride channel  H-CLIC1 gi|4588526 26906,73047 5,02    0,24 0,36 0,11 
rho GDP dissociation inhibitor (GDI) alpha  H-GDIa gi|4757768 23192,6992 5,02 1,30    0,83 0,50 
Serine (or cysteine) peptidase inhibitor, clade A, member 
3K  M-SPIA3K gi|16741103 46869,96094 5,05  6,78  0,77  0,28 
serine (or cysteine) proteinase inhibitor, clade B 
(ovalbumin), member 5  H-Serpinb5 gi|4505789 42111,44922 5,72  2,93  0,28  0,38 
serine (or cysteine) proteinase inhibitor, clade B 
(ovalbumin), member 1 variant  H-SPIB1 gi|62898301 42742,71094 5,9 1,72 2,61    0,71 
serine (or cysteine) proteinase inhibitor, clade B 
(ovalbumin), member 5  M-SPIA3K        1,71 8,15 0,68   
serine (or cysteine) proteinase inhibitor, clade B 
(ovalbumin), member 5  H-SPIB1        1,01  0,42  0,29 
serpina1b protein  M-Serpina1b gi|15929675 45593,39844 5,31 1,07 2,06    0,84 
SH2 phosphatase 1  M-SHP-1 gi|4097668 67675,25 7,66 1,53    0,83 0,46 
calpain 2, large subunit  H-CAPN2 gi|4502563 79955,82031 4,92 2,23  5,20  0,25  
 
Others proteins 
 
chain L, Igg2a Fab Fragment (50.1) Complex With 16-
Residue Peptide (Residues 311-328 Of Hiv-1 Gp120 (mus 
culus) M-Igg2a gi|442937 23956,59961 5,07    0,96 0,81 0,49 
protein phosphatase 1, catalytic subunit, gamma isoform  H-Ppp1cc gi|4506007 36959,71875 6,13  1,09  0,87  0,45 
transformation-related protein 14  H-TRP14        2,66    0,06 
transformation-related protein 14  H-TRP14 gi|33415057 42791,69141 5,49  2,31  0,86  0,01 
vinculin isoform meta-VCL  H-mVCL gi|7669550 123721,8125 5,5  1,04  0,93  0,19 
 
Unknown proteins 
 
unnamed protein product  H-unmd gi|21757045 52406,42188 4,99  1,11 3,20    
unknown (protein for IMAGE:2650358)  M-2650358 gi|116283288 51882,26172 8,84     0,85 0,46 
 Table 3-p5 
 
unknown (protein for IMAGE:2650358)  M-2650358 gi|116283288 51882,26172 8,84     0,92 0,52 
unnamed protein product  M-unmd gi|51452 58833,12891 5,48  1,01 5,66    
unnamed protein product  M-unmd gi|26341396 64960,71094 5,49  1,05 4,97    
unnamed protein product  M-unmd gi|74137565 68687,71875 5,78  1,12 4,10    
unnamed protein product  M-unmd gi|74137565 68687,71875 5,78  1,16 3,69    
unnamed protein product  M-unmd gi|26341396 64960,71094 5,49  1,18 3,54    
unnamed protein product  M-unmd gi|74220592 70647,97656 5,22  1,20 2,64    
unnamed protein product  M-unmd gi|74198645 56293,51172 5,25  1,23 2,47    
unnamed protein product  M-unmd gi|26341396 64960,71094 5,49  1,23    0,05 
unnamed protein product  M-unmd gi|74208631 70827,17188 5,32  1,25    0,11 
unnamed protein product  M-unmd gi|74219251 51285,17969 7,92  1,27    0,18 
unnamed protein product  M-unmd gi|74143673 56857,73828 5,43  1,29    0,31 
unnamed protein product  M-unmd gi|74220199 68455,45313 5,15  1,31    0,34 
unnamed protein product  M-unmd gi|74179916 27358,78906 6,34  2,34    0,78 
unnamed protein product  M-unmd gi|12845061 43003,78125 6,58  2,46    0,83 
unnamed protein product  M-unmd gi|74178174 92418,25 4,74  2,64    0,84 
 unnamed protein product M-unmd         2,18 0,36 0,41  
unnamed protein product  M-unmd gi|26341396 64960,71094 5,49  1,01 2,20 0,97   
 unnamed protein product M-unmd         1,69 0,42 0,49  
 unnamed protein product M-unmd          0,80 0,69 0,40 
unknown (protein for IMAGE:2650358)  M-unmd gi|116283288 51882,26172 8,84    0,89 0,80 0,41 
unnamed protein product M-unmd         1,90 0,37 0,67  
unnamed protein product M-unmd         1,78 0,40 0,74  
unnamed protein product M-unmd         1,60 0,49 0,75  
 unnamed protein product M-unmd         1,57 0,51 0,79  
unnamed protein product  M-unmd gi|26341396 64960,71094 5,49   1,40 0,53 0,79  
unnamed protein product  M-unmd gi|74143673 56857,73828 5,43   1,32 0,59 0,85  
unnamed protein product  M-unmd gi|50815 42157,89844 6,56 3,48 9,61    0,93 
 
 
 Table 3-p6 
 
 
                                                                                                                                                                                                       Table 4-p1 
 
Table 4. Differential expression proteins in GI-101A cells (Protein profiling using 2-DE; Delta2D software; MALDI-TOF). 
(GI-101A cells with and without VAVC GLV-1h68 treatment; time points were taken 12, 24 and 48 hours after virus infection; fold of 
enhancement or reduction of protein expression after virus infection are shown; highly expression in red and  down-regulated in blue)  
 
Fold of enhancement Fold of suppression 
>5 >5 
3 to 5 3 to 5 
2 to3 2 to 3 
 
 
Protein name Abbr Accession MW pI 
12hpi 
(+)fold 
24hpi 
(+)fold 
48hpi 
(+)fold 
12hpi 
(-)fold 
24hpi 
(-)fold 
48hpi 
(-)fold 
 
Viral proteins 
 
20 kDa virion core protein V-A12L gi|137349 20506,2207 9,57 4,50 21,61 30,84       
30k DNA binding phosphoprotein V-I3L gi|2772696 30008,4707 5,68 1,91 2,53 2,83       
beta-galactosidase  V-bGal gi|37780061 117625,8672 5,37 1,11 2,63 6,27       
beta-galactosidase V-bGal gi|644832 116130,9531 5,28   1,79 4,67 0,59     
dsRNA dependent PK inhibitor  V-E3L gi|2772689 21490,82031 5,19 1,64 2,33 3,53       
hypothetical protein m8238R  V-Hyp8238 gi|56713587 24638,28906 6,35 2,44 10,45       0,72 
hypothetical protein VACWR125  V-A6L gi|66275922 43146,62109 8,08 1,31 2,88 4,48       
lacZ [Integrative translation probe vector pTP1] V-LacZ gi|91983328 115411,6875 5,3   1,23 2,82 0,35     
major core protein  V-A10L gi|56713513 102184,5391 5,83   2,55 3,42 0,89     
major core protein P4b  V-A3L gi|2772718 72577,88281 6,37 1,10 2,42 2,71       
p4b precursor of core protein 4b  V-A3L gi|66275919 72577,84375 6,28 1,52 2,44 3,18       
                                                                                                                                                                                                       Table 4-p2 
 
putative 43.1k protein  V-A6L gi|2772720 43072,44141 5,71   2,27 2,89 0,87     
ssDNA-binding phosphoprotein  V-I3L gi|37551517 29994,44922 5,68 5,05 7,22 6,47       
 
Cytoskeleton proteins  
  
ARP3 actin-related protein 3 homolog  H-ARP3 gi|5031573 47340,98047 5,61 1,43 1,94 2,03       
chromosome 20 open reading frame 3  H-C20 gi|24308201 46450,85156 5,82       0,83   0,57 
keratin 18  H-Krt18 gi|12653819 48002,5313 5,4       0,48   0,50 
keratin 8, isoform CRA_d  H-Krt8 gi|119617060 62105,26953 5,79       0,61   0,44 
radixin  H-Rdx gi|4506467 68521,39063 6,03 2,46 2,20 2,52       
tropomodulin 3  H-TMOD3 gi|6934244 39556,28125 5,08       0,50   0,60 
tropomyosin 4  Human H-TPM4 gi|54696134 28617,57031 4,67 1,82 2,00 2,60       
tubulin, beta polypeptide  H-Btub gi|57209813 47735,98828 4,7       0,85   0,51 
  
Stress response  
 
chaperonin containing TCP1, subunit 8 (theta) variant  H-CCT8 gi|62896539 59612,51172 5,42       0,70   0,43 
gamma subunit of CCT chaperonin  H-CCtg gi|671527 60292,25 6,23   1,31   0,56   0,69 
heat shock 70kDa protein 1A variant  H-hsp701a gi|62089222 77447,71094 5,97       0,10     
heat shock 70kDa protein 1A variant  H-hsp701a gi|62089222 77447,71094 5,97   1,05   0,58   0,68 
heat shock 70kDa protein 4-like  H-HSPA4L gi|31541941 94452,52344 5,63       0,99   0,50 
HSP90AA1 protein  H-HSP90AA1 gi|12654329 64349,69922 5,1       0,63   0,32 
HSPA9 protein  H-HSPA9 gi|21040386 73807,9531 6       0,51   0,48 
t-complex polypeptide 1  H-TCP1 gi|36796 60355,75 6,03 1,12 2,82 3,72       
t-complex polypeptide 1  H-TCP1 gi|36796 60355,75 6,03   1,02   0,33   0,75 
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Translation associated proteins 
 
eukaryotic translation initiation factor 3, subunit 2 beta,  H-Eif3s2 gi|54696060 36591,69922 5,38       0,65   0,55 
eukaryotic translation initiation factor 4B  H-EIF4B gi|49256408 69125,25781 5,55 1,86 2,18 1,90       
eukaryotic translation initiation factor 4B  H-EIF4B gi|49256408 69125,25781 5,55 1,99 3,18 2,96       
eukaryotic translation initiation factor 2, subunit 1 alpha, 
35kDa [synthetic construc H-eIF2 gi|30584065 36202,4609 5       0,73   0,48 
pyrophosphatase 1  H-PP1 gi|11056044 32639,15039 5,54       0,41   0,35 
 
RNA processing 
 
heterogeneous nuclear ribonucleoprotein U (scaffold 
attachment factor A)  H-henuriU gi|55859528 79793,85156 8,06 1,77 2,03 2,47       
prohibitin  H-PHB gi|46360168 29801,92969 5,57       0,31   0,27 
thyroid hormone binding protein precursor Homosapiens H-TRBP gi|339647 57068,67188 4,82 3,41 2,19 1,17       
 
Ubiquitin proteasome pathway 
 
chain B, proteasome activator reg(Alpha) (Homo sapiens) H-PARegA gi|2780871 16284,66992 7,14       0,76   0,33 
proteasome 26S non-ATPase subunit 5  H-PSMD5 gi|4826952 56160,35938 5,35       0,38   0,25 
proteasome activator subunit 2  H-PSME2 gi|30410792 27384,31055 5,54       0,25   0,19 
proteasome activator subunit 2  H-PSME2 gi|30410792 27384,31055 5,54       0,80   0,21 
proteasome beta-subunit - human H-PSMB gi|631345 25892,85938 5,7       0,97   0,45 
 
Metabolism associated proteins  
 
annexin A1  H-A1 gi|61356735 38718,0117 6,6       0,69   0,41 
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 Chain A, Human B Lactate Dehydrogenase Complexed With 
Nad+ And 4- Hydroxy-1,2,5-Oxadiazole-3-Carbox H-LDHB gi|49259209 36516,1406 5,86 1,07 2,00       0,82 
 chain A, human B lactate dehydrogenase complexed with 
Nad+ And 4- Hydroxy-1,2,5-Oxadiazole-3-Carbox H-LDHB gi|49259209 36516,1406 5,86       0,65   0,58 
creatine kinase, muscle  H-Creatine gi|13938619 43039,91016 6,77 4,30         0,45 
cytosolic malate dehydrogenase  H-MDH1 gi|5174539 36403,01953 6,91 4,30 5,86       0,93 
dimethylarginine dimethylaminohydrolase 2  H-DDAH2 gi|55961454 19946,4297 5,6       0,90   0,41 
enolase 1 variant  H-ENO1 gi|62897945 47167,32031 7,01 2,02 2,33 1,32       
enolase 1 variant  H-Eno1 gi|62896593 47111,28906 7,01       0,92   0,24 
glucose-6-phosphate dehydrogenase  H-G6PD gi|30584817 59332,07031 6,39       0,35   0,46 
Hpast  H-Horf gi|2529707 60664,67188 6,49       0,81   0,52 
PDZ and LIM domain 1 (elfin)  H-PDZ gi|13994151 36049,03906 6,56       0,63   0,43 
peroxiredoxin 2  H-PRDX2 gi|60654143 21991,3203 5,7       0,40   0,42 
peroxiredoxin 6  H-PRDX6 gi|4758638 25019,18945 6 1,30 2,16 2,61       
PGAM1  H-PGAM1 gi|49456447 28816,83984 6,67 3,15 6,74       0,01 
phosphoribosyl pyrophosphate synthetase 2 isoform 2  H-PRPS2  gi|4506129 34746,98047 6,15 2,75 2,08 1,97       
protein disulfide isomerase-associated 4  H-PDIa4 gi|4758304 72886,96875 4,96       0,77   0,46 
spermidine synthase  H-SPDSY gi|63253298 33802,71094 5,3 2,17 1,71 1,38       
TALDO1 protein  H-TALDO gi|48257056 37385,42188 6,35       0,28   0,15 
triosephosphate isomerase 1  H-TPI1 gi|4507645 26652,74023 6,45 2,78 2,56 1,27       
TXNDC4  H-TXDC4 gi|37183214 46897,4102 5,1       0,71   0,59 
 
Signal transduction 
 
COP9 signalosome subunit 4  H-CSN gi|38373690 46239,6719 5,6 1,01         0,46 
human rab GDI  H-GDI gi|285975 50631,85938 5,94       0,80   0,45 
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 mitogen-activated protein kinase kinase 2  H-MKK2 gi|33304081 34317,0117 7,66 1,13         0,48 
rho GTPase activating protein 1  H-Arhgap1 gi|4757766 50404,19141 5,85 1,30 2,02 2,55       
serine protease inhibitor-like SPI-1  V-C12L gi|37551651 40392,98828 5,08 16,68 35,52 41,96       
serpin peptidase inhibitor, clade B (ovalbumin), member 6, 
isoform CRA_d  H-SERPINB6 gi|119575506 42996,25 5,18       0,52   0,26 
YWHAZ protein  H-1433zd gi|49119653 29928,8203 4,7       0,58   0,45 
 
Other proteins 
 
CAPNS1 protein  H-CAPNS1 gi|40674605 28211,67969 4,96 1,56 2,29 2,89       
FK506 binding protein 4 59kDa  H-Fkbp4 gi|61355277 51802,07813 5,35       0,47   0,34 
FK506 binding protein 4 59kDa  H-Fkbp4             0,75   0,50 
ribosomal protein SA, isoform CRA_c  H-RPSA gi|119584991 19625,26953 8,37       0,64   0,45 
 
Unkown proteins  
 
unknown H-unkn gi|158261809 59691,80078 5,34 1,59 1,95 2,71       
unknown  H-unkn gi|62630180 88890,34375 5,44       0,43   0,52 
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Table 5. Differential expression proteins in HT-29 cells (Protein profiling using 2-DE; Delta2D software; MALDI-TOF). 
(HT-29 cells with and without VAVC GLV-1h68 treatment; time points were taken 12, 24 and 48 hours after virus infection; fold of 
enhancement or reduction of protein expression after virus infection are shown; highly expression in red and down-regulated in blue)  
 
Fold of enhancement Fold of suppression 
>5 >5 
3 to 5 3 to 5 
2 to3 2 to 3 
 
Protein name Abbr Accession MW pI 
12hpi 
(+)fold 
24hpi 
(+)fold 
48hpi 
(+)fold 
12hpi 
(-)fold 
24hpi 
(-)fold 
48hpi 
(-)fold 
Protein 
name 
  
Viral proteins 
  
30k DNA binding phosphoprotein  V-I3L gi|2772696 30008,4707 5,68 10,65 ###### 12,78 12,05       
chemokine-binding protein  V-C23L gi|66275798 26349,5293 4,49 13,40 ###### 18,03 8,72       
dsRNA dependent PK inhibitor  V-dsPKI gi|2772689 21490,82031 5,19 6,04 864.671 8,65 6,54       
hypothetical protein VACWR125  V-A6L gi|66275922 43146,62109 8,08 3,50 706.686 7,07 5,82       
major core protein  V-A10L gi|56713513 102184,5391 5,83 3,87 734.005 7,34 7,26       
p4b precursor of core protein 4b  V-A3L gi|66275919 72577,84375 6,28 1,45 209.607 2,10 2,01       
putative DNA-binding virion core protein  V-E11L gi|56713462 28424,65039 6,03 8,07 ###### 20,41 11,57       
ribonucleoside-diphosphate reductase  V-I4L gi|56713400 36922,23828 5,08 5,61 ###### 10,70 9,63       
serine protease inhibitor-like SPI-1  V-C12L gi|37551651 40392,98828 5,08 5,30 727.146 7,27 6,82       
toll/IL1-receptor  V-A46R gi|66275969 27617,65039 4,99 1,93 217.246 2,17 1,23       
 
Cytoskeleton proteins 
 
actin, gamma 1 propeptide  H-ACTG gi|4501887 41765,78906 5,31         0,93 0,52 0,44 
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ARP1 actin-related protein 1 homolog A, centractin alpha  H-ARP1 gi|5031569 42586,89844 6,19         0,94 0,90 0,38 
BiP protein  H-BiP gi|6470150 70887,52344 5,23         0,41 0,66 0,62 
chain A, moesin ferm domain bound to Ebp50 C-terminal 
peptide  H-Moe gi|50513540 34896,30859 9,03 2,01   1,93 1,67       
chaperonin (HSP60) H-Hsp60 gi|306890 60986,3711 5,7 1,15   1,93 2,28       
heat shock 70kDa protein 1A variant  H-hsp701a gi|62089222 77447,71094 5,97 3,22   1,46 1,37       
heat shock 70kDa protein 4 isoform a  H-hsp704 gi|38327039 94271,24219 5,11         0,58 0,54 0,76 
heat shock 70kDa protein 8 isoform 2  H-hsp708 gi|24234686 53484,41016 5,62 31,38 472.297 4,72 16,64       
keratin 1  H-Krt1 gi|17318569 66027 8,16 5,84 478.636 4,79 1,53       
KRT8 protein  H-Krt8 gi|62913980 41082,66016 4,94 1,58   1,48 2,57       
KRT8 protein  H-Krt8 gi|62913980 41082,66016 4,94 2,38 245.634 2,46 3,59       
KRT8 protein  H-Krt8 gi|39645331 55874,19922 5,62 2,79 396.946 3,97 5,95       
PRDX4  H-PRDX4 gi|49456297 30570,8496 5,86         0,81 0,54 0,60 
 
Stress response 
            
stress-induced-phosphoprotein 1 (Hsp70/Hsp90-organizing 
protein)  H-STIP1 gi|5803181 62599,39844 6,4         0,86 0,85 0,59 
 
Translation associated proteins 
 
ATP-dependent DNA helicase II, 70 kDa subunit  H-Ku70 gi|4503841 69799,04688 6,23 1,02         0,58 0,64 
G elongation factor, mitochondrial 1  H-GFM1 gi|18390331 83418,4375 6,58 1,09         0,74 0,59 
KIAA0038  H-KI38 gi|436226 25468,67969 8,66 3,43 519.819 5,20 5,04       
minichromosome maintenance protein 7 isoform 1  H-MCM7 gi|33469968 81256,57031 6,08         0,87 0,70 0,37 
 
RNA processing 
 
lamin A/C transcript variant 1  H-lmnA/C gi|57014043 74036,70313 6,73         0,76 0,71 0,44 
lamin B1  H-lmnB1 gi|5031877 66367,61719 5,11         0,99 0,78 0,31 
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otubain 1  H-otub gi|109148508 31264,41992 4,85         0,88 0,82 0,47 
 
Ubiquitin proteasome pathway 
 
 
Metabolism associated and transport proteins 
 
2-phosphopyruvate-hydratase alpha-enolase; carbonate 
dehydratase  H-ENOA gi|693933 47079,28125 7,01         0,10 0,64 0,40 
annexin A1  H-A1 gi|54696610 38803,0586 6,57 1,81 ##### 3,04 2,72       
 annexin A1 H-A1 gi|1421662 36308,6484 5,63         0,66 0,65 0,52 
annexin A13 isoform b  H-A13B gi|51896029 39719,26172 5,38         0,78 0,11 0,06 
calpain, small subunit 1  H-CSS1 gi|18314496 28281,74023 5,05         0,91 0,60 0,54 
chain A, the crystal structure of dihydrolipoamide 
dehydrogenase and dihydrolipoamide dehydrogenase  H-DLD gi|83753870 50142,91016 6,5         0,56 0,92 0,34 
chain A, ubiquitin-conjugating enzyme E2-25 kda 
(Huntington Interacting Protein 2)  H-HIP2 gi|60594411 22536,61914 5,33 1,05         0,63 0,34 
chain E, crystal structure of human pnp At 2.3a resolution H-Pnp gi|37926571 31996,13086 6,49         0,84 0,64 0,56 
dimethylarginine dimethylaminohydrolase 1  H-DDAH1 gi|6912328 31101,92969 5,53         0,64 0,73 0,55 
dimethylarginine dimethylaminohydrolase 2  H-DDAH2 gi|7524354 29625,4492 5,66         0,89 0,77 0,40 
enolase 1 variant  H-ENO1 gi|62896593 47111,28906 7,01         0,60 0,90 0,69 
enolase 2  H-Eno2 gi|5803011 47239 4,91         0,84 0,60 0,27 
galactose mutarotase (aldose 1-epimerase)  H-Galm gi|20270355      1,57   1,03       0,59 
glucosidase II  H-Glu2 gi|2274968 106832,6484 5,71 2,56   1,40 2,12       
glucose-6-phosphate dehydrogenase  H-G6PD gi|30584817 59332,07031 6,39         0,40 0,65 0,22 
hypothetical protein  H-Hyp gi|12052754 20432,64063 6,29         0,31 0,47 0,19 
hypothetical protein  H-Hyp gi|31873364 33087,82813 8,14         0,73 0,71 0,59 
kinesin-like 8 isoform a  H-KNSL8 gi|41871946 68597,61719 5,82         0,52 0,71 0,63 
lasp-1 protein - human H-Lasp1 gi|2135552 29786,19922 6,11         0,60 0,61 0,38 
mRNA decapping enzyme  H-Dcp gi|7661734 38585,01953 5,93 1,09         0,39 0,56 
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N-acetylneuraminic acid phosphate synthase  H-NANS gi|12056473 40281,44922 6,29         0,91 0,93 0,56 
NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa 
(NADH-coenzyme Q reductase)  H-NADHD gi|21411235 79388,5 5,8         0,67 0,77 0,42 
NADP-dependent isocitrate dehydrogenase  H-NIDH gi|3641398 46658,53906 6,34         0,86 0,92 0,49 
nascent-polypeptide-associated complex alpha polypeptide  H-NACA gi|5031931 23369,71094 4,52 4,66   1,73 1,06       
peptidase (mitochondrial processing) alpha  H-Pmpca gi|24308013 58215,60156 6,45         0,94 0,28 0,65 
platelet-activating factor acetylhydrolase, isoform Ib, beta 
subunit 30kDa  H-LIS-1 gi|4505585 25553,11914 5,57 1,09     0,82 0,53 
triosephosphate isomerase 1  H-TPI1 gi|4507645 26652,74023 6,45         0,61 0,80 0,51 
TXNL2 protein  H-TXNL2 gi|48257132 32594,74023 5,36   257.026 2,57   0,63   0,69 
 
Signal transduction 
 
serine or cysteine proteinase inhibitor clade B member 5  H-SPIB5 gi|60817455 42083,42188 5,72 1,04   1,15       0,57 
interferon-induced Mx protein Homo sapiens H-Mx gi|188901 75530,25 5,65 1,04         0,67 0,48 
thioredoxin reductase GRIM-12  H-GRIM12 gi|3820535 54579,92969 6,36 1,51   1,63       0,27 
rho GTPase activating protein 1  H-Arhgap1 gi|4757766 50404,19141 5,85         0,90 0,54 0,35 
DJ-1 protein  H-DJ-1 gi|31543380 19878,49023 6,33         0,85 0,62 0,50 
DJ-1 protein  H-DJ-1 gi|31543380 19878,49023 6,33         0,95 0,76 0,57 
interferon-induced Mx protein Human H-Mx gi|188901 75530,25 5,65         0,87 0,41 0,45 
proteasome (prosome, macropain) subunit, beta type, 2  H-PSMB2 gi|30585195 22934,75977 6,51         0,56 0,47 0,43 
proteasome activator subunit 2  H-PSME2 gi|30410792 27384,31055 5,54         0,68 0,98 0,56 
serine (or cysteine) proteinase inhibitor, clade B 
(ovalbumin), member 1 variant  H-SPIB1 gi|62898301 42742,71094 5,9         0,85 0,68 0,49 
 
Other proteins 
 
chain A, molecular basis for the recognition of 
phosphorylated and phosphoacetylated histone H3 by  H-MolB gi|83754467 29242,32031 4,97         0,97 0,89 0,46 
hypothetical protein  H-Hyp gi|59016665 32559,26953 6,31         0,46 0,48 0,23 
 Table 5-p5 
 
hypothetical protein DKFZp762H157.1 - human 
(fragment) H-HypDK gi|11276938 73890,09375 6,46 2,01   1,93 1,62       
hypothetical protein LOC79017  H-HypLoc gi|13129018 20994,33008 5,07         0,93 0,58 0,57 
integrin beta 4 binding protein isoform a  H-Ibbp gi|4504771 26582,18945 4,56         0,73 0,73 0,54 
KIAA0193  H-KI193 gi|20521842 49370,12109 4,83 1,97 237.479 2,37       0,72 
programmed cell death 6 interacting protein  H-Pdcd6ip gi|22027538 95963,1172 6,13         0,95 0,89 0,45 
RuvB-like 1  H-RuvB1 gi|4506753 50196,30859 6,02         0,59 0,49 0,56 
transformation-related protein 14  H-TRP14 gi|33415057 42791,69141 5,49         0,00 0,15 0,23 
transformation-related protein 14  H-TRP14 gi|33415057 42791,69141 5,49         0,32 0,27 0,35 
tumor necrosis factor type 1 receptor associated protein 
TRAP-1 - human H-TRAP1 gi|1082886 75294,8672 8,43         0,58 0,68 0,53 
 
Unknown proteins 
 
unnamed protein product  H-unmd gi|34534595 65922,46094 4,45         0,44 0,45 0,01 
unnamed protein product  H-unmd gi|22760040 34008,57813 5,31         0,87 0,60 0,26 
 
 
 
  Table 6-p1 
 
 
Table 6. Differential expression proteins in PC-3 cells (Protein profiling using 2-DE; Delta2D software; MALDI-TOF). 
(PC-3 cells with and without VAVC GLV-1h68 treatment; time points were taken 12, 24 and 48 hours after virus infection; fold of 
enhancement or reduction of protein expression after virus infection are shown; highly expression in red and  down-regulated in blue)  
 
Fold of enhancement Fold of suppression 
>5 >5 
3 to 5 3 to 5 
2 to3 2 to 3 
 
Protein name Abbr Accession MW pI 
12hpi 
(+)fold 
24hpi 
(+)fold 
48hpi 
(+)fold 
12hpi 
(-)fold 
24hpi 
(-)fold 
48hpi 
(-)fold 
 
Viral proteins 
 
30k DNA binding phosphoprotein  V-I3L gi|2772696 30008,4707 5,68 6,41 11,09 12,59    
beta galactosidase [UAS-less reporter vector pMELbeta] V-bGal gi|37812657 118482,3672 5,49  6,55 13,27    
beta-galactosidase V-bGal gi|595694 123444,8281 5,37  3,61 6,37 0,95   
beta-galactosidase V-bGal gi|644832 116130,9531 5,28  1,80 2,69 0,74   
hypothetical protein m8218R  V-hyp8218R gi|56713567 27620,60938 4,85 8,52 17,00 21,52    
major core protein  V-A10L gi|56713513 102184,5391 5,83  4,42 4,78    
morphogenesis-related, substrate of B1R kinase  V-VLTF4 gi|66275900 22286,59961 6,86 5,14 7,58 12,08    
morphogenesis-related, substrate of B1R kinase  V-VLTF4 gi|66275900 22286,59961 6,86 5,51 9,91 12,36    
p4b precursor of core protein 4b  V-A3L gi|66275919 72577,84375 6,28  3,30    0,70 
putative 43.1k protein  V-A6L gi|2772720 43072,44141 5,71  1,60 3,76 0,46   
putative DNA-binding virion core protein  V-E11L gi|56713462 28424,65039 6,03 3,47 17,19 19,77    
renilla luciferase/neomycin phosphotransferase fusion 
protein [CMV hRluc-neo Flexi Vector pF9A] V-Ruc gi|114054347 65953,07031 5,15  2,80 2,14    
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ribonucleoside-diphosphate reductase  V-I4L gi|56713400 36922,23828 5,08 2,99 5,37 8,90    
serine protease inhibitor-like SPI-1  V-C12L gi|37551448 38215,5 4,69 8,42 14,80 14,56    
 
Cytoskeleton proteins 
 
tropomyosin 3 isoform 2  H-Tpm3 gi|24119203 29014,74023 4,75   9,79  0,74  
keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) 
(Keratin-9) (K9) H-Krt9 gi|81175178 62091,91016 5,19 2,26 1,77 1,46    
keratin like  H-Krtl gi|951272 27379,2793 5,45 2,38  1,18  0,96  
keratin 7  H-Krt7 gi|67782365 51354,30859 5,4 2,42 1,99    0,63 
keratin 7  H-Krt7 gi|12803727 51387,35938 5,42 2,61 2,18 1,97    
keratin 8  H-Krt8 gi|49256423 53717,12109 5,52 2,71 2,23    0,62 
keratin 19  H-Krt19 gi|34783124 45586,96875 5,11 2,93 2,43    0,67 
ACTB protein  H-ActB gi|15277503 40194,07031 5,55    0,44 0,56 0,54 
gamma-actin Homo sapiens H-ActG gi|178045 25861,96094 5,65  1,01 1,07 0,53   
alpha actinin 4  H-ACTN4 gi|2804273 102204,398 5,27    0,54 0,49 0,33 
ARP2 actin-related protein 2 homolog (yeast)  H-ARP2 gi|15778930 44732,25 6,3    0,85 0,78 0,52 
ARP3 actin-related protein 3 homolog  H-ARP3 gi|5031573 47340,98047 5,61    0,55 0,61 0,72 
tubulin, beta, 4 variant  H-Btub gi|62897639 50340,19922 4,83    0,66 0,72 0,60 
chain A, crystal structure of soluble form of clic4  H-CLIC4 gi|109157428 29818,2207 5,89    0,47 0,37 0,44 
gelsolin (amyloidosis, Finnish type)  H-GlsCap gi|55960301 28935,71094 7,71    0,90 0,66 0,26 
HS1 binding protein (HAX1)  H-HAX1 gi|55663095 28473,43945 4,82    0,79 0,45 0,29 
L-plastin variant  H-LCP1 gi|62898171 70214,82813 5,2    0,22 0,11 0,14 
L-plastin  H-LCP1 gi|4504965 70244,84375 5,2   1,28 0,56 0,86  
moesin  H-Msn gi|4505257 67777,78906 6,08    0,99 0,87 0,53 
moesin  H-Msn gi|4505257 67777,78906 6,08    0,73 0,73 0,51 
stomatin (EPB72)-like 2 variant  H-Stom gi|62897765 38524,21094 6,88    0,82 0,90 0,46 
 
Stress reponse 
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CCT2  H-TCP1 gi|48146259 57424,05859 6,01  3,97 6,86 0,97   
chaperonin containing TCP1, subunit 5 (epsilon)  H-CCT5 gi|24307939 59632,80859 5,45    0,80 0,66 0,52 
chaperonin containing TCP1, subunit 5 (epsilon)  H-CCT5 gi|24307939 59632,80859 5,45    0,67 0,63 0,42 
chaperonin containing TCP1, subunit 8 (theta) variant  H-CCT8 gi|62896539 59612,51172 5,42    0,57 0,64 0,56 
DnaJ homolog, subfamily C, member 9  H-DNAJC9 gi|27597059 29891,08984 5,58    0,52 0,71 0,97 
gamma subunit of CCT chaperonin  H-CCtg gi|671527 60292,25 6,23    0,88 0,86 0,56 
heat shock 70kDa protein 4 isoform a variant  H-Hsp704 gi|62087882 87949,21094 5,44    0,60 0,73 0,50 
heat shock 70kDa protein 4 isoform a variant  H-Hsp704 gi|62087882 87949,21094 5,44    0,47 0,65 0,45 
heat shock 70kDa protein 8 isoform 1  H-hsp708 gi|5729877 70854,21875 5,37  1,41 2,11 0,99   
heat shock 70kDa protein 8 isoform 1  H-hsp708 gi|5729877 70854,21875 5,37    0,54 0,45 0,37 
heat shock 70kDa protein 8 isoform 1  H-hsp708 gi|5729877 70854,21875 5,37    0,65 0,59 0,66 
heat shock 70kDa protein 8 isoform 1  H-hsp708 gi|5729877 70854,21875 5,37    0,62 0,52 0,48 
heat shock protein HSP 90-alpha (HSP 86) (NY-REN-
38 antigen) H-HSP90 gi|92090606 84606,67969 4,94    0,55 0,34 0,06 
HSP90AA1 protein  H-HSP90 gi|12654329 64349,69922 5,1    0,36 0,46 0,24 
KIAA0201  H-KI201 gi|40788905 106673,8438 5,82    0,54 0,59 0,59 
oxygen regulated protein precursor  H-Orp gi|5453832 111266,2109 5,16    0,92 0,88 0,10 
oxygen regulated protein precursor  H-Orp gi|5453832 111266,2109 5,16    0,65 0,88 0,05 
t-complex polypeptide 1  H-TCP1 gi|36796 60355,75 6,03    0,46 0,57 0,63 
 
Translation associates proteins 
 
ATP-dependent DNA helicase II  H-Ku70 gi|10863945 82652,27344 5,55    0,48 0,50 0,10 
ATP-dependent DNA helicase II  H-Ku70 gi|10863945 82652,27344 5,55    0,71 0,85 0,50 
  Table 6-p4 
 
ATP-dependent DNA helicase II  H-Ku70 gi|10863945 82652,27344 5,55    0,64 0,70 0,32 
DNA replication licensing factor MCM4 H-MCM4      43,47 22,21 7,36    
elongation factor Tu, mitochondrial precursor (EF-Tu) 
(P43) Homosapiens H-EF-G gi|1706611 49510,17969 7,26  1,05  0,92  0,34 
eukaryotic translation elongation factor 1 gamma  H-EEF1g gi|15530265 50115,17188 6,25    0,73 0,71 0,58 
eukaryotic translation initiation factor 3, subunit 9 eta, 
116kDa  H-Eif3s9 gi|51094703 88625,02344 4,96    0,23 0,56 0,49 
eukaryotic translation initiation factor 4B  H-EIF4B gi|50053795 69110,28125 5,55    0,26 0,57 0,29 
eukaryotic translation initiation factor 4B  H-EIF4B gi|50053795 69110,28125 5,55    0,04 0,31 0,01 
KIAA0038  H-KI38 gi|436226 25468,67969 8,66  1,58 2,02    
minichromosome maintenance protein 7 isoform 1  H-MCM7 gi|33469968 81256,57031 6,08    0,90 0,95 0,34 
PPA1 protein  H-PPA1 gi|33875891 35448,64063 5,95 2,73 4,83 8,16    
ribosomal protein, large, P0  H-ARPP0??? gi|12654583 34252,73828 5,42    0,36 0,42 0,35 
TB3-1 Homo sapiens H-TB3-1 gi|338687 47965,16016 9,52     0,56 0,22 
 
RNA processing 
 
adhesion regulating molecule 1 precursor  H-ADRM1 gi|28373192 42126,80859 4,96    0,69 0,31 0,49 
ash protein  H-ash gi|28876 18567,17969 6,65    0,79 0,43 0,52 
aspartyl-tRNA synthetase  H-AspS gi|45439306 57100,03125 6,11    0,31 0,64 0,46 
glycyl-tRNA synthetase  H-GlyS gi|116805340 83112,60938 6,61    0,59 0,62 0,52 
heterogeneous nuclear ribonucleoprotein C (C1/C2)  H-hnRNPC gi|14249959 32373,91016 5 4,24 13,33 10,74    
heterogeneous nuclear ribonucleoprotein H3 isoform b  H-hnRNPC gi|14141159 35216,37891 6,36 2,73 3,07 5,67    
heterogeneous nuclear ribonucleoprotein K  H-hnRNPK gi|55958544 47527,64063 5,46 2,05 2,52 3,43    
hnRNP C2 protein Homo sapiens H-hnRNPC2 gi|337455 33278,39063 5,11 2,41 2,13 2,76    
HNRPF protein  H-HNRPF gi|16876910 45670,85938 5,38 2,24 3,86 3,61    
poly(rC) binding protein 1  H-PCBP1Ê gi|5453854 37501,96875 6,66 2,46 2,00    0,84 
SARS protein  H-SARS gi|111494145 58369,82031 6,05 1,20    0,97 0,46 
splicing factor SF3a60  H-SF3a60 gi|551450 58740,23047 5,3 1,16 2,07 2,68    
  Table 6-p5 
 
TALDO1 protein  H-TALDO gi|48257056 37385,42188 6,35 1,49 2,67 3,76    
  
Ubiquitin proteasome pathway 
              
human 26S proteasome subunit p97  H-PSMD2 gi|1060888 100121,7734 5,08    0,48 0,69 0,83 
otubain 1  H-otub gi|109148508 31264,41992 4,85    0,75 0,55 0,57 
Proteasome (prosome, macropain) 26S subunit, ATPase, 
1  H-PSMC1 gi|16741033 49172,73047 5,92    0,69 0,56 0,67 
proteasome 26S ATPase subunit 4 isoform 1  H-26S4 gi|5729991 47336,53906 5,09    0,52 0,62 0,61 
proteasome 26S non-ATPase subunit 5  H-PSMD5 gi|4826952 56160,35938 5,35   1,10 0,53 0,56  
proteasome subunit Y  H-PSMB6 gi|558528 25299,40039 4,8    0,79 0,47 0,60 
ubiquitin activating enzyme E1  H-UBE1 gi|35830 117715,3438 5,57    0,47 0,61 0,29 
ubiquitin activating enzyme E1  H-UBE1 gi|35830 117715,3438 5,57    0,39 0,50 0,16 
 
Metabolism associated  and transport proteins 
 
aconitase 1  H-ACO1 gi|8659555 98336,57813 6,23  2,36    0,37 
acylamino acid-releasing enzyme  H-APEHÊ gi|556514 81240,64844 5,29    0,42 0,50 0,31 
adenosine kinase Homosapiens H-AK gi|1224125 38714,62891 6,28  2,23 1,54    
AGM1  H-AGM1 gi|56203408 55453,94141 5,76    0,63 0,83 0,59 
aryl hydrocarbon receptor interacting protein  H-AIP gi|4502009 37640,14844 6,09 3,76 2,17 2,11    
chain A, crystal structure of human sar1a in complex 
with Gdp H-Sar1a gi|93279951 23160,89063 7,19    0,01 0,01 0,21 
chain A, horf6 a novel human peroxidase enzyme H-Horf gi|3318841 25011,19922 6    0,71 0,42 0,34 
chain A, horf6 a novel human peroxidase enzyme H-Horf gi|3318841 25011,19922 6    0,73 0,69 0,54 
COMT protein  H-COMT gi|33875419 20032,23047 5,36 5,52 10,90 24,97    
copine I  H-CpnI gi|4503013 59021,53906 5,52    0,65 0,62 0,53 
copine III  H-CpnIII gi|4503015 60092,12891 5,6    0,71 0,75 0,50 
creatine kinase  H-Ck gi|180570 42591,26172 5,34     0,80 0,41 
  Table 6-p6 
 
dipeptidylpeptidase 9  H-DPP9Ê gi|51988902 96551,14844 6,05    0,50 0,63 0,00 
endoplasmic reticulum protein 29 isoform 1 precursor  H-ERp29 gi|5803013 28975,15039 6,77    0,88 0,79 0,58 
enolase 1 variant  H-ENO1 gi|62896593 47111,28906 7,01 1,88 2,11 1,20    
enolase 2  H-Eno2 gi|5803011 47239 4,91    0,69 0,71 0,59 
ERO1-like (S. cerevisiae)  H-ERO1L gi|14250470 54357,10156 5,62    0,45 0,30 0,19 
glucosidase II  H-Glu2 gi|2274968 106832,6484 5,71    0,59 0,89 0,21 
glutathione S-transferase M3 (brain)  H-GSTM3 gi|14250650 26556,15039 5,37    0,72 0,45 0,72 
glutathione synthetase  H-GS gi|4504169 52352,26172 5,67    0,55 0,70 0,85 
glycerol-3-phosphate dehydrogenase 2 (mitochondrial)  H-GPD2 gi|4504085 80763,53125 6,98 2,25 2,44 1,31    
glyoxalase I  H-GLO gi|1881782 20764,25 5,12    0,08 0,02 0,76 
GSPT1 protein  H-GSPT1 gi|33874734 68403,96094 5,22    0,52 0,55 0,32 
guanine monophosphate synthetase  H-GMPS gi|4504035 76666,95313 6,42  1,82    0,26 
heat shock 70kDa protein 5 (glucose-regulated protein, 
78kDa)  H-GRP78 gi|16507237 72288,42969 5,07    0,64 0,96 0,32 
Hpast  H-Hpast gi|2529707 60664,67188 6,49  1,33    0,28 
hypothetical protein  H-Hyp gi|31873302 47063,33984 7,57  2,05    0,94 
inosine monophosphate dehydrogenase 2  H-IMPDH2 gi|66933016 55769,64844 6,44  1,12    0,51 
karyopherin alpha 6  H-KPNA6 gi|6912478 59991,44922 4,89    0,23 0,25 0,15 
lasp-1 protein - human H-Lasp1 gi|2135552 29786,19922 6,11 1,50  1,33  0,47  
leukotriene A4 hydrolase  H-LTA4H gi|4505029 69241,24219 5,8 1,05    0,68 0,22 
mitochondrial ATP synthase, H+ transporting F1 
complex beta subunit  H-ATPF1 gi|89574029 48083,03906 4,95    0,79 0,78 0,42 
NADH dehydrogenase (ubiquinone) Fe-S protein 1, 
75kDa (NADH-coenzyme Q reductase)  H-NADHD gi|21411235 79388,5 5,8    0,36 0,05 0,02 
NDUFV2  H-NDUFV2 gi|48145973 27331,9707 8,22    0,38 0,41 0,54 
N-ethylmaleimide-sensitive factor  H-NSF gi|21040484 82542,07031 6,52 2,35    0,97 0,02 
oxoglutarate (alpha-ketoglutarate) dehydrogenase 
(lipoamide) isoform 1 precursor  H-OGDH gi|51873036 115861,3984 6,4     0,98 0,37 
phosphoglucomutase 2  H-PGM2 gi|14603253 68298,39844 6,17    0,77 0,67 0,54 
  Table 6-p7 
 
phosphoglycerate dehydrogenase  H-PHGDH gi|23308577 56614,39844 6,29  1,06  0,93  0,57 
protein disulfide isomerase  H-PDI gi|860986 56643,71875 6,1    0,70 0,59 0,91 
replication protein A2, 32kDa  H-RPA2 gi|56204165 30137,01953 6,45 1,46 1,28 2,04    
SEC23B protein  H-SEC23B gi|13529299 86407,57031 6,43    0,79 0,31 0,04 
spermine synthase  H-SPMSY gi|21264341 41241,78125 4,87    0,55 0,65 0,83 
succinate dehydrogenase complex, subunit A, 
flavoprotein precursor variant  H-Sdha gi|62087562 73129,52344 6,94  1,71  0,84  0,27 
TALDO1 protein  H-TALDO gi|48257056 37385,42188 6,35    0,58 0,93 0,65 
TPI1 protein (Triosephosphate isomerase) H-TBI1 gi|47682755 27420,24023 8,48  2,25    0,93 
twinfilin-like protein  H-TWFl gi|6005846 39523,26953 6,37     0,88 0,42 
TXNDC5 protein  H-TXNDC5 gi|12654715 36155 5,32    0,77 0,70 0,41 
ubiquinol-cytochrome c reductase core I protein 
Homosapiens H-QCyRe gi|515634 52585,42188 5,94    0,72 0,82 0,05 
 
Signal transduction 
 
ANXA3  H-A3 gi|47115233 36451,73828 5,76 1,30 2,01 2,61    
BiP protein  H-BiP gi|6470150 70887,52344 5,23   1,10 0,56 0,71  
Chain A, Human Dj-1 With Sulfinic Acid H-DJ1 gi|50513593 19886,48047 6,33    0,24 0,57 0,90 
chloride intracellular channel 1  H-CLIC1 gi|55961458 26167,26953 4,95   2,19 0,88 0,51  
cytidylate kinase  H-CMPK gi|7706497 25838,34961 8,14   1,09 0,00 0,00  
G3BP  H-G3BP gi|49168554 52132,10938 5,42    0,44 0,65 0,23 
GIPC1 protein  H-GIPC1 gi|33872740 32677,91992 5,89    0,71 0,58 0,51 
high-mobility group box 1  H-HMGB1 gi|55958715 22036,3203 9,61 1,27 1,15 2,46    
phosphoglucomutase 1  H-HMGB1 gi|30584157 61444,5117 6,2 1,03 1,12    0,56 
P21-activated kinase 2  H-PAK2 gi|47482156 58104,9609 5,78    0,29 0,53 0,54 
rho GTPase activating protein 1  H-Arhgap1 gi|4757766 50404,19141 5,85    0,47 0,50 0,20 
zinc finger protein 259  H-ZNF259 gi|4508021 50893 4,66    0,23 0,59 0,17 
 
  Table 6-p8 
 
Other proteins 
 
dendritic cell protein variant  H-Ga17 gi|62896687 42443,82813 5,41    0,64 0,50 0,88 
hypothetical protein  H-Hyp gi|31874844 46340,05078 5,55    0,49 0,46 0,42 
hypothetical protein  H-Hyp gi|51491236 47911,62891 8,12    0,69 0,58 0,57 
hypothetical protein  H-Hyp gi|51476352 42920,98047 5,27    0,75 0,84 0,59 
immunoglobulin binding protein 1  H-IGBP1 gi|4557663 39197,5 5,26 1,61 1,10 2,64    
integrin beta 4 binding protein isoform a  H-Ibbp gi|4504771 26582,18945 4,56    0,75 0,52 0,86 
KIAA0885 protein  H-KI885 gi|40788973 91993,1875 5,62  2,76    0,97 
KIAA0885 protein  H-KI885 gi|40788973 91993,1875 5,62    0,52 0,56 0,25 
leucine aminopeptidase 3  H-ALP3 gi|41393561 56130,80859 8,03     0,88 0,41 
mitofilin  H-Mtfln gi|8131894 68145,28125 5,57 2,23 1,84    0,27 
NOP17  H-NOP17 gi|8923598 32342,36914 5,05   2,02 0,82 0,79  
nudC domain containing 1  H-NUDCD1 gi|23618846 66733,28125 4,99 2,12 1,71 1,14    
plastin 3  H-PLS3Ê gi|7549809 70766,21094 5,41    0,83 0,59 0,46 
programmed cell death 6 interacting protein  H-Pdcd6ip gi|22027538 95963,1172 6,13 1,21 1,29    0,53 
programmed cell death 6 interacting protein  H-Pdcd6ip gi|22027538 95963,1172 6,13 1,06 1,21    0,48 
programmed cell death 6 interacting protein  H-Pdcd6ip gi|22027538 95963,1172 6,13  1,01  0,73  0,38 
protein phosphatase 2, catalytic subunit, beta isoform  H-PPP2CBÊ gi|4758952 35552,32813 5,21   1,07 0,48 0,78  
Protein SET (Phosphatase 2A inhibitor I2PP2A) (I-
2PP2A) (Template-activating factor I) (TAF-I) (HLA H-SET gi|46397790 33468,69922 4,23 1,29    0,93 0,56 
reticulocalbin 1 precursor  H-RCN1 gi|4506455 38866,16016 4,86    0,62 0,61 0,52 
tetratricopeptide repeat domain 1  H-TTC1 gi|4507711 33505,17188 4,78   1,06  0,52  
transglutaminase 2 isoform a  H-TGM2 gi|39777597 77279,67188 5,11    0,37 0,44 0,27 
tumor rejection antigen (gp96) 1 variant  H-gp96 gi|62088648 65912,28906 5,08    0,12 0,35 0,05 
UV excision repair protein RAD23 homolog A variant  H-RAD23A gi|62089006 41230,51172 4,66 1,23    0,64 0,29 
vinculin isoform meta-VCL  H-mVCL gi|7669550 123721,8125 5,5    0,58 0,65 0,28 
vinculin isoform meta-VCL  H-mVCL gi|7669550 123721,8125 5,5    0,64 0,76 0,44 
  Table 6-p9 
 
vinculin isoform VCL  H-VCL gi|4507877 116649,3203 5,83    0,67 0,75 0,49 
 
Unknown proteins 
 
unknown (protein for IMAGE:3529287)  H-unkn gi|52790434 37696,98047 8,56 2,04 2,20 1,11    
unknown [synthetic construct] H-unkn gi|62288518 31111,46094 6,3 2,86 2,21 1,39    
unnamed protein product  H-unkn gi|18676733 28025,11914 6,5    0,55 0,56 0,20 
unnamed protein product  H-unkn gi|34534595 65922,46094 4,45    0,21 0,50 0,16 
unnamed protein product  H-unkn gi|21748975 47011,35938 5,45    0,68 0,59 0,25 
unnamed protein product  H-unkn gi|35218 75811,5625 5,41    0,77 0,73 0,57 
unnamed protein product  H-unkn gi|35218 75811,5625 5,41    0,75 0,62 0,39 
 
 
 
